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SUMMARY 
 
The inflammatory response consists of a well-defined and regulated multi-step 
cascade leading to extravasation of leukocytes from the blood to sites of 
inflammation. The transmigration of leukocytes is initiated by their interaction with the 
endothelium, a process regulated by selectins, a family of cell adhesion molecules. 
This Ph.D. thesis is focused on E-selectin - a C-type type (Ca2+-dependent) lectin.  
Excessive recruitment of leukocytes, as observed in inflammatory diseases 
(e.g. asthma or arthritis), is problematic because the inflammatory response itself 
becomes harmful. Consequently, the modulation of leukocyte recruitment by 
interfering with cell tethering is of therapeutical interest. 
Sialyl Lewisx (sLex) is the minimal carbohydrate epitope of physiological 
ligands recognized by E-selectin. This moderate binder (in the millimolar range) has 
served as a lead structure for the design of more potent E-selectin antagonists. This 
optimization process was supported by NMR and SPR, leading to the first generation 
of low micromolar antagonists of E-selectin. These contributions are presented in this 
thesis.  By ligand-based NMR experiments a better understanding of the physical 
basis of the interaction was obtained. 
In a next step, fragment-based methods that have emerged as a new strategy 
in drug discovery were successfully applied to the lead optimization of E-selectin 
antagonists. The improved affinities as well as the increased residence time 
impressively demonstrate the potential of the applied fragment-based approach.  
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1. General introduction  
 
1.1 Drug discovery  
 
1.1.1 Overview 
 
The drug discovery and development (DDD) process is complex, challenging 
and expensive. Traditionally, the discovery phase is divided into five steps (Figure 1).  
 
Target 
Validation
Target to
Hit
Hit 
to Lead
Lead 
Optimization ADMET
Clinical
Studies Registration Market
Discovery Development
 
 
Figure 1. General steps of drug discovery and development process. 
 
 The first step is the identification and validation of a target according to its 
involvement in the particular disease and its “drugability”. Currently, most of the 
targets are proteins, e.g. G-protein-coupled-receptors [1], and can be classified in 
different categories: receptors, enzymes, channels and hormones (Figure 2).  
 
 
 
 
 
 
 
 
 
 
Figure 2. Main classes of current drug targets (adapted from Bleicher et al. [2]) 
 
After target discovery and validation, hits have to be identified for the selected 
target. Thus, a primary screen of large libraries of compounds is rapidly performed. 
For this purpose, divers types of libraries can be used: natural products (NPs), 
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collections of synthesized compounds, as well as combinatorial libraries [2,3]. In this 
step, contributions from computer-aided drug design (CADD) and structure-based 
drug design often play a key role, especially when NMR and X-ray data of the target 
are available. After their validation, selected hits enter the dose-response screening 
in order to choose compounds with the most promising lead profile (selectivity, 
potency). Lead optimization is achieved in order to improve the drug-like profile of the 
candidates. Guided by the structure-activity relationship (SAR), medicinal chemists 
further optimize the leads, their pharmacodynamics (PD) and their pharmacokinetic 
(PK) properties as adsorption, distribution, metabolism, excretion and toxicity 
(ADMET).  
The time range for the discovery and development phase, resulting in the 
entry of a new drug in the market is long, approximately 15 years. In 2003, DiMasi et 
al. [4] estimated the cost of the process to be US$ 800 million. In 2006, Adams et al. 
[5] re-evaluated the total cost as varying between US$ 0.5 and US$ 2 billion. This 
broad range results from the variation of costs depending on the indication and the 
novelty of both target and drug.  
Pharmaceutical industries put significant effort into improving the productivity 
of the DDD process in order to bring more innovative drugs to the market. As a 
consequence of the high safety standards, the Food and Drug Administration (FDA) 
and other worldwide safety authorities approve only a restricted number of New 
Molecular Entities (NMEs) per year (26 in 2009) [6]. In view of these conflicting goals, 
a substantial improvement of the DDD process is unavoidable, especially due to 
growing pressures such as patent expiration or even more demanding regulatory 
requirements that have to be faced [7,8]. Therefore, in modern-drug discovery, a 
combination of virtual screening and medicinal chemistry with high throughput 
technologies tends to reduce time and costs and improve efficacy of the DDD 
process [8]. In the development phase of the candidates (Figure 1), phase II and 
phase III of the clinical development are the most expensive ones. Paul et al. 
therefore proposed an alternative development paradigm including the establishment 
of proof-of-concept (POC) leading to a reduction of the number of NMEs reaching the 
clinical studies but increasing their probability to reach market [7]. 
Research for new, efficient and cost effective techniques in the process of 
drug discovery and development is unambiguous. In that respect, label-free assays 
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that limit the generation of false positive and false negative results are highly 
attractive for pharmaceutical firms. Isothermal titration calorimetry (ITC), analytical 
centrifugation (AUC), mass spectroscopy, nuclear magnetic resonance spectroscopy 
(NMR) and biosensors represent a set of attractive methods [9]. Frequently, two or 
more techniques are used simultaneously to improve the reliability of hit identification 
[10].  
 
1.1.2 Surface plasmon resonance in drug discovery 
 
Optical biosensors can be used in all steps of the discovery and development 
process, including target identification and validation, screening, assay development, 
lead selection and optimization, ADME and quality control [9,11-14]. The 
miniaturization and automation of the platforms make this technology even more 
attractive. Optical biosensors that exploit surface plasmon resonance (SPR) are 
nowadays the most popular class of biosensors. Indeed, this surface-sensitive 
method allows high-throughput, does not require any label for the detection and the 
measurements are performed in real-time. Those characteristics, as well as 
considerable recent advance in instrumentation and experimental design place 
optical biosensors in a key position in drug discovery [12]. As an example, Biacore 
4000 commercialized by GE Healthcare is dedicated to screening of fragments and 
evaluating of low molecular weight compounds. In addition, almost all types of 
molecule can be immobilized on a biosensor surface (protein, nucleic acids, lipids, 
carbohydrates) and a broad range in the size of the analytes exists (low molecular 
weight compounds of a few 100 Da up to large particules such as virus) [15]. Despite 
recent improvements in the instrument hardware, experimental design and data 
analysis [14], the analysis of low molecular weight compounds remains challenging. 
Last but not least, the set of parameters accessible from SPR-biosensor analyses is 
significant: association and dissociation rates, enthalpy, entropy, stoichiometry, IC50, 
and inhibition constant. 
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1.1.3 Nuclear magnetic resonance in drug discovery 
 
Also traditionally dedicated and developed for applications in chemistry and 
structural biology, nuclear magnetic resonance (NMR) has more recently found a 
central role in the drug discovery and development process. In 1996, Abbott 
Laboratories highlighted the role of NMR in the drug discovery process with their 
SAR-by-NMR, an NMR-driven method based on perturbation of the target spectra in 
the presence of ligands [16]. Since then, in addition to complementary research 
areas, NMR increased its range of application in pharmaceutical research and is 
used throughout numerous research and development steps from the primary high-
throughput screening to binding studies [13]. 
NMR in drug discovery can be divided in two types of methods according to 
the molecule detected: ligand or target.  Ligand-based investigations are focused on 
the difference in the NMR properties of a ligand in the bound state compared to the 
free form. In the bound state, a ligand will exhibit the same NMR properties as the 
target: fast relaxation, slow diffusion and negative NOEs. This approach presents a 
number of advantages: labeled targets are not required, smaller amount of the target 
are needed compared to target-based screening, and some degree of information on 
the binding epitope and binding mode can be extracted. In addition, most of the 
ligand-based NMR methods rely to 1D experiments, e.g. STD and relaxation [17-19]. 
The limitations of this method are the range of affinity that can be detected (mM to 
µM affinities). High affinity ligands can be a source of false negative 
(undistinguishable from the target). For low affinity ligands, recent publications 
opened new possibilities [20].  
In target-based methods, low affinity ligands can be detected and the 
specificity of the binding characterized. In addition, detailed structural information can 
be obtained. Nevertheless, significant quantities of the target, usually isotopically 
labeled are required, which is a clear limitation to their application. In addition, most 
of the experiments are 2D, which implies long acquisition time e.g. HSQC [17-19]. 
Both methods exhibit positives and negatives aspects and provide 
complementary information. The use of one or the other approach is clearly 
dependent on the material available (labeled or non-labeled target, quantities). 
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1.2 Selectins 
 
1.2.1 Selectins in the inflammatory cascade 
 
The inflammatory response is a complex biological response of the body to 
defend itself against various injuries or infections (e.g. viruses, bacteria, fungi, 
damaged cells). The main actors of this defense are leukocytes, which circulate in 
the body in search for alert signals from sites of tissue damage or infection. The 
inflammatory response consists of a well-defined and regulated multi-step cascade 
leading to extravasation of leukocytes from the blood (mainly post-capillary venules) 
to the site of inflammation. This process is part of the innate immune response. After 
reaching the site of damaged tissue by chemotaxis, leukocytes act by phagocytosis 
and release of pro-inflammatory mediators like chemokines or platelet activating 
factors. Four major steps are distinguished in the inflammatory response process 
(Figure 3):  
 
• Inflammatory stimuli 
• Tethering and rolling of the leukocytes 
• Integrin activation leading to firm adhesion 
• Transendothelial migration 
 
 
 
Figure 3. Successive steps of leukocyte transmigration and the role of selectins (adapted from [21] 
and by courtesy of Dr. A. Voegtli). 
 
In the first step, proinflamatory mediators are released on the site of injury by 
the immune cells already present in the tissues (e.g. macrophages), which act as an 
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alert signal for the start of the inflammatory cascade. The consequence is the 
expression of cell adhesion molecules (CAMs) on the endothelial surface. The 
leukocytes recruitment is a receptor-mediated process, initiated by interactions 
between leukocytes and the endothelium [22]. Selectins are a family of CAMs 
involved in the early stages of those interactions. The expression of E- and P-selectin 
on the endothelium surface is initiated by the release of proinflammatory mediators 
(thrombin, histamine). In that process, E-selectin is synthesized de novo and its 
expression is induced by TNF-α, interleukin 1 (IL-1) or lipopolysaccharide (LPS) [23]. 
In contrast, after stimuli such as histamine or thrombin, P-selected is transported 
from α-granules of platelets and Waibel-Palade bodies of endothelial cell to the 
surface within minutes [24,25]. In addition, a few hours later, stimulation by cytokines 
such as TNF-α induces the expression of P-selectin. In the next step, selectins bind 
to endogenous ligands expressed on the leukocyte surface (PSGL-1 and ESL-1) in a 
fast association/dissociation process which leads to reduced mobility of the 
leukocytes from 1-10 mm/s down to 5 µm/s before becoming fully stationary. The 
principal role of E-selectin in this process was shown in E-selectin deficient mice, 
where the leukocytes rolled two to four times faster than in wild mice [26]. A third 
member of the selectin family, the L-selectin, is constitutively expressed on the 
surface of leukocytes and is involved in interactions with its ligand GlyCAM-1 in the 
“secondary tethering” process. This process describs the interaction between 
leukocytes in the flow and leukocytes already associated on the endothelium [27].  
At the end of the leukocyte recruitment process, the expression of E-selectin is 
stopped and return to basic level, P-selectin is removed from the surface by 
endocytosis and L-selectin is cleaved by metalloproteases. By promoting the 
tethering and the rolling of leukocytes along the endothelial surface in the early stage 
of the inflammatory cascade, selectins play a key role in the initiation of the 
extravasation process [28]. The kinetics of the expression of the different CAMs is 
precisely regulated and a global maximum level is reached 4 h after activation 
(Figure 4). 
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Figure 4. Kinetic profile of the expression of adhesion molecules after activation by inflammatory 
mediators (Adapted from Bevilacqua et al. 1994). 
 
Fundamental to transmigration, integrin mediates tight adhesion to the 
endothelium and finally, migration of the leukocytes to the endothelial junctions. The 
process ends with the passage of the recruited leukocytes across the endothelium 
via diapedesis (Table 1) [29-31].  
 
Table 1. Proteins involved in the different stage of leukocyte extravasation. Leukocytes adhering on 
the endothelium are show at the bottom [32]. 
 
Steps of homing 
process Protein families Members 
Rolling Selectins 
E-selectin 
P-selectin 
L-selectin 
Firm adhesion Integrins 
LFA-1 
VLA-4 
Mac-1 
Transmigration 
Integrins 
Immunoglobulin superfamily 
Glycoproteins 
LFA-1,VLA-4 
PECAM-1 (CD-31), JAM-1 
CD-99 
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1.2.2 Role of selectins in human inflammatory diseases 
 
Two categories of inflammation can be distinguished: acute and chronic. In 
both, an excessive recruitment of leukocytes, as observed in inflammatory diseases 
(e.g. asthma or arthritis) is problematic, because the inflammatory response itself 
becomes harmful. A contrario, a lack of leukocytes recruitment also appears 
problematic by deacreasing the host’s response. Consequently, the modulation of 
leukocyte recruitment via interference with cell tethering is of therapeutic interest. The 
physiological and pathophysiological role of selectins was revealed with the first 
studies in selectin-deficient mice models where multifocal infections where detected 
[33,34].   
Those first insights revealed the likelihood of the importance of the selectin-
leukocytes interaction in inflammatory diseases. The consequences of preventing 
selectin-ligand interactions lead to a dramatic impact on the progression of diseases 
in animal models [35,36], and thereby reveal the key role of selectins in numerous 
deseases. Thus, in vasculitis and atherosclerosis, an enhanced expression of E-
selectin was observed inducing an accumulation of leukocytes in the tissues [37-39]. 
In ischemia and reperfusion injuries, prolonged hypoxia induces an increase of the 
leukocytes-endothelium interaction mediated by P- and E-selectin [40,41]. The role of 
selectin was also demonstrated in other diseases like sepsis [42], asthma [43], 
gastrointestinal inflammation [44] or rheumatoid arthritis [45]. A strong upregulation 
of the selectin ligands has also been observed in cancer metastasis. Indeed, high 
levels of expression of sLex/a were observed in many solid tumors and 
adenocarcinomas [46-51]. During metastasis, it was shown that malignant cells 
follow the pathway of leukocytes to be spread in the organism (Figure 5).  An 
enhancement of the sialylation and fucosylation of the mucin surface protein, which 
interacts with selectins was reported to participate to the progression of carcinoma 
cells metastasis [52]. Therefore, carbohydrates epitopes, which bind to selectins, are 
tumor-associated antigens [53] and can be used in diagnosis [52]. 
 
 
 
 
 
 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Role of Selectins in cancer metastasis [54]. 
 
Based on the studies mentioned above, blocking the selectin-ligand interaction 
would provide considerable benefits for patients suffering from inflammatory 
diseases. Established treatments of inflammation are based on non-steroidal anti-
inflammatory drugs (NSAIDs, e.g. salicylates and cyclooxygenase (COX) inhibitors) 
as well as steroid-based drugs (e.g. cortisol). Such treatments are palliative and short 
and long term side effects are well documented. An alternative approach is possible 
with antibody therapies (e.g. Enbrel, Wyeth) but the high costs of treatment limit their 
use. The development of small molecular antagonists of selectins, which could 
interfere in the early stage of the inflammatory cascade and limit the leukocytes 
recruitment, appears extremely attractive, but is nevertheless challenging. This PhD 
thesis reports the improvement of the potency of E-selectin antagonists guided by 
Biacore and NMR at the Institute of Molecular Pharmacy. 
 
1.2.3 Selectin family 
 
Lectins recognize carbohydrate structures of glycoconjugates (proteins or 
lipids) or soluble carbohydrates and are present in plants, in which they were initially 
discovered, as well as in animals. They are divided into 4 groups [55]: 
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• C-type lectins characterized by a calcium dependant binding 
• P-type lectins characterized by recognition of phosphorylated mannose 
residues 
• S-type lectins or galectins characterized by the presence of free thiol groups in 
their structure 
• Other lectins 
 
Selectins are single-chain transmembrane glycoprotein belonging the group of 
C-type lectins. Three members, E-, P- and L-selectin, represent the selectin family. 
They are distinguished by their first identification site (Table 2). 
 
Table 2. Selectin family members. 
 
 L-selectin E-selectin P-selectin 
Date of identification 1983 [56] Late 1980’s [23] 1984 [57] 
Site of first 
identification Leukocytes Endothelium Platelets 
Synonyms 
CD62L 
LAM-1 
LECAM-1 
CD62E 
ELAM-1 
LECAM-2 
CD62P 
LECAM-3 
GMP-140 
PADGE 
Molecular weight 
calculated 42 kDa 64 kDa 86 kDa 
Molecular weight 
observed 90 kDa [58] 115 kDa [59] 140 kDa [60] 
 
A high degree of glycosylation considerably increases the molecular weight for 
each selectin (Table 2). All selectins are transmembrane glycoproteins and share 
common structural motifs (Figure 6). A C-type lectin domain at the N-terminus, which 
contains the carbohydrate recognition domain (CRD) followed by an epidermal 
growth factor (EGF)-like domain, a variable number of consensus repeats (CRs), a 
transmembrane segment and a short C-terminal tail are present in all selectins [61]. 
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 L-selectin E-selectin P-selectin 
Lectin domain (with CRD) 120 120 118 
EGF domain 35 35 40 
CRs 177 380 572 
TM domain 23 24 24 
Cytoplasmic tail 17 32 35 
 
Figure 6. Structure of L-, E- and P-selectin. Number of amino acids of each motif for each selectin is 
mentioned in the table. 
 
An overall homology of about 50% is found between the members of the 
selectin family. For the lectin and the EGF domains, the primary sequence is highly 
conserved (up to 65 %) [62]. A calcium ion present in the CRD domain plays a major 
role in the carbohydrate recognition [63] together with the EGF domain that 
enhances the carbohydrate binding potential. Nevertheless, the role of the EGF 
domain in the interaction with the ligand remains unclear (stabilization of the 
conformation of the binding domain and/or direct interaction with the ligand [64,65]).  
The major difference between the members of the selectin family is the 
number of short CRs. The primary sequence of these domains is less conserved 
between the selectin (40 % of homology [62]). These domains may act as spacers 
between cells involved in the interaction since it was shown that a depletion of the 
CRs in P-selectin affect the leukocytes rolling [66,67]. The transmembrane domain 
anchors the selectin to the plasma membrane and a short C-terminal cytoplasmic 
domain is postulated to be involved in signal transduction [68]. 
 
 
C-Type Lectin domain EGF domain CRs
Transmembrane domainCyoplasmic tail Plasma membrane
L-selectin
E-selectin
P-selectin
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1.2.4 Selectin ligands 
 
1.2.4.1 Natural ligands 
 
Selectins are carbohydrate binding proteins recognizing sialylated and 
fucosylated terminal glycan epitopes on glycoproteins and glycolipids. The three 
members of the selectin family recognize a common carbohydate epitope found in 
the trisaccharides Lewisx (Lex) and Lewisa (Lea) as well as in their sialylated 
derivatives, sialyl Lewisx (sLex) and sialyl Lewisa (sLea) (Figure 7) [69-72]. 
 
 
 
 
 
 
 
 
 
Figure 7. Common carbohydrates epitopes recognized by the selectin family. The sialic acid moieties 
are highlighted in red. 
 
Seven glycoproteins were identified as L-selectin ligands and are shown in 
Table 3. The glycosylation-dependant cell adhesion molecule 1 (Gly-CAM-1), a sialo-
mucin stored in cytoplasmic granula of endothelial cells in lymph node tissue is so far 
the best characterized L-selectin ligand [73-77]. N-acetyl neuraminic acid (Neu5Ac), 
L-fucose and sulfationated oligosaccharides were found to contribute to the binding 
[73-79]. 
In 1993 [80], P-selectin glycoprotein ligand-1 (PSGL-1) was discovered and is 
so far the best characterized natural P-selectin ligand. This 125 kDa glycoprotein 
forms dimers via a cysteine disulfide bridge and is also a natural ligand of E- and L-
selectin. Nevertheless, the interaction of PSGL-1 with L- and P-selectin required 
additional sulfation of the three N-terminal tyrosine residues [81,82]. Three natural 
ligands for E-selectin have been identified: E-selectin ligand-1 (ESL-1), a 150 kDa 
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non-sulfated N-linked glycoprotein ligand [83,84], PSGL-1 and carbohydrates motifs 
present on L-selectin of human neutrophiles [85]. 
 
Table 3. L-, P- and E-selectin natural ligands. Major ligands are highlighted on the figure adapted  
from Kneuer et al., shown below [86]. 
 
 L-selectin P-selectin E-selectin 
Natural 
Ligands 
• GlyCAM-1 
• CD-34 
• MAdCAM-1 
• podocalixin-like protein 
• endomucin 
• endoglycan 
•  PSGL-1 
• PSGL-1 
• Heat stable antigen (CD-
24) 
• ESL-1 
• PSGL-1 
• L-selectin 
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1.2.4.2  Sialyl Lewisx as a lead for selectin antagonists 
 
The tetrasaccharide sialyl Lewisx is the minimal carbohydrate epitope 
recognized by all three selectins [87,88]. Therefore, it serves as a lead structure in 
selectin antagonist research [89,90]. sLex exhibits a relatively low affinity for the 
selectins (in the mM range) as shown in Table 4 [90-92].   
 
Table 4. Affinity of sLex for E-, P- and L-selectin [28]. 
 
 E-selectin P-selectin L-selectin 
KD [µM] 100-2000 7800 3900 
IC50[µM] 100-750 520-1300 2300 
 
As for all the natural ligands of selectins, sLex exhibits fast association and 
dissociation constants (kon∼ 104 M-1s-1 and koff ∼ 1s-1) [93]. 
The essential pharmacophores of sLex were determined by studies of systematic 
variations of functional groups (Figure 8). These are: 
 
• Hydroxyl groups in 3- and 4-position of the fucose moiety [94,95] 
• Hydroxyl groups in 4- and 6-position of  galactose [96] 
• Carboxylic acid of neuraminic acid [95] 
 
 
 
 
 
 
 
 
Figure 8. Essential pharmacophores of sLex for the binding to E-selectin (in bold). 
 
Several studies showed that the D-GlcNAc moiety is not directly involved in 
the binding process [97,98]. D-GlcNAc serves as a spacer to optimally position the 
pharmacophores from L-fucose and the D-galactose for binding. 
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In order to develop low molecular weight antagonists starting from sLex as 
lead structure, a deeper understanding of the ligand-protein complex is mandatory. 
Data from NMR spectroscopy, X-ray crystallography and in-silico studies provides 
growing insight into this specific carbohydrate-protein interaction. Dr. D. Schwitzer 
and Dr. M. Porro gave an overview on this topic in their dissertations [99,100]. 
 
Computational studies and NMR experiments agreed in the conformational 
stability of the core of sLex in solution [101-107]. However, the co-existance of two 
orientations of Neu5Ac in solution is strongly suggested by the presence of NOE’s 
between the proton in the 3-position of galactose and the protons in 3- and 8-position 
of  Neu5Ac [105-107]. 
Structural information on the bioactive conformation was obtained in the 
presence of the protein by trNOE-NMR and STD-NMR experiments [108-110]. The 
pharmacophores of sLex in close contact with E-selectin are indicated in Figure 9.  
 
 
 
                           
 
 
 
 
          A                                                              B 
        
Figure 9. (A) Bioactive conformation of sLex from trNOE experiments [108-110]. NOE between proton 
in the 3-position of D-galactose and the 8-position of Neu5Ac are indicated with arrow. (B) Schematic 
view of the pharmacophores of sLex binding to E-selectin and part of the amino acid involved in the 
binding (specified under brackets, side chain (sc) or backbone (bb)).  
 
In 2000, Somers et al. published X-ray crystallography data of sLex  in complex 
with E- and P-selectin based on the crystal structure of the apoprotein published in 
1994. These data show the involvement of the hydroxyl in 3- and 4-position of  
fucose in complexing the calcium ion. In addition, the hydroxyl in the 2-position of 
fucose binds to Glu107 and Asn83 mediated by water molecule. Glu92 and Tyr94 appear 
to be involved in interactions with hydroxyl groups in the 5- and 6-position of 
H3 
H8 
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galactose. The carboxylate of neuraminic acid is involved in a tyrosine supported salt 
bridge with Arg97 and is the only contact of this moiety with the protein. Finally, the 
role of the D-GlcNAc moiety as a spacer was finally supported by the X-ray structure 
(Figure 10). 
 
 
 
Figure 10. Interaction between sialyl Lewis x and E-selectin highlighting the coordination of the 
calcium by D-fucose (top) and on the interactions from Neu5Ac-D-Gal (bottom) (adapted from Somers 
et al., 2000).  
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1.2.4.3 Recent advances in selectin antagonists  
 
An overview of selectin antagonists in preclinical and clinical trials was 
recently reported by Ernst and Magnani [111]. The numerous glycomimetic, low 
molecular weight antagonists of the selectins are based on sLex and are de novo 
synthesized. An exception is efomycine M (Figure 11), a natural product supposed to 
bind to the selectins. Efomycine, presented as a potential target in psoriasis 
treatment, is now in preclinical trials [112]. Nevertheless, a recent publication from 
Bonin et al. suggest a mode of action separate from pan-selectin inhibition [113]. 
Kaila et al. at Wyeth reported in 2005 the activity of quinic acid derivatives as new 
leads. As a continuity of this work, PSI-697 (Figure 11) was found and is currently in 
clinical development, although poor IC50s were reported (in the µM range) [114]. As a 
third example, of special relevance for this thesis, GMI-1070 (Figure 11) is a 
promising pan-selectin inhibitor based on sLex structure. In march 2009 the 
successful completion of Phase I clinical trials was announced showing the 
compounds safety and the positive pharmakinetic evaluation. This compound, 
developed by GlycoMimetics Inc. Gaithersburg, MD, USA in cooperation with the 
Institute of Molecular Pharmacy will enter this year in phase II clinical trials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Structure of GMI-1070, PSI-687 and efomycine M. 
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2. Aim of the thesis 
 
Selectins are a family of cell adhesion molecules involved in the inflammatory 
cascade, i.e. in the interaction of leukocytes with the endothelium. As a result, 
extravasation of leukocytes from the circulation to the site of inflammation is 
observed. Excessive extravasation of leukocytes as observed in inflammatory 
diseases is problematic. The modulation of leukocyte recruitment by interfering with 
cell tethering is therefore of therapeutical interest and selectins, involved in the early 
stage of the process, are a possible target. At the IMP, the selectin project is aimed 
at the synthesis of carbohydrate mimics antagonizing selectins.  
Sialyl Lewisx (sLex), the minimal carbohydrate epitope of the physiological E-
selectin ligand, has served as a starting point for the design of more potent selectin 
antagonists. In the literature, sLex and selectin ligands in general have been reported 
with various affinities as a result of the wide variety of biological in vitro and in vivo 
assays applied. As a result, the reported values display a large variance and make 
the comparison of antagonists synthesized almost impossible. Therefore, the 
necessity of an assay that delivers accurate affinity data was fundamental. SPR 
biosensor technology is an excellent method for that purpose. In addition to 
evaluating the potency of the antagonists, kinetic rate constants and thermodynamic 
parameters can be assessed leading to a more thorough understanding of the 
binding event. One aim of the thesis was to implement SPR technology into the 
ligand optimization process of E-selectin antagonists.  
In parallel, ligand-based NMR methods were planned for a further 
understanding of the physical basis responsible for the observed affinity. A particular 
focus was binding epitope studies by STD-NMR with the first generation of E-selectin 
antagonists synthesized at the IMP.  
By Biacore and NMR characterization of selectin/antagonist interactions, 
guidance for the design of the second generation of E-selectin ligands should be 
established.  
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3. Affinity and kinetic evaluation of the first generation of E-selectin 
antagonists using Biacore Technology  
 
3.1 Introduction 
 
3.1.1 Locked conformations: a successful strategy for development of 
selectin antagonists  
 
The optimization of ligands in a spatial pre-organization corresponding to the 
bioactive conformation is a well-known concept in medicinal chemistry. By reducing 
the entropic cost required for adopting the appropriate binding conformation, a higher 
binding affinity can be obtained. In 1993, Carver described a new approach that he 
called “site-directed presentation”. Based on the reduction of the flexibility of 
oligosaccharides, this mechanism should improve the affinity and the specificity 
towards their target [1]. Success of this approach was reported in many publications, 
including applications to HIV proteases inhibitors [2-5], as well as the stabilization of 
the bioactive conformation of a trisaccaride mimicking the LPS of bacteria to improve 
the binding of an antibody [3,4]. More recently, in 2006, Bastida et al. reported a new 
strategy for the design of aminoglycosides to overcome bacterial resistance by using 
conformationally locked compounds [6]. 
The development of selectin antagonists in our research group is based on the 
design of sLex mimics with preorganized pharmacophores [7].  In 1997, Kolb and 
Ernst reported the existence of a correlation between the affinity of E-selectin to sLex 
and the preferential conformation, predicted in-silico [8,9]. Later on, an agreement 
between computational predictions and the bioactive conformation determined by 
trNOE NMR was observed [10]. 
Following the idea of a pre-organization of the antagonists in their bioactive 
conformation, series of sLex mimics were synthesized with different strategies by Dr. 
D. Schwitzer and Dr. A. Titz during their Ph.D. studies [11,12]. Therefore, a 
compensation of the low enthalpic contributions would be obtained by reduction of 
the entropy costs [13].  In this chapter of the present thesis the development of a 
Biacore assay for the characterization of a first generation of more potent E-selectin 
antagonists is shown. Dr. Daniel Schwitzer synthesized the majority of these ligands 
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by focusing on minimizing the entropic costs upon binding by modifying substituents 
of the lead compound BW-69669 with the idea of a stabilization of the bioactive 
conformation. The Biacore assay developed allowed a direct evaluation of the 
improved potencies of the antagonists, in a real-time measurement format under flow 
conditions.   
 
3.1.2 Biacore Technology 
 
3.1.2.1 Surface plasmon resonance (SPR) phenomenon 
 
The Biacore system uses a detection principle based on the phenomenon of 
surface plasmon resonance. Sensor chip chemistry and an integrated flow system 
allow real-time detection of molecular interactions on the sensor surface. Surface 
plasmon resonance arises as a result of an electron charge density wave and is 
based on total internal reflexion (TIR), an evanescence electric field (E) and surface 
plasmon waves.  A light beam that propagates through two non-absorbing media of 
different refractive indeces will only be totally reflected at the interface at a critical 
incidence angle (θ). When this angle is exceeded, the energy of the refracted light 
beam is kept constant but an electric field intensity called evanescence wave (E) 
leaks into the medium of lower refractive index. E decreases exponentially with the 
distance to the surface. The presence of a thin metal film (usually a non-magnetic 
metal like gold) at the interface induces the excitation of surface plasmons when E 
penetrates this layer. Surface plasmons are waves of oscillating surface charge 
densities in a conducting metal. Resonance occurs for a specific incidence angle and 
leads to a drop in the intensity of the reflected light [14,15].  
In an experimental setup, resonance is only dependent of the angle of the 
incident light and the refractive index of the second medium. Biosensors monitor 
changes in refractive index of the solution very near to the surface by adjusting the 
incident light angle until resonance is detectable [16-18]. Such a change is converted 
into a response signal measured in resonance units (RU) that corresponds to a shift 
in the resonance angle of 10-4 degree [17]. The measurement of a biomolecular 
interaction by SPR is based on the fact that binding of molecules to the surface alters 
the refractive index. Indeed, the mass of the molecules directly influences the 
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refractive index (1 RU = 1pg/mm2 in the case of proteins) [18]. The sensitivity of the 
detection depends on: 
 
• the type of ligands, 
• the distance from the surface (due to the exponential decay of E), 
• effects occurring around the interface (e.g. electrostatic attraction, 
conformational changes). 
 
3.1.2.2 Typical Biacore experiment 
 
In a typical Biacore experiment, one binding partner is immobilized on the 
sensor chip (name as target) and the other is injected (name as ligand or analyte) 
(Figure 1). 
 
 
 
 
Figure 1. Schematic overview of the experiemental set-up of a Biacore 3000. The SPR-based 
detection mode (schematized on the right) allows to monitor the binding of an analyte to the target in 
real-time. 
 
Different types of molecules can be immobilized on the biosensor surface 
(oligosaccharides, nucleotides, proteins). In the following, I will focus on an assay 
involving a protein as a target immobilized on a CM5 sensorchip. The CM5 is the 
most frequently used, commercially available biosensor chip. In such a surface, a 
protecting polymer made from carboxymethyl dextran chains covers a gold layer in 
order to limit non-specific binding to the gold surface and to facilitate immobilization. 
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The immobilization of a protein is a crucial step in a Biacore assay, because 
the natural folding and the binding affinity must be retained. Two parameters of the 
immobilization have to be considered: the orientation (random or site-specific) and 
the type of linkage (covalent or non-covalent) [19]. Random and covalent coupling 
usually generates stable surfaces with high density. In the covalent coupling 
approach, functional groups of the target are utilized to form covalent bonds (e.g. 
amine, hydroxy, thiol). The randomization of the attachment, due to multiple 
immobilization sites, might result in a loss of activity due to involvement of amino 
acids in or close to the binding site, conformational changes and/or steric hindrance.  
 
Amine coupling is the most frequently used immobilization technique for 
proteins due to the high availability of accessible primary amine groups on protein 
surfaces  (lysine resides and N-terminus) (Figure 2A).  In a first step, the carboxyl 
groups of the dextran matrix are activated by N-hydroxysuccinimide (NHS) / 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC), leading to reactive esters. Then, 
these reactive esters react with accessible primary amino groups of the protein 
resulting in a covalent coupling. The efficiency of the process is increased by working 
at a pH just below the pI of the protein inducing an optimum surface attraction. At that 
pH, only small fraction of the primary amines are deprotonated. The protonated 
amines cannot react with the activated esters of the dextran matrix but interact with 
the negative charges of the matrix. Only the deprotonated amino groups are 
available for the covalent coupling [20].  
 
Thiol coupling could be used for a direct immobilization of protein with a more 
defined orientation due to the lower abundance of cysteine residues in proteins 
compared to amino groups. Finally, aldehyde coupling is used in some studies, since 
it offers a possibility for direct immobilization. These groups can be natively present 
on carbohydrate residues of the protein or can be artificially introduced. Therefore, 
this coupling mode enables a better-oriented immobilization. 
 
Another approach for the immobilization is the capture approach based on a 
specific biomolecular interaction between the target and a high affinity capturing 
molecule covalently immobilized on the surface (Figure 2B). This approach leads to a 
site-oriented immobilization. Three major classes of capture can be described: 
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antibody-antigens, protein-natural ligand and capture via introduction of an affinity 
tag. The disadvantage of these methods is the non-covalent character of the 
immobilization that can lead to instability of the surface. Indeed, bleeding of the 
surface is frequently observed and can significantly influence the quality of the data, 
especially in the case of low molecular weight ligand characterization with low signal 
intensities. One non-negligible advantage is the possibility of regeneration of the 
surface, which reduces the amount of sensor chips needed and ensure a good 
quality of the target throughout the studies. However, as it will be shown in this work, 
the regeneration of capture surface is not always possible.  
 
To overcome the instability of capture surfaces, the use of a crosslink capture 
method was suggested (Figure 2C).  In this approach, the target is covalently linked 
to the intermediate of immobilization [21].  
 
 
 
 
 
 
 
Figure 2. Different possibilities for target immobilization. A: Direct immobilization (e.g. via amine 
coupling); B: capture assay via a high-affinity capturing molecule; C: crosslink capture assay. 
 
Frequently, in drug discovery large molecules (e.g. proteins) are immobilized 
and small ligands are screened resulting in low signal intensity. Different approaches 
can ameliorate insufficient signal intensities, such as attaching the small ligand on 
the surface and injecting the large molecule [22] or performing a competitive assay 
[23]. Unfortunately, both alternatives contain disadvantages e.g. the higher protein 
consumption. Non-specific binding cannot be avoided in either of the assay formats 
previously described. In addition, the problem of mass transport is a factor that 
complicates the measurement [24,25]. This phenomenon might occur, when the 
interaction between ligand and target is comparable or faster than the diffusion of the 
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ligand from the bulk solvent to the surface. Increasing on the flow rate and reducing 
the surface density can reduce mass transport effects. 
 
In summary, each immobilization strategy presents advantages and 
disadvantages. The Biacore technology offers a broad range of alternative 
immobilization procedures and for every target the most appropriate should be 
carefully selected. 
 
As described above, when a ligand is injected onto the surface, a shift in the 
resonance angle is monitored in real time. The plot of the signal versus time is called 
a sensorgram and the different phases of a binding event can be visualized on it: 
association, steady-state, dissociation and regeneration (Figure 3A-D). The steady 
state is reached when associating and dissociating molecules are in equilibrium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Typical sensorgram obtained for a standard interaction measurement. The different phases 
of the binding are indicated: the injected ligand starts to bind to the target (A) until reaching a steady-
state (B). When the injection of the ligand is interrupted and replace by running buffer, the dissociation 
of the ligand becomes visible (C). The regeneration step (D) is needed only if remaining ligand has to 
be removed from the surface. 
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3.1.2.3 Kinetic and affinity evaluation 
 
Proper data evaluation and interpretation is critical, especially when measuring 
low molecular weight compounds like carbohydrates. There is a risk of fitting data 
that deviates from an expected model (e.g. due to poor experimental design, low 
purity of ligands and/or target heterogeneity) with a more complex model [26,27]. 
Therefore, assay design should be kept easy and data fit with a simple 1:1 binding 
model should be the method of choice in a first attempt [Eq. (1)].  
 
             A + B                   AB                              (1) 
 
The 1:1 binding model can be extended to 1:2 binding site model and, if 
suspected or reported, a mass transfer coefficient might be introduced. A global 
analysis approach is implemented in the Scrubber software package and provides 
accurate and robust results by fitting simultaneously the association and dissociation 
phases of the entire data set [28]. The equilibrium binding constant is accessible 
from two approaches: 
 
• The kinetic rate constant ratio [Eq. (2)] 
 
  
! 
KD =  koff
kon
M[ ] and KA =  kon
koff
M-1[ ]              (2) 
 
• Steady state signals at different concentrations using the saturation binding 
plot [Eq. (3)] 
 
  
! 
Req =  KA •  C  • Rmax
1 +  KA  • C • n( )
RU[ ]                       (3) 
 
Req: equilibrium response signal, Rmax: maximum response, C: concentration, KA: equilibrium 
association constant, n: steric interference factor  
 
The possibility to assess specificity, affinity and kinetics is of particular interest, 
placing SPR as an indispensable tool in drug discovery. In the traditional drug 
kon 
koff 
 
 
45 
discovery process, high throughput screening (HTS) is used for the identification of 
new lead compounds. To be identified as a hit, molecules must preferably fulfill 
criterions like specificity, low affinity, low molecular weight (LMW), low molecular 
complexity [29], small number of rings [30], small number of rotatable bonds [30],and 
low polarity [31]. After validation, the optimization of the pharmacokinetic and 
pharmacodynamic profile is performed via structure–based drug design in medicinal 
chemistry [32]. In the two steps previously described, compounds are rated by an in 
vitro evaluation of their affinity for the target (KD or IC50). This is not representative of 
an in vivo environment where the kinetics of the interaction ought to play an 
important role. Having early information on the kinetics of the lead molecule could 
reduce attrition rates in later stages of the drug development process, which is 
economically highly desired. Indeed, a long residence time of the drug-target binary 
complex characterized by the dissociation half-life (t1/2) is reported as beneficial for 
pharmacological profiles [33]. Prolonged drug-target dissociation times enable 
dosage reduction, which is an effective gain for drug discovery. In a Biacore analysis, 
molecules can be rated according to their affinity and kinetic parameters, both 
accessible from the sensorgrams. Therefore, compounds exhibiting an identical 
affinity (KD) can show completely different binding kinetics. The high degree of 
reproducibility and the close agreement with other techniques such as analytical 
ultracentrifugation (AUC), stop-flow fluorescence (SFF) and isothermal titration 
calorimetry (ITC) for kinetic as well as for thermodynamic parameter are the main 
reason for the important role Biacore plays in the drug discovery process [34,35]. 
Nevertheless, it has to be mentioned that immobilization of a target is a critical and 
delicate step that has to be designed properly for each assay. A disadvantage of 
working with immobilized target is the risk of restriction in rotational freedom and 
accessibility of the binding site that can influence affinity and kinetics [33]. 
 
3.1.3 Structure of E-selectin/IgG and LecEGF_CR2 constructs 
 
E-selectin/IgG was produced in Chinese hamster ovary (CHO-K1) cells kindly 
provided by Dr. Frank Kolbinger from Novartis (Basel, Switzerland). The E-selectin 
construct consists of the C-type lectin domain (Lec domain), the epidermal growth 
factor (EGF) domain and six consensus repeats (CRs) of human selectin fused to a 
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human IgG1 (Fc part) tail (Figure 4A and B). The fused Fc region is part of the 
human immunoglubulin G type 1. The human immunoglobulin G contains two light 
(L) and two heavy chains (H). Each heavy chain is composed of four units: one 
variable (VH) and three constant (CH1, CH2 and CH3). A hinge region exists between 
CH1 and CH2. This flexible area contains the cleavage site of papain (Figure 4A). E-
selectin/IgG contains the hinge region, CH2 and CH3 domains (Figure 4B). The 
theoretical molecular weight of the chimeric protein is 86.7 kDa. Because of a high 
degree of glycosylation, the observed molecular weight was evaluated to be 148 
kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Structure of wild-type selectin (A), E-selectin/IgG construct (B) and LecEGF_CR2 construct 
(C) produced in CHO-K1 cells.  
 
The LecEGF_CR2 construct (Figure 4C and 5C) was also produced in CHO-
K1 cells. Cell transformation, culture and LecEGF_CR2 purification were done in 
house by Roland Preston. LecEGF_CR2 construct consist of the lectin domain 
followed by the EGF domain and two CRs. The theoretical molecular weight of the 
chimera protein is 31.3 kDa. Because of a high degree of glycosylation, the observed 
molecular weight was evaluated to 70 kDa by SDS-PAGE electrophoresis under 
denaturated conditions. 
C-type lectin domain
C-type lectin domain
C-type lectin domain
EGF
EGF
EGF
CRs
6 x CRs
2 x CRs
Transmembrane 
domain
Cytoplasmic 
domain
NH2
NH2
NH2
IgG (Fc)
COOH
COOH
COOH
120 36 63 23 17-35Residues
A
B
C
120 36 388 236Residues
120 36 129Residues
 
 
47 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Representative structure of human immunoglobulin G (A), E-selectin/IgG (B) and 
LecEGF_CR2 construct (C). 
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3.2 Materials and Methods 
 
For all ligands measured, the chemical structure can be found in Appendix III.  
 
3.2.1 Biacore 
 
Instrumentation  
 
Biomolecular interaction analyses by surface plasmon resonance (SPR) were 
performed on a Biacore® 3000 system (GE Healthcare, Upsalaa, Sweden). All vials, 
caps and other consumables were purchased by GE Healthcare. Research grade 
CM5 sensor chips were used in all analyses (GE Healthcare, Freiburg, Germany). 
Desorb and sanitize procedures were regularly performed in accordance to 
manufacturer recommendations as well as an annual check by a service technician.  
 
Reagents 
 
Immobilization buffers (10 mM sodium acetate at pH values of 4.0, 4.5, 5.0 
and 5.5), BIAdisinfectant solutions, normalizing solutions, BIAdesorb solutions and 
amine coupling kit including ready-to-use EDC, NHS and ethanolamine were 
purchased from GE Healthcare.  
HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.005% polysorbate 20 (v/v), pH 
7.4) ready-to-use was purchased from GE Healthcare and used as the running buffer 
in all the immobilization procedures. For the interaction analyses, 5% DMSO (v/v) 
(D8418, Sigma-Aldrich Chemie, Steinheim, Germany) and 20 mM calcium chloride 
(C3306, Sigma-Aldrich Chemie, Steinheim, Germany) were added to HBS-P buffer. 
This running buffer was filtrated (using nitrocellulose membranes with a pore size of 
0.44 µm) before adding DMSO and degazed [ultrasonic bath for 10 min under 
reduced pressure (50 mbar)].  
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Software  
 
Data were processed with Scrubber-2.0a (BioLogic Software Pty Ltd., 
Campbell, Australia).  Equilibrium binding constants were determined using a simple 
steady-state affinity 1:1 binding model. Kinetic data were also fit with Scrubber-2.0a. 
Double referencing was applied to correct bulk effects and other systematic artifacts 
(subtraction of reference surface and blank injection) [36]. 
 
3.2.2 Expression and purification of E-selectin/IgG  
 
CHO-K1 cells were transformed with the cloned gene of E-selectin/IgG 
(Appendix I) in the laboratory of Dr. Frank Kolbinger from Novartis (Basel, 
Switzerland) [37,38]. Cell culture and purification of E-selectin/IgG were done in-
house by Katrin Lemme and Dr. Said Rabbani.  Cells were cultivated at 37 °C with 5 
% CO2 and 80 – 90% humidity in TC-Flask NunclonTM Δ Surface (NuncTM, Rochester, 
NY). The culture medium was Ham’s Nutriment Mixture F-12 with L-glutamine 
(GIBCO® Invitrogen, Switzerland) supplemented with Fetal Calf Serum (GIBCO® 
Invitrogen, Switzerland) 10% (v/v), Penicillin 50 000 U (10 000 U/ml Sigma-Aldrich, 
Switzerland) and Streptomycin (10 mg/ml Sigma-Aldrich, Switzerland) 50 mg. The 
medium from CHO-K1 cell culture containing the secreted E-selectin/IgG was 
collected weekly and filtrated through a 0.45 µm sterile filter. The protein was purified 
in two steps by Fast Protein Liquid Chromatography (FPLC-apparatus Biologic-HR 
from Bio-Rad) at 4 °C.  The first affinity chromatography was performed with a 
protein A column (HiTrapTM protein A HP from GE Healthcare, Switzerland) following 
standard procedure from the manufacturer [39].  In a second purification step, the 
monoclonal anti-E-selectin blocking antibody 7A9 was used as a ligand in the 
stationary phase. This antibody was expressed in B lymphocyte hybridoma cells (HB-
10135, ATCC®, Otsuka Pharmaceutical Co., Japan) and purified at the IMP by Dr. 
Jing Yu [40]. The 7A9 was coupled to cyanogen bromide activated sepharose 
(Cyanogen bromide-activated-Sepharose® 4B, Sigma Aldrich, Buchs, Switzerland) 
according to the manufacturer’s protocol [41]. After elution, the pH was adjusted to 
pH 7 with 2.5 M Tris buffer and cooled on ice. For both chromatography, proteins 
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were detected at 280 nm and the progress was controlled by Biologic HR software 
(version 2.10, Bio-Rad). The eluted E-selectin/IgG was concentrated using centrifugal 
filter devices (Amicon® Ultra–4, 10k molecular weight cut-off from Millipore 
Corporation, Billerica, MA, USA) at 6’000 rpm at 4 °C.   
SDS-PAGE and Coomassie Brillant Blue Staining were used to check the 
purity of the E-selectin/IgG. Western-blot analysis for a specific detection of E-
selectin/IgG was also performed [42-44]. The concentration of E-selectin/IgG was 
determined by Bradford Protein Assay (BPA) [45] and/or High Pressure Liquid 
Chromatography (HPLC) [46].  The HPLC measurement was performed on an HPLC 
system  Model 2695 (Waters Alliance, Milford, MA) employing a 100 x 2 mm column 
packed with POROS R1/10 (Dr. Maisch HPLC, Morvay Analytic GmbH, Basel, 
Switzerland). The column was kept at 60 °C. Eluant A was water containing 0.1% 
TFA. Eluant B was a 1:9 mixture of water:aceonitrile containing 0.09% TFA. A 
gradient from 20% B to 90% B was run for 20 min at a flow rate of 0.2 ml/min. UV 
detection was performed at 214 nm and the progress was controlled using Empower 
Pro software. 
Figure 6A shows a single band below 150 kDa on the SDS-PAGE. The 
Western-blot analysis (Figure 6B) confirmed that the protein isolated was E-
selectin/IgG.  
 
 
 
 
 
 
 
 
 
 
Figure 6: SDS-PAGE (A) and Western-blot (B) of E-selectin/IgG after purification. 
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3.2.3 Expression and purification of LecEGF_CR2 construct 
 
 CHO-K1 cells were transformed with the cloned gene for the LecEGF_CR2 
construct (Appendix II). Cloning, expression and purification of LecEGF_CR2 
construct was done in-house by Roland Preston [44]. The methods to produce this 
protein were similar to those previously described for E-selectin/IgG construct (see 
section 3.2.2). In contrast to the purification procedure used for the E-selectin/IgG 
construct, only a one-step affinity chromatography on a 7A9 antibody substituted 
column was performed for purification. 
 
3.2.4 Direct amine coupling of E-selectin/IgG 
 
pH scouting  
 
A pH scouting was performed in order to evaluate the pH dependence for an 
optimal immobilization of E-selectin/IgG onto the biosensor surface.  E-selectin/IgG 
was diluted to a concentration of 40 µg/ml with different acetate buffers (10 mM, pH 
4.0, 4.5, 5.0 and 5.5) or HBS-N buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) 
purchased from GE Healthcare. These solutions were sequentially injected over a 
CM5 sensor chip for 3 min at a flow rate of 10 µl/min. A 50 mM NaOH solution was 
injected for 30 sec at a flow rate of 20 µl/min in order to wash the surface between 
each sample injection. An optimal attraction of E-selectin/IgG to the surface was 
observed at pH 5.0.  
 
Immobilization procedure  
 
A preconditioning of the surface was achieved prior to usage by injecting 
successively 20 µl of 50 mM NaOH, 10 mM HCl, 0.1% SDS and 100 mM H3PO4 at a 
flow rate of 50 µl/min. The cycle of injections was repeated twice. After 
preconditioning, the sensor chip was used within the next four hours for the 
immobilization. 
HBS-P buffer was used as running buffer for the amine coupling procedure. 
The carboxy groups of the dextran matrix of the CM5 sensor chip were activated for 
10 min with a 1:1 mixture of 0.1 M 3-(N,N-dimethylamino)propyl-N-ethylcarbo-diimide 
 
 
52 
(EDC), and 0.1 M N-hydroxysuccinimide (NHS) at a flow rate of 10 µl/min. This 
activation step produced reactive succinimide esters on the CM5 surface. A stock 
solution of E-selectin/IgG (0.4 mg/ml in 50 mM Tris buffer, 150 mM sodium chloride, 
pH 7.6) was diluted to 40 µg/ml in 10 mM sodium acetate buffer pH 5.0. Injection of 
100 µl of the 40 µg/ml solution was performed onto the activated surface at a flow 
rate of 10 µl/min. A surface capacity of 7’500 RU of E-selectin/IgG was achieved. 
Finally, the residual activated sites of the surface were blocked by injection of 1 M 
ethanolamine•HCl, pH 8.0. The flow path was changed to the reference flow cell. The 
same protocol was applied without injection of E-selectin/IgG sample to prepare a 
reference surface.  
 
Assay validation 
 
DS-04115 was synthesized in-house by Dr. Daniel Schwitzer [47] and used as 
a test compound for the validation of the assay. A 20 mM stock solution was 
prepared in HBS-N buffer. 
HBS-P buffer was supplemented with 20 mM calcium chloride and used for all 
interaction experiments. In order to evaluate the binding affinity, a serial dilution of a 
broad range of concentrations starting at 8 mM was injected at a flow rate of 20 
µl/min for 1 minute. Analysis of the data was accomplished with Scrubber (version 
2.0a). Five buffer blanks preceded the injection of the serial dilution. One buffer blank 
was also injected at the end of the run.  
 
3.2.5 Capture-based assay format 
 
3.2.5.1 Preparation of protein A surface 
 
Staphylococcus protein A was purchased from Sigma (P6031, Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland) and the amine coupling kit from GE Healthcare. 
The kit included all reagents needed for the immobilization procedure [N-
hydroxysuccinimide (NHS), 3-(N,N-dimethylamino)propyl-N-ethylcarbo-diimide 
(EDC), ethanolamine•HCl (EA)]. 
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Concentration and pH scouting of protein A 
 
Stock solution of protein A was prepared by dissolving 1 mg lyophilized protein 
in 1 ml water. pH and concentration scouting were performed in order to evaluate the 
pH and concentration dependence for an optimum immobilization of protein A onto 
the biosensor surface.  Protein A was diluted to a 40 µg/ml concentration with 
different acetate buffers (10 mM, pH 4.0, 4.5, 5.0 and 5.5) or HBS-N buffer (10 mM 
HEPES, 150 mM NaCl, pH 7.4) purchased from GE Healthcare. These solutions 
were sequentially injected over a CM5 sensor chip for 3 min at a flow rate of 10 
µl/min. A 50 mM NaOH solution was injected for 30 sec at a flow rate of 20 µl/min in 
order to wash the surface between each sample injection. The best interaction 
between the dextran matrix of the biosensor surface and protein A was observed at 
pH 5.0. Therefore, the concentration scouting was performed by injection of a serial 
dilution of protein A (10, 20 and 40 µg/ml) in acetate buffer, pH 5.0. The same 
injection parameters as those used for the pH scouting were applied and 30 µg/ml 
was a suitable concentration to achieve appropriate level of immobilization. 
 
Immobilization procedure of protein A  
 
Two cycles of injections prior to usage were done for the preconditioning of the 
surface. The cycle consisting of successive injections of 20 µl of 50 mM NaOH, 10 
mM HCl, 0.1% SDS and 100 mM H3PO4 at a flow rate of 50 µl/min were performed. 
After preconditioning, the sensor chip was used within the next four hours for the 
immobilization. 
HBS-P buffer was used as running buffer for the amine coupling procedure. 
The carboxy groups of the dextran matrix of the CM5 sensor chip were activated for 
10 min with a 1:1 mixture of 0.1 M 3-(N,N-dimethylamino)propyl-N-ethylcarbo-diimide 
(EDC), and 0.1 M N-hydroxysuccinimide (NHS) at a flow rate of 10 µl/min.  A stock 
solution of protein A (1 mg/ml in 50mM phosphate buffer, pH 7.0) was diluted to 30 
µg/ml in 10 mM sodium acetate buffer pH 5.0. Injection of 100µl of the prepared 
dilution was performed onto the activated surface at a flow rate of 10 µl/min. Surface 
capacities of protein A from 6’800 to 7’800 RU were achieved. Finally, the residual 
activated sites of the surface were blocked by injection of 1 M ethanolamine HCl, pH 
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8.0. The same protocol was applied with a protein A sample prepared sequentially or 
in parallel and used to prepare a reference surface.  
 
3.2.5.2 Preparation of anti-human IgG (Fc specific) surface 
 
Polyclonal goat anti-human IgG (Fc specific) was purchased from Sigma 
(I2136, Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and the amine coupling kit 
from GE Healthcare. 
 
Concentration and pH scouting of anti-human IgG 
 
A 2.1 mg/ml stock solution of antibody anti-human IgG in 10 mM phosphate 
buffer, pH 7.0 containing 15 mM sodium azide was used for scouting procedures. 
Both pH and concentration scouting assays were performed in order to evaluate the 
optimal immobilization conditions for anti-human IgG onto the biosensor surface.  
Anti-human IgG was diluted to a 42 µg/ml concentration with different acetate buffers 
(10 mM, pH 4.0, 4.5, 5.0 and 5.5) or HBS-N buffer (10 mM HEPES, 150 mM NaCl, 
pH 7.4) purchased from GE Healthcare. These solutions were sequentially injected 
over a CM5 sensor chip for 3 min at a flow rate of 10 µl/min. A 50 mM NaOH solution 
was injected for 30 sec at a flow rate of 20 µl/min in order to wash the surface 
between each sample injection. The same cycle of injection was repeated with a 14 
µg/ml sample of anti-human IgG diluted in acetate buffers (10 mM, pH 4.0, 4.5, 5.0 
and 5.5). For both, the 42 µg/ml and the 14 µg/ml concentrations, the best interaction 
between the dextran matrix of the biosensor surface and anti-human IgG was 
observed at pH 5.5. Therefore, the concentration scouting was performed by injection 
of dilutions of anti-human IgG (7, 21 and 30 µg/ml) in acetate buffer, pH 5.5. The 
same injection parameters as those used for the pH scouting were applied. 
 
Immobilization procedure of anti-human IgG 
 
The preconditioning of the surface prior to usage and the activation of the CM5 
sensor chip surface was done as previously described in section 3.2.5.1 for the 
protein A immobilization procedure.  
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HBS-P buffer was used as running buffer for the amine coupling procedure. A 
stock solution of anti-human IgG (2.1 mg/ml) was diluted to 21 µg/ml in 10 mM 
sodium acetate buffer pH 5.0. A hundred microliter of the 21 µg/ml solution was 
injected onto the activated surface at a flow rate of 10 µl/min. Surface capacities of 
anti-human IgG from 14’000 to 16’000 RU were achieved. Finally, the residual 
activated sites of the surface were blocked by injection of 1 M ethanolamine•HCl, pH 
8.0. The same protocol was applied with a anti-human IgG sample prepared 
sequentially or in parallel and used to prepare a reference surface.  
 
3.2.5.3 Capture of E-selectin/IgG on protein A or E-selectin IgG surface 
 
Following the protein A or anti-human IgG coupling, the flow path was 
changed to exclude the reference flow cell containing only protein A. E-selectin/IgG 
was diluted to a 50 µg/ml concentration using 10 mM acetate buffer, pH 5.5. This 
solution was injected at a flow rate of 5 µl/min for 20 min over a single flow-cell, 
designated the active flow cell. Densities of approximately 7’800 RU of E-selectin/IgG 
were achieved on the protein A surface and approximatly 9’000 RU on the anti-
human IgG surface. The active and reference flow cells were equilibrated for twelve 
hours in HBS-P buffer containing 20 mM calcium chloride at a flow rate of 2 µl/min. 
The surface was equilibrated in HBS-P buffer supplemented with 20 mM calcium 
chloride (C3306, Sigma-Aldrich Chemie, Steinheim, Germany) at a flow rate of 2 
µl/min for twelve hours. After usage, the chip was stored in HBS-P buffer containing 
20 mM calcium chloride at 4°C. 
 
3.2.5.4 Validation of the capture-based assay 
 
Compounds were synthesized in-house by Dr. Daniel Schwitzer [47], Jonas 
Egger [48] and Bea Wagner and dissolved to prepare a 50 mM stock solution in 
DMSO. For all compounds tested, the chemical structure are displayed in Appendix 
III. 
GMI-1077 and DS-0548 were used as test compounds for the validation of the 
capture assay. These compound were analyzed in a static cell-free ligand binding 
assay (Dr. John L. Magnani, Glycomimetics Inc., Rockville, USA) [49,50]. In this 
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assay, the inhibition of E-selectin was measured under equilibrium conditions. E-
selectin/IgG was coated on a 96 well plate and a weak binder competed with sialyl 
Lewisa polymer coupled to horseradish peroxydase (sLea-PAA-biotin/SA-HRP). IC50 
were standardized to the value of BW-69669 measured in parallel on the same plate. 
This standardization avoids fluctuation of IC50 values due to variations in the well 
plate. Affinity values are expressed in relative IC50 (rIC50) after normalization to sialyl 
Lewisx (sLe x), which was taken as a reference compound with an IC50 of 1 mM (rIC50 
= 1.0). rIC50 values of 0.080 for BW-69669, 0.008 for DS-0548 and 0.004 for GMI-
1077 were obtained. Stock solutions of compounds (50 mM) were prepared in DMSO 
(Sigma-Aldrich Chemie, Steinheim, Germany). 
HBS-P buffer supplemented with 20 mM calcium chloride and 5% DMSO (v/v) 
was used for all Biacore experiments. In order to evaluate the binding affinity, a serial 
dilution with a broad range of concentrations starting at 0.5 mM was injected at a flow 
rate of 20 µl/min for one minute. Following the assay with a broad range of 
concentrations, nine concentrations, optimized based on the rough estimate of the 
affinity constant, of a twofold dilution of ligand was randomly injected in duplicate. 
Determination of the affinity constant was accomplished in Scrubber (version 2.0a) 
after double referencing (against buffer blank and reference flow cell) and a solvent 
correction. The KD was derived from the equilibrium binding response by applying a 
single-site model with a 1:1 binding event.  
 
3.2.5.5 Evaluation of the surface activity 
 
The maximum response for a SPR signal can be calculated using Eq. (4): 
 
          
  
! 
Rmax = MWanalyte
MWtarget
•densitytarget • valency                               (4)  
 
Table 1 summarizes parameters of the equation that differs according to the 
format of the biacore assay.  
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Table 1. Parameters of equation 1 according to different Biacore assay format. 
 
 
The surface activity corresponds to the ratio Rmax(experimental) /Rmax (calculated) 
 
3.2.5.6 DMSO tolerability 
 
DMSO was purchased from Sigma (Sigma-Aldrich Chemie, Steinheim, 
Germany) and stored in a desiccator. A stock solution of 50 mM in DMSO was 
prepared for all the ligands. The stock solutions were prepared and stored in 
polypropylene tubes (Treff AG, Degersheim, Switzerland), which are compatible with 
this solvent. A concentration of 5% DMSO (v/v) was maintained constant in the 
running buffer (HBS-P, 20 mM calcium chloride, 5% DMSO) and the ligands dilutions.   
To take into account and eliminate the effect of the high refractive index of DMSO on 
the signals, a calibration curve was needed [51]. Two solutions were prepared: 
solution A (1 ml of running buffer + 50 µl HBS-P containing 20 mM calcium chloride) 
and solution B (1 ml of running buffer + 1 µl of DMSO). 
Solutions A and B were mixed in different proportions to prepare a series of 
five calibration solutions (Table 2) containing an increasing amount of DMSO 
[respectively 4.76%, 4.84%, 4.93%, 5.01% and 5.09% (v/v)]. 
 
Table 2. Calibration solutions of DMSO. 
 
 1 2 3 4 5 
A (µl) 400 300 200 100 0 
B (µl) 0 100 200 300 400 
 
Biacore assay MWtarget densitytarget valency 
Direct amine coupling 
 
MWE-selectin/IgG density E-selectin/IgG 2 
Capture assay via protein A 
 
MWE-selectin/IgG + 
MWproteinA 
density E-selectin/IgG + 
densityproteinA 
2 
Capture assay via anti-human 
IgG 
 
MWE-selectin/IgG + 
MWanti-human IgG 
densityE-selectin/IgG + 
densityanti-human IgG 
4 
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DMSO calibration solutions were injected prior to each assay. Five blank 
buffer injections preceded and 1 blank buffer followed the injection of the DMSO 
calibration solutions. 
 
3.2.5.7 Evaluation of synthesized E-selectin antagonists  
 
Based on the lead structure BW-69669 [52], several derivatives were 
synthesized in -house by Dr. Daniel Schwitzer, Jonas Egger and Beatrice Wagner in 
order to stabilize the bioactive conformation of the ligand in solution. Two capture-
based assays for the immobilization of E-selectin/IgG were established and validated 
(see section 3.2.5). Improvement of the potency of the ligands was evaluated with 
the capture assay, which used anti-human IgG to immobilize the E-selectin/IgG. 
Stock solutions of ligands (50 mM) were prepared. The KD values obtained with 
Biacore were compared to rIC50 values obtained from the static cell-free ligand 
binding assay.  
A CM5 sensor chip was prepared as described in section 3.2.5. Binding 
experiments were performed in HBS-P buffer supplemented with 20 mM calcium 
chloride and 5% DMSO. Prior to compound evaluation, the surface was equilibrated 
in HBS-P buffer supplemented with 20 mM calcium chloride and 5% DMSO (v/v) 
(D8418, Sigma-Aldrich Chemie, Steinheim, Germany) at a flow rate of 5 µl/min for 
four hours. 
For each experiment, ten twofold dilutions of the ligand were randomly 
injected. For the initial determination of ligand binding isotherms, each concentration 
was injected in duplicate or triplicate. In later studies, to increase the throughput, two 
to three concentrations per assay were repeated in duplicate.  DS-0565 and GMI-
1077 were chosen as reference compounds. The stability of the surface after 
immobilization and its use to determine binding constants was followed by injection of 
ten twofold dilutions of a reference compound. Prior to each assay, DMSO solutions 
and blank injection of buffer were performed as described in section 3.2.4.6. After 
usage, the chip was stored in HBS-P buffer containing 20 mM calcium chloride at 
4°C. 
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3.2.6 Thermodynamic analyses 
 
Enthalpic and entropic contributions were determined for a better 
characterization and understanding of the binding affinity of carbohydrate mimics to 
E-selectin. A set of four ligands DS-04115, GMI-1077, DS-0565 and DS-0567 was 
selected based on their structural properties and affinity (Table 3). 
 
Table 3. Structure, rIC50 (determined by static cell-free assay) and KD (mean value, Biacore) of DS-
04115, GMI-1077, DS-0565 and DS-0567. The general structure of BW-69669 derivatives is shown 
below. 
 
Compound R2 R3 
rIC50 competitive 
binding assay 
GMI, ref. sLex 
KD [µM] 
[Biacore] 
 
DS-04115 H Methyl 0.016 7.89 
GMI-1077 Benzoate Methyl 0.004 1.45 
DS-0567 Benzoate Ethyl 0.007 1.49 
DS-0565 Benzoate Cyclopropyl 0.032 5.36 
 
 
 
 
 
 
All ligands were measured at several temperatures between 10 and 30 °C and 
evaluated by applying a van’t Hoff plot [53]. The E-selectin/IgG was captured on an 
anti-human IgG surface as described in section 3.2.5.2 and 3.2.5.3. The binding 
analyses were carried out as described in section 3.2.5.7. The Biacore 3000 was 
stabilized over night for each measured temperature. 
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3.2.7 Reverse assay: immobilization of an E-selectin antagonist onto the 
sensor chip surface 
 
Immobilization of JE-14 
 
JE-14 was synthesized in-house by Jonas Egger and designed to be coupled 
to the biosensor surface via amine coupling.  
Two cycle of injection prior to usage were done for the preconditioning of the 
surface. Successive injections of 20 µl of 50 mM NaOH, 10 mM HCl, 0.1% SDS and 
100 mM H3PO4 at a flow rate of 50 µl/min were performed. After preconditioning, the 
sensor chip was used within the next four hours for the immobilization. HBS-P buffer 
was used as running buffer for the amine coupling procedure. A reference flow cell 
was first prepared by activation of the carboxy groups of the dextran matrix of the 
CM5 sensor chip with a 1:1 mixture EDC/NHS at a flow rate of 10 µl/min for 10 
minutes. Afterwards, the residual activated sites of the surface were immediately 
blocked by injection of 1 M ethanolamine•HCl (EA), pH 8.0.  
The flow path was changed to exclude the reference flow cell. A mixture of 
sodium borate buffer (10 mM sodium tetraborate, 1 M NaCl, pH 8.5, GE Healthcare, 
Freiburg, Germany) containing 0.004% (v/v) of N-ethyldiisopropylamine (0340, Fluka, 
Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) was prepared. This solution was 
used to dissolve JE-14 to a 20 mM stock solution. A sample of JE-14/EA 1:1 was 
injected onto the activated flow cell at a flow rate of 5 µl/min for 7 minutes. A final 
concentration of 1 mM of JE-14 was used. Finally, the residual activated sites of the 
surface were blocked by injection of 1 M EA, pH 8.0. Additional active flow cells were 
prepared with lower densities of JE-14 on the surface by injecting ratios of JE-14/EA 
at 1:10, 1:50 and 1:100. Biacore experiments were performed in HBP-P buffer 
supplemented with 20 mM calcium chloride. 
 
Reverse assay with LecEGF_CR2 construct 
 
A stock solution of LecEGF_CR2 construct (6.7 mg/ml in HBS-P, pH 7.4) was 
diluted to 40 µM in HBS-P buffer at pH 7.4 supplemented with 20 mM calcium 
chloride. For determination of the binding constant, ten twofold dilutions of 
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LecEGF_CR2 construct were injected. HBS-P buffer containing 20 mM calcium 
chloride was used as running buffer. A series of five buffer blanks was injected prior 
to protein sample injection and one buffer blank was injected at the end of the run. 
Equilibrium binding constants were determined using the steady-state response fit to 
a 1:1 binding model as well as calculated by the ratio of dissociation and association 
rates. 
 
Reverse assay with E-selectin/IgG 
 
A stock solution of E-selectin/IgG (23 mg/ml in HBS-P, pH 7.4) was diluted to 
58 µM in HBS-P buffer at pH 7.4 supplemented with 20 mM calcium chloride. A final 
concentration of 5% DMSO was present in the E-selectin/IgG dilution. For the 
determination of the binding constant, ten twofold dilutions of E-selectin/IgG were 
injected. HBS-P buffer containing 20 mM calcium chloride and 5% DMSO was used 
for both, serial dilution of the protein and as running buffer. The surface was 
equilibrated with the running buffer for two hours before running the protein dilutions. 
DMSO calibration solutions were injected prior to the protein dilutions. Five blank 
buffer injections preceded, and one blank buffer followed the injection of the DMSO 
calibration solutions. One buffer blank was also injected at the end of the run, after 
the last protein injection. Equilibrium binding constants were determined using the 
steady-state response fit to a 1:1 and a 1:2 binding models. 
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3.3 Results and discussion 
 
For all antagonists measured, the chemical structure can be found in Appendix III.  
 
3.3.1 Development of an E-selectin Biacore assay 
 
3.3.1.1 Direct amine coupling of E-selectin/IgG 
 
Immobilization of E-selectin/IgG 
 
 Direct covalent immobilization by amine coupling (e.g. Arg97, Lys111, Lys112, 
Lys113) [54] might involve amino acids located in the binding site of E-selectin and 
therefore prevent the interaction with an antagonist. Nevertheless, this coupling 
approach remains interesting, since it generally generates a stable surface with a 
high density of protein. This is essential for ligands with low signal intensities, such as 
carbohydrates. For this reason, the possibility of a direct amine coupling of E-
selectin/IgG was evaluated. The optimization of the pH attraction is not a necessity 
but is usually applied to limit sample consumption. In general, proteins adopt different 
conformations at different pH due to changes in intramolecular hydrogen bonds. 
Under native conditions, protein can change back to its native folding. Thus, one has 
to keep in mind the risk of an effect of amine coupling to the matrix on the protein 
conformation. An optimal pH attraction is usually: 
 
• below the pI of the protein (surface of the protein predominantly positively 
charged), 
• not at the pI (negative and positive charges are canceled, repulsive 
electrostatic forces are reduced and dispersive forces predominates inducing 
aggregation and precipitation), 
• not too acidic to reduce risk of non denaturation. 
 
 High surface attraction of E-selectin/IgG was observed in the range of pH 4.0-
5.0. This was in good agreement with the pI of 5.4 for E-selectin/IgG, since the 
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positively charged protein is electrostatically attracted to the carboxylate surface. For 
the immobilization, 40 µg/ml of E-selectin/IgG was injected at pH 5.0 (Figure 7). The 
concentration is chosen in order to have a slow velocity that enable a better control 
and a better reproducibility of the immobilization level. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Amine coupling profile of E-selectin/IgG performed at pH 5.0; 1: activation of the surface 
with EDC/NHS; 2: E-selectin/IgG injection; 3: Deactivation step by ethanolamine injection. 
 
 On a CM5 sensor chip, an immobilization level of 7’500 RU was obtained. The 
system was stabilized for several hours with HBS-P buffer supplemented with 20 mM 
calcium chloride (5 µl/min). 
 
Validation process of directly coupled E-selectin/IgG 
 
 DS-04115 was used for testing the direct covalent coupling of E-selectin/IgG 
to the biosensor surface. The relative estimated affinity of 0.018 [relative to sLex 
(rIC50)], was known from the static cell-free ligand binding assay (see section 
3.2.5.4). This assay is based on a competition between an analyte (here DS-04115) 
and sLea-PAA-biotin/SA-HRP. The affinity value was normalized to sLex (rIC50 = 1). 
In addition, to avoid the deviation of the absolute values between different plates, 
BW-69669 was measured on the same plate as an internal reference. According to 
this assay, the KD of DS-04115 was expected to be in the µM range.  
 
 In the Biacore assay, no response was observed below a concentration of 60 
µM of DS-04115 and no saturation of E-selectin/IgG was achieved even at millimolar 
concentrations (Figure 8). This observation is rationalized through section 3.2.5.2, 
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namely that no or only a limited amount of E-selectin/IgG was immobilized on the 
chip surface with an accessible binding pocket. Therefore, another immobilization 
strategy had to be considered. 
 
 
 
 
 
 
 
 
 
 
Figure 8: Sensorgrams (A) and binding isotherm plot (B) of DS-04115 to E-selectin/IgG immobilized 
via direct amine coupling at pH 5.0. 
  
3.3.1.2 Immobilization of E-selectin/IgG by a capture assay on a protein A 
surface 
 
The E-selectin/IgG (Figure 9) consists of a C-type Lectin domain which 
corresponds to the carbohydrate recognition domain, an epidermal growth factor 
(EGF) and 6 consensus repeats domains (CRs) of E-selectin fused to the Fc part of 
human immunoglobulin G1 (hIgG1).  Initially, the Fc part was introduced for the 
purification of E-selectin/IgG. Use of staphylococcal protein A or streptococcal protein 
G to capture an antibody on a sensor chip has been described [55-57]. Therefore, 
use of protein A was considered to be promising for the immobilization of E-
selectin/IgG. Protein A was immobilized by the standard amine coupling procedure 
and E-selectin/IgG was captured on the prepared surface. 
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Figure 9: Schematic structure of E-selectin wild type (A) and E-selectin/IgG (B). 
 
Amine coupling of protein A 
 
High surface attraction was observed at pH values of 4.0, 4.5 and 5.0 from a 
pH scouting procedure which used a 40 µg/ml solution of protein A (Table 4). This 
result was in agreement with the pI of 5.1 for protein A. Even though protein A should 
remain native at pH 4.0, a pH of 5.0 was preferred for the coupling reaction. The 
concentration was decreased to 30 µg/ml in order to achieve the desired level of 
immobilization (6’000- 8’000 RU). 
 
Table 4. pH scouting profile of protein A at 40 µg/ml. 
 
pH Response 
[RU] 
7.4 63.7 
5.5 4’036 
5.0 13’051 
4.5 16’552 
4.0 12’106 
 
With the optimized conditions, immobilization levels of 7’000-8’000 were 
obtained on CM5 sensor chips. The procedure was run in parallel for the reference 
cytoplasmic domainCOOH
CRs
EGF
C-Type Lectin domain
A B
hIgG1 (Fc)
C-Type Lectin domain
EGF
CRs
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and the active flow cell. Prior to the capture of E-selectin/IgG, the protein A surface 
was stabilized under a 5 µl/min flow of HBS-P for several hours.  
Capturing of E-selectin/IgG on the protein A surface   
 
For E-selectin/IgG capture, 100 µl of a 50 µg/ml solution of protein was 
injected at a flow rate of 5 µl/min for 20 minutes (Figure 10). This procedure enabled 
the capture of a sufficient amount of E-selectin/IgG (7’800 RU).  
                        A                                                                 B 
 
 
 
         
                                    1              2               3 
 
 
                      
 
 
Figure 10: (A) Amine coupling profile of protein A performed at pH 5.0; 1: activation of the surface 
with EDC/NHS; 2: protein A injection; 3: Deactivation step by ethanolamine injection. (B) Capturing of 
E-selectin/IgG following the protein A immobilization.  
 
A drift of the baseline was observed at the end of the injection due to the non-
covalent binding between protein A and E-selectin/IgG. The surface was stabilized 
overnight in HBS-P buffer supplemented in 20 mM calcium chloride.  
 
3.3.1.3 Immobilization of E-selectin/IgG by a capture assay on a anti-human 
IgG surface 
 
An alternative approach for the immobilization of E-selectin/IgG was the use of 
an anti-human IgG antibody as an intermediate protein for the capture. In 2005, 
Beauharnois and coworkers reported a similar approach for P-selectin/IgG and L-
selectin/IgG [58,59].  
 
A 2.1 mg/ml stock solution of polyclonal anti-human IgG (Fc specific) 
purchased from Sigma was used in all capture assays involving an antibody. 
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Amine coupling of polyclonal anti-human IgG 
 
In a pH scouting procedure, high surface attraction was observed at pH values 
between 4.0 and 5.5. A 42 µg/ml solution of antibody anti-human IgG was used 
(Table 5). At pH 5.5, the surface attraction appeared linear with time until reaching 
saturation. A pH of 5.5 was preferred for the coupling even though a lower pH should 
not affect the stability of an antibody.  
 
Table 5. pH scouting profile of polyclonal anti-human IgG at 42 µg/ml. 
 
 
pH Response [RU] 
7.4 26.6 
5.5 33’827 
5.0 36’084 
4.5 29’263 
4.0 20’740 
 
 
According to the pH scouting, five concentrations of antibody (7, 14, 21, 30 
and 42 µg/ml) were tested at pH 5.5. A clear correlation between concentration and 
surface attraction was observed (Table 6).  A concentration of 21 µg/ml showed a 
suitable level of immobilization, while 7 and 14 µg/ml gave a low response and 42 
and 30 µg/ml an undesired high response. 
 
Table 6. Concentration scouting profile of anti-human IgG at pH 5.5. 
 
Concentration 
[µg/ml] 
Response 
[RU] 
7 -1’759 
14 2’252 
21 8’600 
30 12’803 
42 33’827 
 
 
 
68 
Capturing of E-selectin/IgG on the anti-human IgG surface   
 
For the capture of E-selectin/IgG, 100 µl of a 50 µg/ml solution of protein were 
injected at a flow rate of 5 µl/min for 20 minutes (Figure 11). This procedure enabled 
the capture of high amount of selectin (10’000 RU) and appeared to be more efficient 
in terms of surface density.  
 
As for the protein A capture assay, a drift of the baseline was observed at the 
end of the injection due to the non-covalent binding between anti-human IgG and E-
selectin/IgG. The surface showed a high stability after equilibration overnight in HBS-
P buffer supplemented with 20 mM calcium chloride. 
 
 
 
 
 
 
                                               1           2       3                                             4 
 
 
 
 
 
 
Figure 11. Profile of the capture assay of E-selectin/IgG. 1: activation of the surface with EDC/NHS; 2: 
amine coupling of anti-human IgG (21 µg/ml, pH 5.5); 3: deactivation step by ethanolamine injection; 
4: capturing of E-selectin/IgG(50 µg/ml, pH 5.0).  
 
3.3.1.4 Comparison of the capture assay via protein A and via anti-human 
IgG 
  
Since we plan to detect low molecular weight antagonists (carbohydrate 
derivatives, MW 600-1000 Da), a high density of immobilized active E-selectin/IgG 
will positively influence the quality of the data. As previously shown, a high density of 
E-selectin/IgG (7’500 RU) can be immobilized by direct amine coupling. 
Unfortunately, the orientation of the immobilized E-selectin/IgG was not suitable for 
the binding assay. Capturing approaches led to an oriented attachment of E-
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selctin/IgG and were therefore an obvious solution for generating highly active 
surfaces.  
Because of their strong binding affinity to the Fc fragment of human IgG, two 
intermediates were used for the capture: protein A and anti-human IgG (Fc specific). 
A strong affinity between the captured target and intermediate protein is a 
prerequisite for generating stable surface and avoiding surface bleeding frequently 
observed in capturing assays. E-selectin/IgG was successfully captured on both 
types of surfaces (see sections 5.2.5.1 and 5.2.5.2). In order to select the approach 
that leads to the best quality of data, GMI-1077 and DS-0548 were tested over the 
two surfaces. The results are summarized in Table 7 and Figure 12.  
 
Table 7. (A) Active flow cell profiles for comparison of capturing approach via protein A and via anti-
human IgG. (B) Evaluation of the surface activity and binding affinity of GMI-1077 (1-62.5 µM) on a 
protein A surface and an anti-human IgG surface. (C) Binding affinity of DS-0548 (0.1-25 µM) on a 
protein A surface and an anti-human IgG surface. 
 
A. 
B. 
Intermediate 
protein for 
immobilization 
Exp. KD  
[µM]* 
Exp. Rmax  
[RU]* 
Calc. Rmax 
[RU]** 
Activity  
[%]*** 
protein A 
anti-hIgG(Fc) 
1.77 
2.14 
11.31 
33.61 
58.20 
101.80 
19.40 
33 
C. 
Intermediate 
protein for 
immobilization 
Exp. KD  
[µM]* 
Exp. Rmax  
[RU]* 
Calc. Rmax 
[RU]** 
Activity  
[%]*** 
protein A 
anti-hIgG(Fc) 
1.52 
1.82 
12.70 
22.14 
62.20 
103.20 
20.40 
21.50 
*Experimental values obtained by fitting the steady state responses to a 1:1 binding model **Calculated value obtained with 
equation 1 *** Ratio Exp. Rmax/Calc. Rmax 
 
 
 
 
 
 
Intermediate protein for 
immobilization [µg/ml] pH 
Surface 
capacity [RU] 
E-selectin/IgG 
[µg/ml] pH 
Surface 
capacity [RU] 
protein A, 30 µg/ml 
anti-hIgG(Fc), 21 µg/ml 
5.0 
5.5 
8’500 
14’800 
50 
50 
5.0 
5.0 
6’200 
11’500 
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                                 A                                                    C 
 
 
 
 
 
 
                           B                                                     D 
 
 
 
 
 
 
 
 
Figure 12. Sensorgrams and binding isotherm plots of GMI-1077 for E-selectin/IgG. Influence of the 
intermediate protein for immobilization on the evaluation of the binding activity; A,B: protein A; C,D: 
anti-human IgG. 
 
As shown in Figure 12 for GMI-1077, the quality of the sensorgrams was 
improved by using anti-human IgG as an intermediate protein to capture E-
selectin/IgG. A better Rmax and therefore an improvement of the signal-to-noise ratio 
were achieved. A similar observation was made for DS-0548, but at a lower 
proportion. As a consequence, the surface activity was considerably improved for 
GMI-1077. For both compounds, the dissociation constants (KDs) obtained by fitting 
the steady state response with a one-to-one binding model showed comparable 
values (Table 7) in both formats. As will be shown later, the difference in affinity 
obtained with the two capturing assays was in the range of the fluctuation observed 
for the same compound measured on different surfaces with the same capturing 
procedure. Therefore, this fluctuation cannot be directly attributed to the intermediate 
protein used for the capture.  
 
In conclusion, the direct amine coupling of the E-selectin/IgG on the surface 
was aborted due to the poor orientation of the protein. Therefore, a capture assay 
appeared an obvious solution. Antibody anti-human IgG was chosen as an 
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intermediate protein in the capture assay of E-selectin/IgG, because it generates 
more densely packed surfaces and higher Rmax than protein A. These parameters are 
required for the detection of small molecules on large targets as this is the case with 
E-selectin/IgG and carbohydrate-based ligands.  
 
3.3.2 Further optimization of the E-selectin/IgG Biacore capture assay  
 
3.3.2.1 Dependence of the binding affinity upon surface density 
 
An amine coupling of three different concentrations (10, 20 and 30 µg/ml in 10 
mM acetate buffer pH 5.5) of the anti-human IgG antibody was performed in order to 
investigate a dependence of the binding affinity upon the surface density. For this 
procedure, 100 µl of each antibody solution was injected on activated flow cells for 10 
minutes. Increasing capacities were achieved, as shown in Table 8, fourth column. A 
solution of 50 µg/ml of E-selectin/IgG was prepared in 10 mM acetate buffer, pH 5.0. 
After deactivation of the residual reactive succinimide esters groups, the protein 
solution was captured over the antibody surfaces. Each surface was prepared 
independently and different levels of capture were observed (Table 8, seventh 
column). 
 
Table 8. Surface capacity of anti-human IgG antibody observed after amine coupling procedure with 3 
different concentrations (10, 20 and 30 µg/ml) at pH 5.5 (right). Capture of E-selectin/IgG on 
increasing surface capacities of anti-human IgG (left). 
 
Surface 
density* Antibody anti-
hIgG(Fc) [µg/ml] 
pH 
Surface 
Capacity 
[RU] 
E-selectin/IgG 
[µg/ml] pH 
Surface 
Capacity 
[RU] 
Low 
Medium 
High 
10 
20 
30 
5.5 
5.5 
5.5 
5’963 
12’089 
15’860 
50 
50 
50 
5.0 
5.0 
5.0 
6’270 
9’405 
8’568 
*Surface density total (E-selectin/IgG + antibody) 
 
As expected, a correlation between the surface capacity of the immobilized 
antibody and the surface capacity of E-selectin captured was observed (Table 8, low 
and medium surface densities). However, this effect was not linear and up to a 
certain limit (≈ 13’000 RU), a further increase of the immobilization level of antibody 
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(Table 8, high density) showed a decrease of about 1’000 RU of the E-selectin/IgG 
captured (Table 8, Figure 13 and 15).  
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Density of captured E-selectin/IgG with respect to the density of covalently linked anti-
human IgG. 
 
The influence of the density of E-selectin/IgG on the detected affinities was 
evaluated with the ligand DS-0565. The relative affinity (rIC50 = 0.032) was known 
from the static cell-free ligand binding assay (see section 3.2.5.4). The 
measurements were done in triplicate over the three surfaces described above 
(Table 8). A single binding site model was used and fit best with the experimental 
data. A clear difference was observed between the low density surface (Figure 14A-
B) and both medium and high density surfaces (respectively Figures 14C-D and 14E-
F).  
The sensorgrams in Figure 14A showed a lower response compared to 
medium and high-density surfaces (Figures 14C and 14E). In addition, the standard 
deviation was higher and therefore the fit was of poorer quality (Figure 14B). This 
was most likely due to the overall lower signal intensity leading to a lower signal-to-
noise ratio.  
No clear differences were observed between medium and high surface 
densities of protein (Figure 14C and E). This showed that an overload of the antibody 
on the surface did not improve the quality of the data. Even though the amount of E-
selectin/IgG captured was lower at high density of antibody, a minor impact on the 
data was observed.  
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        A                                                C                                                   E  
 
 
 
 
 
 
 
 
       B                                                  D                                                    F 
 
 
 
 
 
 
Figure 14. Sensorgrams and binding isotherm plots of DS-0565 for E-selectin/IgG. Influence of the 
surface density of the intermediate protein used for the immobilization of E-selectin/IgG on the 
evaluation of the affinity; A,B: 5’963 RU; C,D: 12’089 RU; E,F: 15’860 RU. 
 
KD values were obtained by fitting the signals to a single binding site model 
(Table 9). The KD value observed with the low surface density differs by a factor of 
two from the results with medium and high surface densities. This can be explained 
by the lower signal-to-noise ratio leading to higher standard deviation and poorer fit 
as already mentioned.  
For further understanding of the results obtained with medium and high 
density surfaces, the surface activity was also evaluated and correlated with the 
surface densities.  
 
Table 9. Evaluation of the surface activity and binding affinity of DS-0565 (0.98-62.5 µM, triplicate 
injections) at three different anti-human IgG surface densities. 
 
Surface 
density* 
Exp. KD  
[µM]** 
Exp. Rmax  
[RU]** 
Calc. Rmax 
[RU]*** 
Activity  
[%]**** 
Low 
Medium 
High 
2.94 
4.07 
4.86 
16.76 
35.27 
35.07 
48 
84 
95 
34.9 
42 
36.9 
 
*Surface density total (E-selectin/IgG + antibody) **Experimental values obtained by fitting the steady state responses to a 1:1 
binding model ***Calculated value obtained with equation 1 **** Ratio Exp. Rmax/Calc. Rmax 
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A decrease of activity following an increase of the surface density of the target 
has been observed by D. Ricklin [60] with GSLA-2. A similar effect has also been 
reported by Huber and coworkers [61] with cyclophilin D. In both cases, the target 
was directly covalently linked to the surface. In our assay a similar observation was 
witnessed between medium and high surface densities and the corresponding 
surface activity. However, as shown in Figure 15, the explanation for the observed 
effect is different due to the capture format applied. Indeed, the surface activity is 
related to the level of immobilized E-selectin/IgG and not to the total surface density. 
An increase in the level of immobilized E-selectin/IgG led to an increase of surface 
activity (Figure 15A-B). As already mentioned, a further increase of the antibody on 
the surface resulted in a higher total surface density but was not beneficial for the 
capture of the E-selectin/IgG (Figure 15B-C-D). The most plausible explanations for 
this effect are steric hindrance and reduce accessibility of the binding sites. This was 
discussed by Huber et al. [61] and can be applied to the antibody-E-selectin/IgG 
interaction discussed herein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Schematic structure of; A: low; B: medium; C: high and D: very high density surfaces of the 
E-selectin/IgG capture assay. 
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3.3.2.2 Non-specific contribution from the intermediate used for the capture 
to the observed binding  
 
It is desirable to have a negligible interaction between the intermediate protein 
used for the capture and the ligand, although the impact of a non-specific contribution 
can be determined with the reference flow cell. In order to evaluate the importance of 
this parameter in our assay, the binding affinity of GMI-1077 was evaluated with a 
dextran surface reference cell and an anti-human IgG reference cell (Table 10, 
Figure 16). The ligand was injected in parallel over the active flow cell and the two 
types of reference flow cells (Table 10, Figure 16). 
 
Table 10. Binding affinity of GMI-1077 calculated with two types of reference cells: dextran matrix and 
anti-human IgG as the intermediate protein used for the capture. 
 
Reference 
Exp. KD  
[µM]* 
Rmax 
[RU] 
dextran 1.34 21.13 
anti-human IgG 1.16 20.07 
*Experimental values obtained by fitting the steady state responses to a 1:1 binding model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Sensorgrams and affinity isotherm plots of GMI-1077 with two types of reference cells; 
A,B: dextran matrix; C,D anti-human IgG as the intermediate used for the capture. 
A C 
 
B 
 
D 
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The interaction between the intermediate protein used for the capture and the 
ligand appeared to be negligible in the range of the injected concentrations (Table 10 
and Figure 16). However, at highest injected concentrations (0.2-1 mM), an increase 
of the non-specific binding was detected and strongly influenced the signal of the 
compound (data not shown).  
 
3.3.2.3 Impact of the quality of the protein 
 
In order to study the influence of the quality of the E-selectin on the surface 
activity and the binding affinity, an increasing proportion of denaturated E-
selectin/IgG was captured on a CM5 sensor chip. For this purpose, a solution of E-
selectin/IgG was denaturated by heating at 99 °C for 5 minutes and mixed with native 
protein from the same batch. Three ratios native/denaturated protein were prepared 
and injected over anti-human IgG surfaces (Table 11) with a similar final 
concentration of 48 µg/ml of E-selectin/IgG (native and denaturated). 
 
Table 11. Design of a CM5 with increasing proportion of denaturated E-selectin/IgG immobilized. 
 
Percentage native E-
selectin/IgG 
Surface density of 
antibody anti human IgG 
[RU] 
E-selectin/IgG 
[µg/ml] 
(native + 
heated) 
Surface density of E-
selectin/IgG [RU] 
100 7’050 48 6’300 
50 8’133 48 7’250 
25 7’550 48 7’139 
 
As expected, an increasing amount of denaturated protein resulted in a 
decrease of the experimental Rmax, indicating a loss of activity on the surface (Table 
12 and Figure 17). This drastic decrease cannot be correlated to a difference in 
surface density and therefore cannot be attributed to it (Table 11). Indeed, the 
calculated Rmax was higher with 50 % of active protein but the surface activity 
decreased by a factor of 1.6 compare to the surface without denaturated protein. A 
similar surface density (leading to a similar calculated Rmax) would have led only to 
minor changes in surface activity if the heated protein was still active. 
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Table 12. Evaluation of the binding affinity and surface activity of DS-0565 (0.625-80 µM, duplicate) at 
three different ratios of native/denaturated protein captured on the surface.  
 
Percentage native E-selectin/IgG  Exp. KD  [µM]* 
Exp. Rmax  
[RU]* 
Calc. Rmax  
[RU]** 
Activity 
[%]*** 
100 4.02 21.7 52 41.7 
50 2.38  15.6 59.9 26 
25 1.70 5.6 57.2 9.8 
*Experimental values obtained by fitting the steady state responses to a 1:1 binding model **Calculated value obtained with 
equation 1 *** Ratio Exp. Rmax/Calc. Rmax                                                                                                                               
 
 
 
 
  100% 
   50% 
              25% 
                                                                                                                                   
                                                                                                                        
 
 
 
 
 
 
 
Figure 17. Binding curves are shown of DS-0565 (0.625-80 µM, duplicate) at three different ratios of 
native/denaturated protein captured on the surface. 
 
As a consequence of the decrease in experimental Rmax, observed with 
increasing amount of denaturated E-selectin/IgG, a lower quality of the sensorgrams 
was observed as well as a higher deviation between the duplicates. In addition, the 
capturing of the denaturated protein indicates that the IgG (Fc) part is still functional. 
Nevertheless, the loss of Rmax indicates that denaturated protein does not fully 
contribute to the binding. Obviously, a reduction of Rmax affects the observed KD 
values. Theoretically, similar KDs were expected for the different cases. A 
combination of the parameters mentioned above leads to a variation in the fit of the 
data points by a 1:1 binding model and therefore explain the variation in KDs.  
 
The consistency of the data obtained for DS-0565 binding to E-selectin/IgG is 
seen in section 3.3.5, Figure 27. The KD obtained in Table 11 with 100% active E-
selectin/IgG differs from average of the earlier measurements in section 3.3.4, Table 
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17 by 26% and is within the fluctuation between different measurements of the same 
compound evaluated with the Biacore capture assay. 
 
3.3.2.4 Stability of the surface  
 
A series of E-selectin ligands were measured over the same surface during 
the course of two weeks. To evaluate the stability of the surface during these 
measurements, GMI-1077 was regularly injected and its binding affinity evaluated 
and compared to previous measurements (Figure 18). 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Evaluation of the stability of the surface monitored by three affinity evaluations of GMI-
1077 at day 1, day 5 and day 8 after immobilization. The first column shows the KD values observed 
for twenty measurements of GMI-1077. The line indicates the mean value (1.45 µM +/- 0.44). A 
coefficient of variation of 0.3 was calculated. 
 
A variation in the KDs was observed over the period of eight days, but stayed 
in the range of fluctuation observed for GMI-1077 with the capture assay (Figure 18, 
column 1). A loss of 18% of the density of the surface was observed between first 
and third measurement and can be correlated to a decrease in Rmax (Figure 19). This 
loss has been consistently observed in the capture assay format and reaches a 
stable value after approximately one week. 
 
 
 
 
 
 
GMI-1077     Day 1           Day 5           Day 8 
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Figure 19. Correlation between the Rmax obtained with a 1:1 model fit and the stability of the density of 
the surface. 
 
3.3.2.5 Calcium dependence of the binding 
 
It is well-known that E-selectin binds to sialylated carbohydrates in a calcium 
dependent manner. Therefore, the role of calcium in the Biacore assay was 
examined in order to confirm that the observed binding results from the desired 
specific interaction.   
 
DS-0548 was injected over the same surface under different conditions. 
Results are chronologically shown in Table 13A to D and corresponding binding 
isotherm plots. As shown with the binding isotherm plot B, no signal was observed in 
the presence of 3 mM EDTA, which is content in the running buffer, HBS-EP. After 
equilibration overnight in HBS-P buffer containing 20 mM calcium, a recovery of the 
signal was observed (Table 13C and binding isotherm plot C). Nevertheless, a lower 
signal-to-noise of the sensorgrams was observed as well as a shift of the KD value 
compare to the binding isotherm plot before treatment with EDTA (Table 13A vs C). A 
higher Rmax was observed after equilibration in buffer supplemented with 100 mM 
calcium chloride (Table 13D). However, this enhancement did not significantly 
improve the signal-to-noise and could not be correlated with a recovery of the KD 
value (Table 13A vs D). 
 
 
 
 
Day 1 
Day 5 
Day 8 
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Table 13. Influence of EDTA on the binding affinity of DS-0548 to E-selectin/IgG and corresponding 
binding isotherm plots (A-D). 
 
Binding isotherm Plot Buffer KD [µM] Rmax [RU] 
A HBS-P + 20 mM CaCl2 1.52 12.66 
B HBS-EP - - 
C HBS-P + 20 mM CaCl2 3.53 9.24 
D HBS-P + 100 mM CaCl2 3.80 15.93 
 
 
                                     A                                                 B 
 
 
 
 
 
 
                                        C                                                  D 
 
 
 
 
 
 
These experiments clearly show the correlation between calcium dependency 
and the specificity of the binding in the Biacore capture assay. It also showed, how 
the E-selectin/IgG was affected by a depletion of calcium.  
 
3.3.2.6 Removal of sample interactant from the captured surface 
 
In a direct immobilization, the regeneration leads to the removal of the analyte 
while preserving the activity of the immobilized target (Figure 20A). A clear 
advantage of the capture assay compare to direct immobilization is the possibility to 
re-immobilize “fresh” protein by regeneration of the surface (Figure 20B). In both 
cases, the same terminology of regeneration is used even though it does not lead to 
the same result. For the capture assay, we will use the term “removal” referring to 
both captured molecules and analytes (Figure 20B). Obviously, the activity of the 
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protein used as an intermediate for the capture should not be affected by the removal 
treatment. 
 
 
 
 
 
 
 
 
 
 
Figure 20. A: Regeneration of the surface with direct immobilized target; B: removal of the target from 
a captured surface. 
 
Beauharnois et al. described a removal method for P-selectin/IgG and L-
selectin/IgG captured by a goat anti-mouse IgG by pulse injection of HCl 20 mM, 50 
µl at 50 µl/min [58,59]. 
In our assay, the removal was only partly successful. Fifty percent of the E-
selectin/IgG could be removed even after several pulse injections of HCl 20 mM. The 
achievement of a full regeneration of the surface was never achieved and the quality 
of the protein remaining on the surface probably suffered from the HCl-treatment. 
Therefore, another method for removal was explored by injection of glycine 10 mM at 
low pH.  A removal scouting was performed by successive pulse injection of glycine 
10 mM with decreasing pH (3, 2, 1.5 and 1). Such a treatment allowed a release of 
65 % of E-selectin but also did not allow the complete removal of the target from the 
surface. 
Finally, a third method of regeneration mentioned in an application note and 
recommended by the manufacturer, GE Healthcare, was tested [62]. This procedure 
is alternatively proposed for capture assays in which other removal methods failed. 
The previously tested removal methods were based on injections of acidic solutions. 
In contrast, in this method, basic conditions are claimed to induce a rapid removal of 
the target by a single injection of a solution of 0.5 M NaSCN containing 10 mM NaOH 
for 30 seconds. Several injections were needed to achieve a full regeneration of the 
Direct immobilization Capture assay
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surface. Nevertheless, following regeneration, only 3’400 RU were re-captured (about 
40 % of the level obtained with the first capture). A second injection of E-selectin/IgG 
allowed the capture of an additional 3’300 RU leading to a reasonable level of 
capture (6’700 RU). However, a significant decay of the signal by 2’000 RU was 
observed during the equilibration phase of the surface in buffer. In order to evaluate 
the impact of such a regeneration method, GMI-1077 was injected. The result was 
compared to the signal observed directly after the first capture of E-selectin/IgG 
(Figure 21).  
 
 
                                                                                             Original (R2=0.99) 
                                                                                             egenerated (R2=0.98) 
                                                                                                                   
 
 
 
 
 
 
 
Figure 21. Evaluation of GMI-1077 on the original and regenerated surface. 
 
The interaction between the Fc fragment of the E-selectin construct and the 
anti-human IgG is very high (probably in the same order of magnitude as the 
interaction between IgG and immunoglobulin reported in the nanomolar range [63]). 
Although this is an advantage for the stability of the surface in the capture assay, it 
complicates the regeneration of the surface. The strong basic conditions were 
successful for the removal of E-selectin/IgG from the surface, but also affected the 
anti-human IgG covalently linked to the surface. Indeed, a sizeable reduction in the 
Rmax from the regenerated surface was observed, leading to the conclusion that a 
regeneration step is not suitable in our assay format.  
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3.3.3 Evaluation of BW-69669 derivatives  
 
Sialyl Lewisx (sLex) is the minimal carbohydrate epitope of natural E-selectin 
ligands. This millimolar ligand has served as a starting point for the design of more 
potent E-selectin antagonists (Figure 22). 
 
 
 
 
 
 
 
Figure 22. Structure of Sialyl Lewisx  (KD= 1mM, [64]) 
 
In 1994, Graves and coworkers determined by X-ray crystallography the three 
dimensional structure of the CRD-EGF domain of E-selectin. More recently, in 2000, 
Somers et al. succeeded in resolving the E-selectin/sialyl Lewisx complex by X-ray 
crystallography. The crystallography data are in good agreement with NMR studies 
[10,54,75] concerning the core conformation of the bound sLex and revealed 
important pharmacophores for the binding (Figure 23). 
 
 
 
 
 
 
 
 
 
 
Figure 23. Interactions responsible for sLex binding to E-selectin as determined by X-ray 
crystallography. Part of the amino acid involved in the binding is specified under brackets, side chain 
(sc) or backbone (bb) (Adapted from [54]).  
 
The tetrasaccharide mimic BW-69669 (Figure 24A) showed an improved 
affinity for E-selectin compare to sLex. However, for therapeutic use, this 
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improvement in affinity was not sufficient. In addition, its poor pharmacokinetic profile, 
mainly due to the presence of polar groups, needed to be improved. Therefore, 
based on the lead structure BW-69669, several antagonists were developed. In order 
to increase affinity, to improve kinetics and to optimize drug-like properties, 
derivatives were synthesized by modifying the R groups (Figure 24B).  In particular, 
modifications were sought which led to a stabilization of the bioactive conformation of 
the ligand in solution. These modifications stabilized the desired conformation 
through the addition of spatially demanding groups on R2 and R3 [65]. 
 
  
 
 
 
   A                                                                           B 
 
Figure 24. (A) Structure of BW-69669. The different carbohydrate derivatives moieties are shown in 
different colors (galactose in red, fucose in magenta, GlcNAc mimic moiety in blue and cyclohexyl 
lactic acid in black)  (B) Modified sites to improve the potency. Important pharmacophore for the 
binding were highlighted. 
 
In a first attempt, substitution of the hydroxyl group of BW-69669 in the 2-
position of galactose with a benzoate (LT-0236) led to an increase of affinity by a 
factor of 2.5 (Table 14). A further enhancement was observed by introducing a 
methyl in the 5-position of GlcNAc mimic moiety (DS-04115 vs BW-69669). By 
introducing both aforementioned substituents in the R2 and R3 positions (GMI-1077) a 
gain in affinity by a factor of 30 was achieved compare to BW-69669 (Table 14). KDs 
determined by Biacore were in good agreement with the rIC50 determined by static 
cell-free assay. 
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Table 14. Initial modifications at R2 and R3 and the corresponding KD values. 
 
 
Entries 
 
Compound 
 
 
R1 
 
 
R2 
 
 
R3 
 
 
R4 
 
rIC50 
(competitive binding assay 
GMI, sLex=1) 
KD [µM] 
(Biacore) 
 
1 BW-69669 Na H H H 0.080 45 
2 LT-0236 H Bz H H 0.040 18.8 
3 DS-04115 Na H Me H 0.016 7.89 
4 GMI-1077 Na Bz Me H 0.004 1.45 
 
In parallel, the conformational freedom of GMI-1077 was evaluated by 
MC(JBW)/SD-simulations (Dr. Martin Smiesko). This approach originally proposed by 
Kolb and Ernst [66,67] permits the evaluation of the extent to which the unligated 
GMI-1077 sampled the bioactive window.  
These results are displayed in a 2D internal coordinate system with the “core-
conformation” (x-axis) and the “acid-orientation” (y-axis) as parameters (Figure 25). 
The z-axis (color code) indicates the frequency of occurrence of the value during the 
simulation [66,67]. 
 
 
 
 
 
 
 
 
 
Figure 25. View of the core conformation and the acid orientation [66,67]. 
 
This simulation allowed the comparison of the solution and bound 
conformations of antagonists. The small blue dots indicates bioactive conformation of 
sLex obtained from crystal structure and the larger black square indicates the 
favorable region determined from trNOE-NMR studies [10,68,69]. Compounds 
having a high probability for conformations in the bioactive window were shown to 
O
O
HO
OR2
O
O
HO
OH
OH
O
COOR1
OH
R3
R4
O
O
HO
OR2
O
O
HO
OH
OH
O
COOR1
OH
R3
R4
core conformation acid orientation
 
 
86 
usually have higher affinity to E-selectin, due to their increased pre-organization in 
the bioactive conformation [66,67].  
Figure 26 shows the results obtained with GMI-1077 in solution (Figure 26B) 
and bound to E-selectin (Figure 26D) and the corresponding conformational model 
(respectively, Figure 26A and C). According to the simulation, the reduction of the 
flexibility of the molecule enhanced in the bound state. The agreement between the 
acid orientation and core conformation obtained from both states is representative of 
a good pre-organization of the antagonist. In addition, this pre-organization fits with 
the bioactive window and the favorable region determined by trNOE-NMR. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Conformation of GMI-1077 in solution (A), docking model (C) and MC(JBW)/SD-
simulations and obtained for GMI-1077 in solution (B) and bound to E-selectin (D). 
 
In a next step, R3 was further modified (Table 15). By increasing the steric 
hindrance in this position, a reduction of the ligand flexibility and therefore, an 
improvement of the pre-organization of the antagonist in the bioactive conformation is 
expected. As a consequence, an improved potency of the ligand results.  
An affinity similar to GMI-1077 was observed with R3 being an ethyl group 
(DS-0567) whereas a loss of affinity by a factor of five was observed with a 
cyclopropyl group (DS-0565).  
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Table 15. Additional modifications at R3 and first modification at R4 and the corresponding KD values. 
 
Entries 
 
Compound 
 
 
R1 
 
 
R2 
 
 
R3 
 
 
R4 
 
rIC50 
(competitive binding 
assay GMI, sLex=1) 
 
KD [µM] 
(Biacore) 
 
1 BW-69669 Na H H H 0.080 45 
4 GMI-1077 Na Bz Me H 0.004 1.45 
5 DS-0567 H Bz Et H 0.007 1.49 
6 DS-0565 H Bz CyPro H 0.032 5.36 
7 DS-0548 H Bz (CH2)2COOMe H 0.008 1.62 
8 DS-0560 H Bz Me COOMe - 1.9 
 
Ester groups introduced in position R3 (DS-0548) and R4 (DS-0560) lead to no 
significant change in the binding affinity compare to GMI-1077. The results obtained 
with the Biacore assay are in good agreement with the rIC50 of the cell-free 
competitive binding assay. 
In a subsequent series of modifications, the 2-position of galactose was 
acylated in order to investigate the influence of steric hindrance, polarity, orientation 
of a substituent in this position (Table 16, entries 7 to 10). 
 
Table 16. Additional modifications at R2 and the corresponding KD values. 
 
Entries 
 
Compound 
 
 
R1 
 
 
R2 
 
 
R3 
 
 
R4 
 
rIC50 
(competitive binding 
assay GMI, sLex=1) 
 
KD [µM] 
(Biacore) 
 
4 GMI-1077 Na Bz Me H 0.004 1.45 
9 BW-510 Na parafluoroBz Me H 0.005 1.26 
10 BW-529 Na paramethoxyBz Me H 0.006 0.37 
11 BW-534 Na cyclopropylcarboxylate Me H 0.006 2.05 
12 BW-570 Na acetamide Me H - 1.23 
 
In conclusion, an enhancement of the binding by a factor of 120 was observed 
between the lead compound BW-69669 (KD= 45 µM) and the best compound BW-
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529 (KD= 0.37 µM). An improvement of the affinity by a factor of 30 was observed 
between BW-69669 and GMI-1077. Nevertheless, none of the modifications in 
position R2 and R3 – despite of BW-529, showed a significant improvement of the 
affinity. 
 
3.3.4 Kinetic evaluation of BW-69669 derivatives 
 
Carbohydrates-lectin interactions usually exhibit low affinity and fast 
association and dissociation rates. Slectins are not an exception as shown for their 
interaction with physiological ligands [70-72]. One factor, which rationalizes these 
fast rates, is certainly the shallowness of selectin binding pocket. 
All BW-69669 derivatives exhibited similar fast kinetic profiles as shown in 
Table 17. In addition, the steady state was reached within a few seconds and stayed 
stable during the injection time. 
 
Table 17. Kinetic and affinity evaluation of BW-69669 derivatives. 
 
Analyte kon [105 M-1s-1] koff [s-1] KD kin [µM]* KD eq [µM]** t1/2 [s]*** 
BW-529 8.9 0.3 0.3 0.3 2.6 
BW-570 2.7 0.3 1.3 1.2 2.0 
BW-510 2.2 0.3 1.4 1.3 2.3 
GMI-1077 8.5 0.9 1.0 1.5 0.8 
DS-0567 2.0 0.3 1.6 1.5 2.2 
DS-0548 2.0 0.3 1.8 1.8 2.0 
DS-0560 77.0 1.9 1.6 1.6 0.4 
BW-534 n.d. 0.6 n.d. 2.5 1.1 
DS-0565 1.0 0.4 3.8 4.0 1.9 
DS-04115 2.0 1.3 6.6 6.5 0.5 
LT-0236 n.d. 0.4 n.d. 18.8 1.8 
BW-69669 0.2 1.0 51.8 50.4 0.7 
*calculated KD using KD = koff/kon ** experimental KD derived from steady state response fit to a single binding site model *** 
calculated t1/2 using t1/2 = ln2/koff. 
 
While the observed association rates are in a correct range for drug-like 
molecules, the fast dissociation rates are not suitable. A fast off rate can be 
compensated by increasing concentrations of the compound and/or by optimizing the 
ligand. The first approach is prohibitive for a drug molecule. Therefore, the second 
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approach was used in the selectin project (see Chapter 5). In addition, for a drug-like 
profile, a further improvement in affinity to the low nanomolar regime would be 
desired. 
 
3.3.5 Reproducibility in Biacore experiments 
 
Most of the compounds were measured repeatedly on the same surface as 
well as on different CM5 chips. In order to evaluate the reproducibility of the E-
selectin/IgG capture assay, all the KDs were analyzed by fitting the steady-state to a 
1:1 binding model. The results are presented in Figure 27. The number of 
measurements varies between one (for LT-0236) and twenty (for GMI-1077).  
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Number of values 2 2 4 20 3 3 2 2 7 3 1 2 
Mean KD [µM] 0.34 1.23 1.27 1.5 1.49 1.62 1.9 2.3 5.36 7.64 18.80 44.90 
Std. Deviation 0.06 0.11 0.21 0.51 0.32 0.17 0.23 0.05 0.79 1.07 / 1.27 
CV 0.16 0.09 0.16 0.34 0.22 0.11 0.12 0.20 0.15 0.14 / 0.03 
 
Figure 27. KD reproducibility in Biacore measurements measured at 25°C. For repeated 
measurements, dashes are drawn indicating average values. GMI-1077 with the highest number of 
measurements is highlighted. The coefficient of variation (CV) is defined as the ratio of the standard 
deviation to the mean. It indicates the variance of the distribution and a CV<1 is considered as low-
variance. 
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As shown in Figure 27, the coefficient of variation (CV) is significantly lower 
than 1, indicating the stability and the reproducibility of the assay (low-variance). The 
analysis of these data demonstrates the high degree of reproducibility of the Biacore 
results and clearly shows the improvement of the affinity achieved by modifying the 
lead compound BW-69669. A linear correlation (R2 = 0.83) between the KDs (Biacore 
steady-state signals) and the rIC50 (static cell-free assay) was obtained with a double-
logarithmic scale (Figure 28). The self-consistency of the measured affinities 
supported the accuracy of the Biacore data. 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Linear correlation between KD and rIC50 values on a double logarithmic scale. 95% 
confidence interval is shown in dash lines. DS-0565 and DS-04115 are situated at the limit of the 
interval of confidence and BW-534 is out of this interval.  
 
3.3.6 Thermodynamic analysis 
 
 For a better understanding of the interaction of antagonists with E-selectin, it 
was of interest to determine the entropic and enthalpic contributions to the binding. A 
detailed enthalpy/entropy characterization of carbohydrate-plant lectins with a 
Biacore 2000 was successfully performed and provided interesting information [73]. 
Biacore 3000 also has the capacity for such thermodynamic studies [74]. 
 DS-04115, GMI-1077, DS-0567 and DS-0565 were selected for this analysis 
(Table 15). With DS-04115 and GMI-1077, the influence of a benzoate group in the 
2-position of galactose on the enthalpy/entropy contribution could be studied. DS-
0567 and DS-0565 were chosen for studying the influence of different R3 
substituents. 
-2.5 -2.0 -1.5 -1.0
-1.0
-0.5
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 The analytes were measured at different temperatures between 10 °C and 30 
°C with an increment of 2.5 °C and evaluated by applying a van’t Hoff plot. Enthalpy 
(ΔH) and entropy (ΔS) parameters were calculated using Eq. (5) via the slope (ΔH/R) 
and the y-intercept (-ΔS/R). The free enthalpy (ΔG) was calculated using the Eq. (6). 
 
ln(KD) = (ΔH/R) • 1/T - (ΔS/R)                          (5) 
 
ΔG = ΔH - TΔS                                                  (6) 
 
 The introduction of a benzoate group in the 2-position of galactose led to an 
enhancement of enthalpy and a loss of entropy (Table 18, DS-04115 vs GMI-1077). 
An additional enhancement of enthalpywas observed by replacing the methyl by a 
cyclopropyl group in the 5-position of GlcNAc mimic moiety (Table 18, DS-0565). A 
further decrease in enthalpy was observed in presence of an ethyl in the 5-position of 
GlcNAc mimic moiety (Table 18, DS-0567). 
 A drop in the entropy was observed by replacement of the methyl group in R3 
position by an ethyl or a cyclopropyl (Table 18, GMI-1077 vs DS-0567 and DS-0565). 
The entropy contribution was almost not affected between DS-0565 and DS-0567 
indicating that both substituents in R3 position contribute in a similar way. 
 The evolution of the enthalpy contribution was correlated with a variation of the 
affinity. The unexpected positive enthalpy observed for DS-04115 and GMI-1077 
remains unclear and cannot be explain by a non-linear heat capacity in the range of 
temperature analyzed. Indeed, analyses of the data with linear and non-linear heat 
capacity were performed and the increment between temperature measurements 
was decreased. However, all conditions led to the same thermodynamic profile.  
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Chemical Formula: C42H66N2O17
Molecular Weight: 870.98
Table 18. Thermodynamic characterization DS-04115, GMI-1077, DS-0567 and DS-0565 of the 
binding of to E-selectin/IgG obtained by SPR at 25 °C and associated linear regression of the Van’t 
Hoff plot. 
 
Analyte  KD [µM] N 
∆G∆H-T∆S 
[kJ/mol] ∆H [kJ/mol] T∆S [kJ/mol] 
DS-04115  7.64 1.00 -28.9 +26.89 55.75 
GMI-1077  1.5 1.0 -32.54 +16.09 48.6 
DS-0565 5.36 
 
1.0 
-29.88 -8.35 21.46 
-29.94 -10.2 19.68 
-29.67 -10.89 18.8 
DS-0567 1.49 1.0 -33.82 -16.56 17.26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.7 Reverse assay 
 
JE-14 was specifically designed and synthesized in-house by Jonas Egger in 
order to be covalently linked onto a CM5 sensor chip surface (Figure 29).  
 
 
 
                     JE-14 
 
 
Figure 29. Chemical structure of JE-14 
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Evaluation of JE-14 with the E-selectin/IgG capture assay 
 
In a first step, JE-14 was evaluated using the optimized E-selectin/IgG capture 
assay. Fast binding kinetic were observed and an experimental KD value of 6.01 µM 
was measured from the steady state fit of the sensorgrams to a 1:1 binding model 
(Table 19). The KD calculated from the kinetic parameters is also reported. 
 
Table 19. Kinetic and affinity evaluation of JE-14. Equilibrium binding isotherm plot and kinetic fit of 
the sensorgrams are shown in the bottom. 
 
Analyte kon [104 M-1s-1] koff [s-1] KD kin [µM]* KD eq [µM]** t1/2 [s]*** 
JE-14 4.43 0.28 6.32 6.01 2.47 
*calculated KD using KD = koff/kon ** experimental KD derived from the steady state response fit to a single binding site model *** 
calculated t1/2 using t1/2 = ln2/koff.  
 
 
 
 
 
 
 
 
 
Reverse assay with LecEGF_CR2 construct  
 
In order to validate the quality of the KDs from the capture assay, JE-14 was 
coupled to the surface via the standard amine coupling procedure. Four ratios of JE-
14/ethanolamine (1:1, 1:10, 1:50 and 1:100) were injected on activated surfaces at a 
final concentration of 1 mM of JE-14. Ethanolamine (EA) was co-injected with JE-14 
in order to neutralize activated carboxyl groups of the dextran matrix and therefore 
modulate the density of JE-14 immobilized onto the surface. This procedure led to 
decreased densities of JE-14 immobilized onto the different surfaces. The affinity of 
LecEGF_CR2 construct (Ph.D. thesis of Roland Preston) for the linked compound 
was evaluated by injection of a serial dilution of the LecEGF_CR2 construct starting 
at 40 µM (Table 20). 
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Optimal density of JE-14 needs to be determined for minimizing the mass 
transfer effect and the phenomenon of rebinding of the LecEGF_CR2 construct to the 
surface. Diffusion and convection directly influence the mass transfer of the analyte 
from the bulk solution to the surface. Complications due to mass transfer disturb the 
binding event by introducing a second equilibrium [Eq.(7)]. 
 
                 km                                                   koff 
 Abulk       ⇆      Asurface + L     ⇆     AL                  (7) 
                         km                                                   kon 
 
 
Mass transfer depends on the flow cell dimension (limited impact due to 
miniaturized flow cells in Biacore system), the diffusion coefficient of the analyte and 
the flow rate of the bulk solution. Therefore, high molecular weight of analytes such 
as 70 kDa for the LecEGF_CR2 construct, risk to show mass transfer effects. 
Increasing the flow rate can reduce the influence of mass transfer. However, since a 
relatively high flow rate of the bulk solution, 20 µl/min, was already used, it was 
maintained in order to stay as close as possible to the conditions used in the capture 
assay.  
 
A second parameter for limiting the mass transfer effect was the density of the 
immobilized ligand. With a ratio 1:100 of JE-14/EA, a 1:1 binding model, which 
included mass transfer effects showed a coefficient for mass transfer of 108 M-1s-1. 
The estimate mass transfer coefficient was much higher than the kon of approximately 
104 M-1s-1. Therefore, the conditions for immobilization of JE-14 which led to a high 
signal-to-noise ratio did not exhibit rebinding of the analyte on the surface (flat steady 
state and rapid return to the baseline at the end of the injection) and showed a 
negligible mass transfer effect (Table 20). 
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Table 20. Evaluation of the affinity and binding kinetics of JE-14 for the LecEGF_CR2 construct under 
different conditions of coupling of the ligand on the surface. The corresponding sensorgrams and 
equilibrium binding isotherm plots are presented below. A,E: JE-14/EA 1:1; B,F: JE-14/EA 1:10; C,G: 
JE-14/EA 1:50; D,H: JE-14/EA 1:100. 
 
Ratio  
JE-14/EA 
kon  
[104 M-1s-1] 
koff [s-1] KD kin [µM]* KD eq [µM]** t1/2 [s]*** 
Rmax 
 [RU] 
1:1 n.d. n.d. n.d. 4.42 n.d. 4’380 
1:10 n.d. n.d. n.d. 6.81 n.d. 1’450 
1:50 n.d. 0.12 n.d. 8.6 5.9 375 
1:100 3.23 0.28 8.72 8.88 2.46 254 
 
 
 
 
 
 
A                                               B                                               C                                                  D      
 
 
 
 
 
E                                               F                                                 G                                                  H      
 
 
The kon and koff were similar in the reverse assay and in the captured assay. 
Except for the 1:1 ratio, higher KDs were observed in the reverse assay. This 
fluctuation of about 30% was in the range of those observed with the capture assay. 
This result confirms the accuracy of the capture assay used for evaluation of E-
selectin ligands. 
 
Reverse assay with E-selectin/IgG  
 
The affinity of E-selectin/IgG for the linked compound was also evaluated by 
injection of a serial dilution of the E-selectin/IgG starting at 58 µM over the surface 
containing the lowest density of immobilized JE-14. The assay was run in presence 
of 5% DMSO in order to have measurement conditions as close as possible to the 
capture assay. As shown in Figure 30A, a fit with the simple 1:1 binding site model 
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failed. Nevertheless, the binding signals obtained showed a nearly perfect fit by using 
a 1:2 binding model (Figure 30B). 
 
                       A                                                                       B                                            
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Binding isotherm plot of JE-14 for E-selectin/IgG using a 1:1 binding model (A) and a 1:2 
binding model (B). 
 
The two binding events were analyzed independently as shown in Figure 31 A 
first binding event occurred in the micromolar range (KD = 12.1 µM) and a second in 
the nanomolar range (KD = 320 nM).  
 
 
 
 
 
 
 
 
Figure 31. Isolation of the 2 binding events observed in the biacore reverse assay for characterizing 
the binding of JE-14 to E-selectin/IgG.  
 
The dimeric form of E-selectin (IgG construct) can explain the two observed 
binding events. Indeed, the protein is expressed as a dimer due to the presence of 
the Fc part in the construct. A lower density of JE-14 on the surface would probably 
lead to the observation of only one binding event in the micromolar range, similar to 
the value observed in the capture assay. 
It is known from NMR studies (see chapter 4) and from competitive polymer 
binding assay that both, LecEGF_CR2 construct and E-selectin/IgG have similar 
affinities for mimics of sLex. Therefore, to avoid complications due to the dimer form 
of the E-selectin with an IgG(Fc) construct, LecEGF_CR2 construct will be used in 
future reverse assay experiments. 
KD = 320 nM KD = 12.1 µM 
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3.4 Conclusion 
 
The selectins have been one of the most actively studied families of 
carbohydrate-binding proteins since their discovery in the 1980’s. Because of their 
key-role in leukocytes recruitment, selectins are involved in many acute or chronic 
inflammatory diseases (e.g. arthritis, asthma, allergies, stroke) as well as in cancer. 
In inflammatory diseases, non-steroidal or steroid-based drugs are available, but 
show well-documented side effects. An antibody therapy against chronic 
inflammatory diseases recently emerged, but its utility is limited by high costs. 
Consequently, the modulation of leukocyte recruitment via interference with cell 
tethering is of high therapeutical interest. For cancer treatment, a combined approach 
with chemotherapy and administration of a selectin antagonist is likely to be more 
efficient. Therefore, the identification of a potent selectin antagonist would present 
new therapeutic opportunities. 
One of the research themes at the Institute of Molecular Pharmacy (IMP) is 
aimed on identifying carbohydrate mimics based on the natural ligand of selectin. By 
determining the pharmacophores relevant for the binding event and optimizing the 
pre-organization of the core of the ligands, BW-69669 was developed as a lead 
compound. Based on this tetrasaccharide mimic, several ligands were synthesized in 
order to further improve the potency. In order to evaluate the impact of chemical 
modification of the ligands on the binding event, a fast and reliable assay was 
needed. Biacore technology was available in-house with the advantage of lacking the 
need of any labeling, allowing real-time detection and high degree of automation, the 
necessity of low consumption of protein and ligands and giving access to kinetic and 
affinity parameters. Nevertheless, analyzing small molecules like carbohydrates can 
be very challenging, since the intensity of the signal is directly related to the size of 
the analyte. After failing in the direct amine coupling of the E-selectin to the surface, 
a stable capture assay via anti-human IgG was successfully established and allowed 
the evaluation of numerous E-selectin ligands. Together with NMR studies (see 
Chapter 4), cell-free static assays, ITC measurements and MC(JBW)/SD-simulations, 
the Biacore results provide useful information for the design of more potent 
antagonists. As shown in this chapter, an improvement of the affinity by a factor of 
120 was observed between BW-69669 and the highest affinity compound, BW-529. 
Nevertheless, BW-529 is an exeption and for most of the derivatives synthesized, the 
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affinity reached only low micromolar affinity (e.g. GMI-1077, DS-0567). 
Thermodynamic studies showed an evolution of enthalpy and entropy contributions 
by introducing chemical modification in key positions for the stabilization of the 
bioactive conformation. However, the parameter influencing the thermodynamic 
behavior of the tested selectin antagonist could not be clearly attributed. 
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4. Binding epitope studies of the first generation of E-selectin 
antagonists by STD-NMR 
 
4.6 Introduction 
 
4.6.1 General points 
 
Isidor Rabi first described a “new method for measuring nuclear magnetic 
moment” in 1938 [1], a method which form the basis of continuous wave NMR. After 
the Second World War, in 1946, Felix Bloch and Edward Mills Purcell refined the 
technique for use on solids and liquids [2,3]. For this work, they shared the Nobel 
Prize in physics in 1952. 
Atomic nuclei are composed of nucleons (neutrons and protons) having an 
intrinsic quantum property of spin. The spin quantum number I corresponds to the 
overall spin of the nucleus. As shown by Eq. (1), the important property for NMR is 
the association of the spin with a magnetic moment (µ) colinear to I, where γ is the 
gyromagnetic ratio, specific for each nucleus: 
 
µ =  γ (h/2π) I                 (1) 
 
The magnetic moment allows the observation of NMR absorption spectra 
caused by transitions between nuclear spin levels. In principle, NMR involves two 
steps: 
 
• Alignment of the magnetic nuclear spins in the magnetic field (Bo) 
• Perturbation of the alignment of the spins by applying radio frequency pulse 
 
Most nuclei have no nuclear magnetic moment and do not exhibit NMR 
absorption spectra. However, certain magnetically active nuclei (e.g. 1H, 13C, 15N, 
17O) can adopt nuclear spin states of different energy in a magnetic field. When a 
radio-frequency radiation at the resonance frequency of the nucleus (Larmor 
frequency) is applied, these nuclei can be observed in NMR.   
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Ideally, each nucleus in a molecule experiences a different chemical 
environment and thus can be recognized by a characteristic chemical shift. 
Magnetization can be transferred between nuclei both through chemical bonds (spin-
spin coupling) and through space over short distances (dipole-dipole coupling) [4].  
NMR spectroscopy was originally dedicated mainly to the caracterization of 
smaller molecular structures. Even in its early stage of development, it was 
recognized as an important technique to support pharmaceutical research. In 1965, 
Jardetzky et al.  detected and characterized the binding of penicillin to serum albumin 
[5]. This first report of NMR as a “binding-assay”, opened the door to numerous 
investigations which followed [6-10].  In 1996, the publication of SAR-by-NMR  by 
Abbott Laboratories [11] further demonstrated the potential of NMR in drug design 
and discovery and catalyzed its impact in pharmaceutical research. Since 15 years, 
many new methods, adapted to detect and quantify ligand-target interactions with 
high sensitivity, emerged (e.g. chemical-shift mapping, nuclear-spin relaxation, 
transferred nuclear overhauser effect). The possibility to obtain structural information 
of both the target and the ligand are two desired goals that place NMR as a major 
tool contributing in all phases of drug discovery [12] from primary screening to lead 
optimization.  
 
4.6.2 Detection of ligand-binding by NMR methods 
 
As already mentioned, NMR methods for detecting ligand binding can be 
divided in two categories: ligand-based and target-based. The following text will focus 
on the ligand-based methods, which were used in this thesis. In addition, since 
detailed theoretical framework to explain and predict how ligand-binding modifies 
NMR parameters was reported by Peng et al. [13], these issues will not be discussed 
further. Ligand-observation techniques are based on the detection and observation of 
the resonances of the free ligand. If a ligand was transiently in a bound state during 
the measurement, its rotational and translational motions were modified. The ligand-
observation methods exploit the consequences of the transient bound state on the 
NMR properties: the ligand behaves as a large molecule (Figure 1) [14]. Thus, 
bounds ligands have large transverse relaxation rates, negative and large NOEs, 
highly efficient spin-diffusion and small molecular diffusion coefficients. 
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+
- Fast transverse relaxation
- Slow Brownian motion
- Negative and large NOEs
- Slow molecular diffution
- Efficient spin-diffusion
Target Ligand
- Slow transverse relaxation
- Fast Brownian motion
- Positive and small NOEs
- Fast molecular diffution
In the complex, the ligand has 
similar properties to those of
the target
Complex
 
 
Figure 1. NMR properties of small molecules in a unbound and in an bound form. 
 
One can cited four main advantages of ligand-based methods [15]:  
 
• Small quantities of target are required (typically 1-10 µM).  
• No labeling of the target is required. 
• Rapid evaluation of new targets is possible. 
• Majority of ligand-based screening NMR uses 1H NMR. 
 
The main disadvantages are the required solubility of the ligands and the 
inability to localize the binders on the receptor, as well as a risk of non-specific 
binding increased by the use of high concentration of ligands. Ligand concentrations 
of a few hundred micromolar are usually required to obtain meaningfull data. These 
limitations tend to be minimized due to improvements in the instrumentation, which 
require less and less material, while still keeping a similar or even better sensitivity 
(e.g. cryoprobes, advent of the first 1 GHz NMR spectrometer in 2009 in Lyon, 
France [16]). Recent development in the methods also greatly ameliorated the 
previously cited limitations [17,18]. Finally, a major drawback of the ligand-based 
methods is the need for significant dissociation during the experiments. For this 
reason, only weak ligands can be observed directly when the concentration of the 
ligand is considerably larger than that of the receptor (affinity range between few 
micromolar up to milimolar) [13]. Tightly binding ligands with slow off rates appear as 
non-binders and therefore the risk of false negative is non-negligible. Several 
methods exist to overcome this problem, for example competition assays have been 
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developed e.g. NMR reporter screening [19-21]. If the receptor is available in large 
quantities, a stoichiometric ratio of the ligand to receptor can directly reveal tight 
binding. 
 
Two categories of ligand-based experiments are distinguished:  
 
• those exploiting the alteration of the relaxation parameters and diffusion 
coefficients (selective T1 and T2 enhancement) [22], 
• those exploiting 1H magnetization transfer from the target to the bound ligand 
(STD and waterLOGSY). 
 
These methods are largely used at the Institute of Molecular Pharmacy to 
provide crucial information in the current drug discovery and development projects 
from ligand screening to binding epitope and conformational analysis [23]. Their 
application to the development of E-selectin antagonists is presented in the following 
two chapters of this PhD work.  
 
4.6.2.1 Methods based on relaxation enhancement 
 
In the presence of the protein, an increase of the relaxation rate observed via 
a faster attenuation of the ligand signal at long relaxation periods is a strong 
evidence for the binding [7,8, 24, 25].  The effect can be enhanced by the attachment 
of spin labels to the protein [26].  
 
Transverse relaxation rates 
 
This method was and is the most commonly used, mainly due to its 
dependence on the overall molecular rotational correlation time, τC. Indeed, when the 
ligand binds to the target, its τC becomes transiently as large as for the target. Since 
the rate of transverse relaxation, R2, increases monotonically with τC, the R2,bound ligand 
>> R2, free ligand. 
To detect the binding, it is possible to compare the height and broadening of 
resonance lines in the 1H NMR spectrum of a ligand on the addition of the target.  
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This is due to the fact that the homogeneous linewidth has a fullwidth at half 
maximum height (FWHM) for a given resonance of R2/π. The peak height is also 
affected and proportional to 1/R2.   
Comparison of peak heights in the presence and in absence of the target 
allows the measurement of the free and the bound R2 rates by using a spin-lock (e.g. 
a CPMG pulse train or continuous-wave irradiation) as in R1ρ experiments. In such 
experiment, relaxation times are chosen such that the resonances of the target 
molecule are filtered away but not the resonances of binding ligands.  
In the case of weakly binding molecules and/or low ligand concentrations, the 
sensitivity of the detection is improved by subtracting the spectrum of the target alone 
from all spectra prior to analysis [25]. 
 
Selective longitudinal relaxation rates 
 
The selective longitudinal relaxation time (sR1) of a ligand is also a parameter 
altered by a binding to a macromolecular target. The measurement of a selective R1 
is based on the inversion recovery measurement of a restricted frequency range. 
Selective R1 experiments can also be applied in a screening process with the 
conditions to have isolated and well assigned resonances and to define a separate 
inversion-recovery pulse for each ligand [27]. 
 
4.6.2.2 Methods based on NOEs measurements 
 
A sensitive detection experiment is the saturation transfer difference (STD), 
which measures the transfer of NOE magnetization from the target to the ligand upon 
protein saturation [7,9,14,24,28]. In this experiment, a difference spectrum is 
generated, as indicated in its name. In a first on-resonance experiment, a train of 
frequency-selective radio-frequency pulses is applied to the receptor in a region of 
the spectrum that does not contain resonances of the ligand. Via an efficient process 
of spin-diffusion (due to the large molecular weight of the target), the saturation 
propagates through the target macromolecule. At the ligand-target interface, the 
saturation is transferred to the bound ligand via intermolecular 1H-1H cross relaxation. 
In a second experiment, so-called reference experiment, the radio-frequency train 
 
 
108 
pulses are applied off-resonance. The difference between the on- and off-resonance 
experiments yields the resonances from the ligand that have experienced saturation. 
Applying an R2 relaxation filter prior to detection eliminates the resonances of the 
target in the on-resonance spectrum. The main advantages of STD-NMR are: (i) the 
efficiency of the method with large target macromolecules, (ii) the requirement of low 
quantities of target, and (iii) that only ligands which bind are detected. In 2001, Mayer 
and Meyer introduced the concept of an “amplification factor” in STD experiment [29]. 
It was suggested to accurately estimate the affinity constant (KD) of ligands by 
including this factor that provides an average of the saturated ligand turn-over per 
target. One limitation of the methods is for high-affinity ligands with a long residence 
time. Thus, if the turn-over of saturated ligand is too slow, the population of unbound 
saturated ligands decreases and no STD signal can be recorded. The range of KD 
suitable for STD methods was estimated between 10-3 and 10-8 M [28]. Nevertheless, 
competition STD NMR methods were developed for the detection of high-affinity 
ligands [30]. Many parameters also influence the sensitivity of the method such as: 
efficient magnetization transfer through the target, thus challenging its applicability to 
low proton density receptors, such as oligonucleotide targets. In addition, the degree 
of saturation of the receptor is dependent on a competition between the influx of 
magnetization and various R1 relaxation and leakage mechanism (by exchange with 
solvent protons). Finally, STD is compromised for low molecular weight targets (risk 
of inefficient spin diffusion) [13]. 
In the context of this thesis, STD was applied to determine the epitope 
mapping of sLex bound to E-selectin [31]. Dr. Brian Cutting enhanced the sensitivity 
of the methods through optimization of the excitation scheme [32]. In the present 
chapter, STD experiments were performed on a first-generation of E-selectin 
antagonists in order to get further information on the binding epitopes of those 
compounds. 
 
A second method called Water-Ligand Observed via Gradient SpectroscopY 
(waterLOGSY), is based on the magnetization transfer from the bulk solvent (water) 
to the bound ligand [33]. This experiment is closely related to STD but in that case 
the energy is transferred first to the water, then to the receptor and finally to the 
ligand. Binding compounds are distinguished from non-binding by their differential 
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cross-relaxation properties with water. For the binding ligands, the magnetization is 
transferred rapidly via dipole-dipole interactions to the ligand with a long rotational 
correlation time due to the concomitant contact with the target. This is not the case 
for non-binding ligands. As a consequence, cross-relaxation rates are opposite and 
of different magnitudes and thus, waterLOGSY signals of binding and non-binding 
ligands are also opposite in sign.  In 2008, Günthner and coworkers described a new 
NMR method called SALMON (Solvent Accessibility, Ligand binding, and Mapping of 
ligand Orientation by NMR spectroscopy) based on waterLOGSY for the 
determination of the orientation of a ligand bound to its target by mapping its solvent 
accessibility [34]. In this approach, all protons on non-exchangeable position were 
replaced by deuterium. Therefore, the protonation due to the dissolvation in water, 
required for waterLOGSY, was only possible in exchangeable positions of the 
backbone and side chains. The minimal protonation of the target limited NOEs that 
were not from H2O and supported the fact that the magnetization transfer from water 
to the ligand in the presence of the protein was attributed to water molecules bound 
to the surface of the target. 
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4.7 Material and methods 
 
4.7.1 Instrumentation  
 
All spectra were recorder in-house with a Bruker DRX-500 (Bruker BioSpin 
AG, Fällanden, Switzerland) equipped with Z-gradient SEI probe. Relaxation, STD, 
COSY and TOCSY experiments were measured at 298.15 K, without spinning, and 
with a gas flow of 250 l/h. trNOESY experiments were measured at 310 K with a spin 
rate of 20 Hz, the gas flow increased to 400 l/h. Competitive selective T1 experiment 
were measured at 278.15 K with a spin rate of 20 Hz, the gas flow increased to 400 
l/h. 
In order to limit the protein consumption, Shigemi tubes (Sigma Aldrich GmbH, 
Buchs, Switzerland) were used for samples containing E-selectin. A volume between 
230 and 250 µl was prepared. For samples containing only the ligand, a 500 µl 
volume was prepared and ordinary 5 mm NMR tubes were used (Sigma Aldrich 
GmbH, Buchs, Switzerland). All tubes were cleaned with bidistilled water and washed 
twice with D2O. Most of the experiments were manually run. In a few cases the 
automatic sampler charger (B-ACS 60, Bruker BioSpin AG, Fällanden, Switzerland) 
was used. 
Before each experiment, the spectrometer was optimized for the sample 
introduced in order to achieve an optimum resolution and sensitivity. The first 
procedure is the so-called “tuning and matching” of the probe head. It consists of an 
adjustment of the electrical properties of the coiled circuit for an optimal transmission 
of the radiofrequency pulses and an optimal reception of the signals. The procedure 
was done manually or by using the automated command of XWINNMR 3.6 or 
TOPSPIN 2.1. In a second step, the field frequency was locked according to D2O in 
order to keep the magnetic field homogeneity constant. Finally, an optimization of the 
field homogeneity was done by “shimming”. The procedure was done manually or by 
using the automated command of XWINNMR or TOPSPIN. To verify the optimization 
of the spectrometer to the sample, a single-pulse experiment, preceded by a low-
amplitude presaturation pulse, was recorded for each sample. 
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4.7.2 Reagent 
 
After expression and purification, the E-selectin/IgG and the LecEGF_CR2 
proteins were concentrated using centrifugal filter devices (Amicon® Ultra–4, 10k 
molecular weight cut-off from Millipore Corporation, Billerica, MA, USA) at 6,000 rpm 
at 4 °C.  Following the concentration, a buffer exchange was performed with a 
deutrated buffer (pH 7.4, 20 mM d11-Tris, 150 mM NaCl, 1 mM CaCl2 in D2O, Armar 
Chemicals) using the same centrifugal filter device. Protein samples between 15 and 
60 µM binding site concentrations were used in NMR experiment. 
Fifty mM stock solutions of all the ligand used was prepared in d6-DMSO. The 
final concentration of d6-DMSO did not exceed 10 % in samples containing protein. 
Ligand samples without protein were diluted either in D2O or in deutrated buffer.  
 
4.7.3 Software 
 
Bruker software XWINNMR version 3.6 and TOPSPIN version 2.1, operating 
on a PC running under Linux OS, were used as the interface with the spectrometer 
and to analyze the NMR data. MestReNova version 5.2.3-3833 was used for off-line 
analysis of the spectra. Prism 4 (GraphPad Software Inc., San Diego, USA) was 
used to fit the relaxation data. 
 
4.7.4 Experiments 
 
4.7.4.1 Relaxation experiments 
 
Spin-spin relaxation experiments 
 
The E-selectin/IgG was present at 20-30 µM in binding site concentration as 
determined by Bradford assay. A 50 mM stock solution of compound in d6-DMSO 
was prepared and diluted with deutrated buffer (pH 7.4, 20 mM d11-Tris, 150 mM 
NaCl, 1 mM CaCl2 in D2O, Armar Chemicals) to a final concentration between 1-5 
mM in the samples. Prior to the relaxation experiment, a calibration pulse width was 
performed. For that purpose, a series of experiment with progressively incremented 
excitation pulse duration were recorded. The 360º null was used for the calibration. 
The pulse sequence used for T1ρ determination was adapted from Hajduk [35]. To 
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determine the T1ρ relaxation rate, six experiments were performed with different 
durations of the continuous-wave spin-locked of 2 kHz (10, 50, 100, 150, 200, 250 
ms). The suppression of the signal of water was an important issue due to the 
presence of residual protons from solvent. Traces of non-deuterated D2O resulted in 
enhanced water signals in samples containing the protein. Therefore, a DPFGSE 
water suppression sequence was added at the end of the pulse sequence [36]. For 
each experiment, 8 scans were measured preceded by two dummy scans. The 
recovery delay between successive scans was set to 10 s and the receiver gain was 
adjusted to 256. 
Selective spin-lattice relaxation experiment 
The E-selectin/IgG was present at a binding site concentration of 10 µM, as 
determined by Bradford assay. The pulse sequence for a selective inversion recovery 
was used. A selective 25 ms I-Burp-16 180° pulse was applied to either the ortho-
hydrogen of the benzoate group of GMI-1077 or to the fucose H-6 of BW-69669. The 
resonances of the protons chosen were different from the water resonances to avoid 
artifacts due to radiation dumping [37]. In order to diphase any residual transverse 
magnetization, a 1 ms gradient pulse was applied after the selective pulse. For the 
determination of the selective inversion recovery time, a series of 10 experiments 
with increasing delays, to allow an increasing recovery of the longitudinal 
magnetization, were measured (0.075, 0.125, 0.175, 0.225, 0.3, 0.4, 0.5, 1, 2 and 3 
sec).  
 For competitive experiments, a new series of measurements were performed 
at 278.15 K and the selective pulse was applied to the galactose H-1 of BW-69669. 
This proton was chosen, because, at this temperature, it did not overlap with any of 
the resonances of GMI-1077. In a first step, a sample of E-selectin/IgG (10 µM 
binding site concentration as determined by the Bradford assay) was titrated by BW-
69669 and the corresponding selT1 values were determined.  Then, the selT1 of BW-
69669 at the concentration of 610 µM was measured in presence of E-selectin/IgG 
from the same batch as the one used for the determination of the titration curve. 
Finally, 50 µM of GMI-1077 was added to the sample and the selT1 observed was 
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correlated to an apparent concentration via the titration curve. A relative affinity was 
calculated by applying the Eq. (2). 
  
! 
BW "69669[ ]apparent = BW "69669[ ]real +  KDBW - 69669KDGMI - 1077  *  GMI -1077[ ]           (2) 
4.7.4.2 STD-NMR experiments 
 
In order to collect more information about on E-selectin/antagonists interaction, STD-
NMR experiments with GMI-1077, DS-0567 and BW-580 were performed in the 
presence of E-selectin/IgG or the LecEGF_CR2 construct. 
 
Pulse program parameters 
 
Before recording STD experiment, a calibration pulse was performed on the 
residual H2O resonance (4.73 ppm). 
The sensitivity of the STD experiment was enhanced through the use of an 
optimized excitation scheme [36]. The protein was saturated by applying an E-Burp-1 
90° cosine modulated selective pulse train split to two sidebands. The protein was 
saturated with 40 pulses of 50 ms each. The power level (sp11) was at an optimum 
at 51 dB and the number of scans set to 12K. For each STD, a reference (off-
resonance and without inverting the receiver phase) spectrum was measured. In 
addition, to ensure that there were no subtraction artifacts, a control experiment was 
measured in the absence of the protein at a similar concentration of ligand. For the 
control and the reference experiment, the number of scan was reduced to 1K. 
 
Sample 
 
Different batches of protein were used for the STD experiment and the 
conditions are summarized in Table 1. 
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Table 1. Description of the samples used to record STD-NMR spectra. 
 
Protein 
Protein binding 
site concentration 
[µM] 
Ligand 
Ligand 
concentration 
[mM] 
E-selectin/IgG 30 DS-0567 5 
E-selectin/IgG 30 GMI-1077 1 
LecEGF_CR2 
construct 
15 GMI-1077 1 
E-selectin/IgG 60 BW-580 1 
E-selectin/IgG 30 BW-69669 1 
E-selectin/IgG 30 DS-0560 2 
 
4.7.4.3 Competitive STD-NMR experiment 
 
A competitive STD-NMR experiment was performed with BW-69669 and DS-
0560 [38]. The same pulse program as described in section 4.2.4.2 was used. The 
concentration of E-selectin/IgG binding site was 15 µM and 1 mM of BW-69669 was 
added to the solution. Then, increasing concentrations of DS-0560 were added to the 
mixture (200 µM and 300 µM). 
 
4.7.4.4 Group epitope mapping 
 
Based on the STD experiment, the method of group epitope mapping (GEM) 
developed by Mayer et al. in 2001 was applied to E-selectin antagonists [39]. For 
each assigned resonance, a fractional STD effect was calculated by applying Eq. (3). 
I0 refers to the intensity of the STD signal of the reference spectrum and Isat the 
intensity of the same resonance in the STD spectrum. 
 
  
! 
I0 - Isat( )
I0
             (3) 
 
Each fractional STD effect obtained with Eq. (3) was normalized to the 
fractional STD effect obtained for the fucose H-6. This normalization allowed the 
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comparison between the group epitope mapping obtained for different compounds 
measured.  
 
4.7.4.5 selective TOCSY and COSY experiments 
 
 Changes in the chemical shift of DS-0567 were observed due to both 
binding to the E-selectin/IgG and use of a different buffer. The majority of the 
resonances were re-assigned using selective 1D and non-selective 2D TOCSY 
experiments and a COSY experiment. A sample of E-selectin/IgG, at a binding site 
concentration of 30 µM, was mixed with 5 mM of DS-0567 and used to record 
selective TOCSY spectra.  A COSY experiment was measured with a sample 
containing 5 mM of GMI-1077 and with a sample containing E-selectin/IgG at a 
binding site concentration of 60 µM and 1.88 mM of GMI-1077. 
 
4.7.4.6 trNOESY experiment 
 
 The temperature was increased to 310 K and trNOESY experiments were 
recorded with a sample containing 5 mM of GMI-1077 and with a sample containing 
1.88 mM of GMI-1077 and E-selectin/IgG (60 µM binding site). 
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4.8 Results and discussion 
 
4.8.1 Relaxation experiments of BW-69669 and GMI-1077 in the presence of 
E-selectin/IgG 
 
Measurement of ligand relaxation properties was, and is, largely used to 
identify and characterize protein-ligand interactions. In this kind of experiment, the 
resonances of the ligand are observed. If the ligand is transiently bound to the E-
selectin/IgG during the observation, the signal will be affected. Indeed, in the bound 
state, the ligand does not behave like a small molecule, but like the protein. 
Therefore, a faster relaxation will be observed. This can be explained by the 
dependence of the relaxation rates on the molecular tumbling rate (inverse of the 
correlation time, τc) [40].  A series of relaxation experiments was performed in order 
to check the applicability of NMR to our E-selectin/ligand studies and correlate the 
results with the other techniques used in the project (Biacore and ITC). 
Selective spin-lattice relaxation rates (selT1) and spin-spin relaxation rates 
(T1ρ) were measured in the absence and in the presence of the E-selectin/IgG for 
the lead compound, BW-69669, and the optimized ligand, GMI-1077. Subsequently, 
a competitive selT1 experiment between the two compounds was performed. 
 
4.8.1.1 Spin-spin (T1ρ) relaxation experiments  
 
T1ρ relaxation of BW-69669 
 
Signals were recorded after increasing spin locked times (10, 50, 100, 150, 
200, 250 ms). For one selected peak, E-selectin/IgG exhibited a relaxation rate six 
times higher than BW-69669, because of the high molecular weight (296 kDa). An 
increase of the BW-69669 relaxation rate was observed in presence of the protein, 
indicated a binding event (Figure 2).  
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Figure 2. BW-69669 (1.5 mM) spectra in the presence of E-selectin/IgG at different spin lock times 
(250 ms red, 150 ms blue, 10 ms black) (A). Decay of the signal intensity of BW-69669, E-selectin/IgG 
and mixture of BW-69669 (1.5 mM) with E-selectin/IgG (10 µM binding site) (B). Calculated time 
constants (C).  
 
 
In order to verify that no equilibration time was required, a series of 
measurements was performed immediately after mixing BW-69669 with the protein 
and after 4h at room temperature. No significant difference in the relaxation rate 
could be observed (Figure 3). This indicates, for non-competitive binding, that no 
equilibration time is required prior measurement. 
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Figure 3. Decay of the signal intensity of BW-69669 (1.5 mM), E-selectin/IgG and BW-69669 (1.5 
mM) with E-selectin/IgG immediately after preparing the sample (t0) and after 4h of equilibration at 
room temperature (t) (A). Calculated time constants (B). 
 
T1ρ relaxation of GMI-1077 
 
A similar experiment was conducted with GMI-1077. An enhancement of the 
binding by a factor of 30 was observed between BW-69669 and GMI-1077 with the 
Biacore captured assay. The relaxation rate was calculated at 2 resonances, 8.01 
ppm, corresponding to the resonance of the aromatic ortho-hydrogen of the benzoate 
in the 2-position of galactose, and 3.86 ppm, corresponding to the resonance of the 
non-aromatic hydrogen in the 4-position of galactose. In both cases, an 
enhancement of the relaxation rate by a factor of two was observed in presence of 
the E-selectin/IgG (Figure 4). This clearly demonstrated the binding between E-
selectin/IgG and GMI-1077. 
 
 
 
 
 
 
Time constant 
(s) 
E-selectin/IgG 0.035 
BW-69669 0.200 
E-selectin/IgG + BW-69669 (t0)  0.151 
E-selectin/IgG + BW-69669 (t) 0.156 
A 
B 
BW-69669 
E-selectin/IgG 
BW-69669 + E-selectin/IgG t0 
BW-69669 + E-selectin/IgG t 
 
 
A 
 
B 
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Figure 4. Decays of the signal intensity of the benzoate H-ortho at 8.01 ppm (A) of GMI-1077 and of 
the non-aromatic hydrogen galactose H-4 of GMI-1077 at 3.86 ppm (B). For both resonances, the 
measurement was performed with GMI-1077 (1 mM) in the absence and in the presence of E-
selectin/IgG (30 µM binding site). Calculated time constants for the samples previously described (C).  
 
4.8.1.2 Selective T1 relaxation 
 
Selective T1 relaxation of BW-69669 
 
A selective inversion-recovery sequence was used for the measurement. 
Initially, a selective π pulse was applied at 1.1 ppm corresponding to the fucose H-6. 
This was followed by a delay of either 0.075, 0.125, 0.175, 0.225, 0.3, 0.4, 0.5, 1, 2 
or 3 sec. Finally, a π/2 pulse to make the magnetization observable, and a water 
suppression scheme were applied and the signals recorded (Figure 5).  
 
 
 
                                                                             
  
 
Figure 5. Overlay of spectra of BW-69669 (1.5 mM) in presence of E-selectin/IgG (A). SelT1 
relaxation of BW-69669 (3 mM) in the absence and in the presence of E-selectin/IgG (B). 
A 
 
B 
 
C 
 
A 
 B 
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An increase in the relaxation rate is observed in the presence of the protein. 
However, the effect is less pronounced than the increase observed with the T1ρ 
relaxation experiment.  
 
Selective T1 relaxation of GMI-1077 
 
A selT1 relaxation experiment was performed by applying a selective π pulse 
on the resonances of the benzoate H-ortho in the 2-position of galactose (Figure 6). 
As previously observed for BW-69669, the relaxation rate of GMI-1077 was 
enhanced, indicating the binding. However, the effect was slightly less pronounced 
then the one observed with T1ρ experiment (see section 4.3.1.1).  
 
    
 
 
 
 
 
 
 
Figure 6. Recovery of the signal intensity of GMI-1077 at 8.01 ppm following increasing delays and 
calculated relaxation in the absence (1.88 mM) and in the presence (5 mM) of E-selectin/IgG. 
 
 
4.8.1.3 Competitive binding measurements using selective T1 relaxation 
 
Titration of BW-69669 with E-selectin/IgG 
 
The selT1 pulse sequence was selectively applied to galactose H-1 which did 
not overlap with any of the resonances from GMI-1077. The selT1 relaxation time 
was determined at increasing concentrations of BW-69669 (0.5 – 3 mM). The large 
dependence of the selT1 time constant on the concentration of BW-69669 allowed 
competitive binding experiments to be performed. For the competitive binding 
measured by selT1, an optimum concentration of 0.5 mM for BW-69669 was 
GMI-1077 + E-selectin/IgG 
GMI-1077 
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determined after titration (Figure 7). At that concentration, a change in the fraction of 
the free form of BW-69669 due to the replacement by a competitor will induce a 
significant change in the selT1 time constant.  
 
 
 
 
 
 
 
 
    
 
 
Figure 7. Titration of E-selectin/IgG (10 µM binding site) with BW-69669 and the corresponding selT1 
observed. 
 
Competitive binding experiment with GMI-1077 and relative affinity determination  
 
The titration of E-selectin/IgG with BW-69669 was repeated with a new 
sample of E-selectin/IgG (10 µM binding site). A slight increase in the selT1 was 
found at 0.5 mM of BW-69669 (0.34 s in the first measurement versus 0.38 s in the 
second sample) and at 1 mM (0.41 s in the first measurement versus 0.45 s in the 
second sample). Nevertheless, the shift in selT1 was the same between 0.5 mM and 
1 mM in both sample (Δ = 0.04 s), indicating that the variation between the 
measurements was related to the use of different batches of protein samples. This 
will minimally affect the determination of the relative affinity of GMI-1077, because 
the same batch of protein was used to determine the titration curve and for the 
competitive measurement. In the presence of 50 µM of GMI-1077, the observed 
selective relaxation rate was increased to 0.47 s leading to an apparent 
concentration of BW-69669 of 1.37 mM. The relative affinity was determined by 
applying Eq. (4). 
 
  
! 
BW "69669[ ]apparent = BW "69669[ ]real +  KDBW - 69669
KDGMI - 1077
 *  GMI-1077[ ]            (4) 
 selT1 (s) 
BW-69669 (1 mM) 0.54 
BW-69669 (0.5 mM) + E-selectin 0.34 
BW-69669 (1 mM) + E-selectin 0.41 
BW-69669 (1.5 mM) + E-selectin 0.44 
BW-69669 (2 mM) + E-selectin 0.46 
BW-69669 (2.5 mM) + E-selectin 0.47 
BW-69669 (3 mM) + E-selectin 0.48 
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A relative affinity of GMI-1077 to BW-69669 of 0.066 was determined. This 
result unambiguously showed the considerable enhancement in affinity of GMI-1077 
compare to the lead compound BW-69669. The rIC50 obtained in the static cell free 
assay and the KD obtained in Biacore were normalized to the affinity value of BW-
69669 (Figure 8). High consistency of the data from the different assays format was 
observed confirming the enhancement of the affinity between the lead and the 
optimized compound.  
 
 
 
 
 
 
 
 
 
 
 
 rKD (NMR) 
rIC50  (static cell 
free assay) 
rKD (µM) 
(Biacore) 
GMI-1077 0.066 0.050 0.033 
BW-69669 1 1 1 
 
Figure 8. Titration of E-selectin/IgG (10 µM binding site) with BW-69669 and the corresponding selT1 
observed (black squares). The observed selT1 in the presence of 610 µM of BW-69669 (green 
triangle) and the observed selT1 when 50 µM of GMI-1077 was mixed to 610 µM of BW-69669 (red 
circle) are highlighted. Vertical and horizontal lines show the extent to which the relaxation of BW-
69669 in presence of 50 µM of the competitor GMI-1077 is attenuated and the corresponding apparent 
concentration of BW-69669. 
 
Since the binding of carbohydrate mimics to E-selectin/IgG was successfully 
observed by ligand-based NMR techniques, further studies by STD-NMR were 
conducted in order to collect complementary information about the physical basis for 
the observed affinity. 
 
 
 
 
Concentration 
(mM) 
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4.8.2 Transferred NOESY 
 
In the complex of GMI-1077 with E-selectin/IgG, the proximity between the 
benzyl substituent in the 2-position of galactose and the cyclohexane groups of GMI-
1077 complexed to E-selectin/IgG was investigated by trNOE NMR experiments. The 
measurements were conducted at 310 K to displace the residual water resonance. 
NOEs were observed between galactose H-2 and galactose H-1, galactose H-3, 
galactose H-4, fucose H-6 (Figure 9). With a 2D-COSY experiment, the assignments 
were confirmed. Cross-peaks indicating coupling between two protons in correlation 
spectroscopy are sizable provided they are within two to three bonds. This 
experiment is frequently used for carbohydrate assignment due to the possibility to 
determine each proton by “walking” around the ring through the coupling. 
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Figure 9.  trNOESY of GMI-1077 (1.88 mM) in presence of E-selectin/IgG (60 µM binding site) and 
COSY recorded with the same sample used for the assignement of the resonances. Cross-peak are 
indicated with an asterisk. 
 
* 
* 
 
* 
* 
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In the presence of protein, NOEs were also detected between benzoate H-
ortho, benzoate H-para and benzoate H-meta in the 2-position of galactose. 
However, no NOEs with these hydrogens to other resonances were detected (Figure 
10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. NOESY of GMI-1077 (5 mM) in the direct dimension (A). trNOESY of GMI-1077 (1.88 mM) 
in presence of E-selectin/IgG (B). trNOESY 2D of the benzoate in the 2-position of galactose (C).  
 
 
The global minimal distance estimated between galactose H-2 and galactose 
H-3 is 3.06 Å. Therefore, the absence of NOEs between the benzoate in the 2-
position of galactose and the cyclohexane groups indicate that these groups are 
separated by more than 3.06Å. 
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4.8.3 2D-TOCSY experiments for assignment of the resonances of DS-0567 
in the presence of E-selectin/IgG 
 
 To ensure the purity and the quality of newly synthesized compounds, NMR 
measurements were performed and resonances were assigned. These NMR 
experiments were conducted in deutrated organic solvents (usually deutrated 
methanol) at high concentration of ligand (15-30 mM). In the STD experiments, the 
measurement was performed in the presence of the protein, at lower concentration of 
ligand (1-5 mM) in deutrated Tris buffer. These conditions might influence the 
chemical shift of the resonances. Therefore, 2D-TOCSY (Totally Correlated 
Spectroscopy) experiments were performed in the buffer used for the STD 
experiments and led to the assignment of most of the resonances of DS-0567 (Figure 
11). In these experiments, cross-peaks between coupled protons were observed for 
all protons within a spin-system. In the case of E-selectin ligands, each carbohydrate 
residue is an isolated spin system. Therefore, it is possible to assign each proton of 
the natural monosaccharide units. Considerable spectral overlap existed for the non-
natural units, such as the cyclohexane spacer, precluding the complete assignment. 
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Figure 11. TOCSY experiment of DS-0567 5 mM (0.9 mg in 250 µl) in presence of E-selectin/IgG 30 
µM (1.1 mg in 250 µl). Signals of the benzoate in the 2-position of galactose are expanded on the 
bottom left. 
 
 
4.8.4 STD-NMR experiments of DS-0567 in the presence of E-selectin/IgG 
 
To determine the binding epitope of DS-0567 interacting with E-selectin/IgG, 
STD-NMR experiments were performed. The experiment showed large STD values 
for the benzoate in the 2-position of the galactose moiety (Table 2 and Figure 12), 
which were unexpected, based on the docking experiments with the crystal structure 
[41]. 
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Figure 12: STD and reference spectra of DS-0567 with E-selectin/IgG. Resonances observed for the 
benzoate in the 2-position of galactose are indicated as well as the fucose H-6, taken as a reference 
for the STD-NMR epitope mapping. 
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Table 2. STD-NMR epitope map of DS-0567 with E-selectin/IgG. 
 
 
 
 
 
 
 
 
 
According to docking studies by molecular modeling, the benzoate in the 2-
position of galactose is oriented toward the bulk solvent, which is not compatible with 
large STD values observed. Four hypotheses were suggested to reconcile the 
differences between the STD-NMR and docking results: 
 
(i) Non-specific binding, 
(ii) Artifacts, 
(iii) Related to the dimeric form of the protein, 
(iv) Another binding mode. 
 
4.8.5 Non-specific binding: an issue tested by STD-NMR of DS-0567 with E-
selectin/IgG. 
 
To substantiate or negate hypothesis (i), 2 mM ETDA was added to the 
sample and the STD-NMR experiments repeated. As seen in Figure 13, the STD-
NMR signals are greatly attenuated upon addition of EDTA indicating the calcium 
dependent interaction observed for other E-selectin antagonists. 
 
 
 
 
 
 
Resonance 
DS-0567 
E-selectin/IgG 
benzoate H-ortho 283% 
benzoate H-para 386% 
benzoate H-meta 332% 
galactose  H-4 125% 
cyclohexane 3-ethyl 174% 
fucose  H-1 128% 
fucose  H-6 100% 
O
O
HO
O
O
HO
OH
OH
O
COONa
OH
100%
174%
283% 332%
386%
125%
128%
O
O
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Figure 13: STD-NMR of DS-0567 with E-selectin/IgG (red spectrum) and STD-NMR of DS-0567 with 
E-selectin/IgG and 2 mM EDTA (green spectra). 
 
4.8.6 Artifacts: an issue tested by STD-NMR of DS-0567 with E-selectin/IgG 
 
Different STD-NMR saturation times were recorded in order to verify that the 
signals of the aromatic hydrogens are not artifacts of either spin-diffusion or slow 
relaxation times [42]. As shown in Table 3, the STD-NMR epitope of DS-0567 with E-
selectin/IgG remained essentially constant for all saturation times.  
 
Table 3. Epitope map of DS-0567 binding to E-selectin/IgG with different saturation times. The epitope 
for each saturation time is normalized to the value of the benzoate H-para in the 2-position of 
galactose. 
 
Saturation time 
(ms) 
Bz H-
para 
Bz H-
ortho 
Bz H-
meta 
Non 
aromatic  
(5.14 ppm) 
Non 
aromatic 
 (3.85 ppm) 
200 1.00 0.67 0.82 0.32 0.33 
300 1.00 0.66 0.83 0.34 0.36 
400 1.00 0.60 0.82 0.32 0.37 
500 1.00 0.62 0.90 0.42 0.32 
1000 1.00 0.60 0.89 0.33 0.38 
 
In addition, artifacts from subtraction errors were investigated. Subtraction 
errors were estimated by repeating the STD-NMR experiments with a 5 mM sample 
of DS-0567, but without the E-selectin/IgG. However, no significant subtraction errors 
were observed.  
 
 
ortho  
         
  
          para 
benzoate H 
 meta 
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4.8.7 Large STD values of the benzoate in the 2-position of galactose due 
to the dimeric form of the protein: an issue tested by STD-NMR 
experiments of GMI-1077 and a monomeric E-selectin construct. 
 
The binding epitope of GMI-1077 interacting with E-selectin/IgG was 
determined by STD-NMR experiments. Again, the experiment showed unexpectedly 
large STD values for the benzoate in the 2-position of the galactose (Table 4 and 
Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: STD and reference spectra of GMI-1077 (1mM) with E-selectin/IgG. Resonances observed 
for benzoate in the 2-position of galactose as well as fucose H-6, taken as a reference for the STD-
NMR epitope mapping, are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fucose H-6 
  benzoate H 
 
 meta 
ortho   para 
fucose H-6 
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Table 4. STD-NMR epitope map of GMI-1077 with E-selectin/IgG.  
 
 
 
 
 
 
 
 
 
 
 
To ensure that the STD signals observed were not related to the dimeric form 
of the E-selectin/IgG construct, an STD-NMR experiment in the presence of a 
monomeric E-selectin construct, the LecEGF_CR2 construct, was performed (Table 
5, Figure 15). 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Figure 15: STD-NMR of GMI-1077 with LecEGF_CR2 construct. Resonances observed for the 
benzoate in the 2-position of galactose and fucose H-6 are indicated. The latter was taken as a 
reference for the STD-NMR epitope mapping. 
 
Resonance 
GMI-1077 
E-selectin/IgG  
benzoate H-ortho 404% 
benzoate H-para 500% 
benzoate H-meta 431% 
galactose H-4 245% 
3-methyl cyclohexane 183% 
fucose H-1 278% 
 fucose H-6 100% 
ortho  
      para  
 
benzoate H 
 
meta 
fucose H-6 
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Table 5. STD-NMR epitope map of GMI-1077 with LecEGF_CR2 construct. 
 
 
 
In the presence of the monomeric form, as well as in the presence of the 
dimeric form, the STD signals of the benzoate in 2-position of galactose showed 
large STD values (Figures 14, 15 and 16, Tables 4 and 5). The normalized intensities 
of the STD epitope in the presence of the LecEGF_CR2 construct (monomeric form) 
were lower than those obtained with E-seletin/IgG (dimeric form) (Figure 16). The 
resonances observed for the benzoate in the 2-position of galactose in the presence 
of the dimeric form showed a normalized intensity twice as big as those observed 
with the monomer form. The difference may be due to the difference of molecular 
weight of the two forms (70 kDa vs 396 kDa). In general, the larger the molecular 
weight, the slower the molecular tumbling, leading to a more efficient Overhauser 
transfer between nuclei. It is conceivable, although contradicts an earlier publication 
on the method [43], that different nuclei in E-selectin are saturated to different extents 
depending on the presence of the monomeric or dimeric form. Furthermore, the 
number of consensus repeat in the structure of the chimera protein has been shown 
to influence the binding [44]. Therefore, the presence of less consensus repeat in the 
monomeric chimera of E-selectin leads to a loss of affinity for antagonists. This might 
also have a consequence on the STD signals observed, since the different affinities 
in the two E-selectin forms could be due to a negative impact of the chimera 
construct on binding site. 
 
 
Resonance 
GMI-1077 
LecEGF_CR2 
construct 
benzoate H-ortho 190% 
benzoate H-para 196% 
benzoate H-meta 192% 
galactose H-4 218% 
3-methyl cyclohexane 102% 
fucose H-1 200% 
  fucose H-6 100% 
O
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Epitope map of GMI-1077 with E-selectin monomer 
versus dimer 
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Figure 16: STD-NMR epitope map of GMI-1077 with the monomeric and the dimeric forms of E-
selectin. 
 
4.8.8 STD-NMR experiments of BW-580 
 
To provide further insight into the large STD signals observed for the benzoate 
in the 2-position of galactose, BW-580 was investigated. BW-580 has a cyclopropyl 
carboxylate in the 2-position of galactose. The STD-NMR with E-selectin/IgG showed 
clear STD signals of the cyclopropyl carboxylate (Figure 17 and Table 6).  
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Figure 17: STD-NMR of BW-580 with E-selectin/IgG. Resonances observed for cyclopropyl in the 2- 
position of galactose and fucose H-6 were indicated. The latter was taken as the reference for the 
STD-NMR epitope mapping. 
 
Table 6. STD-NMR epitope map of BW-580 with E-selectin/IgG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Resonance 
BW-580 
E-selectin/IgG 
cyclopropyl H-1 119% 
cyclopropyl H-2  119% 
galactose H-2 111% 
galactose H-3 160% 
3-methyl cyclohexane 79% 
fucose H-2 202% 
fucose H-3 225% 
fucose H-4 189% 
fucose H-6 100% 
fucose H-6 
O
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79%
225%
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4.8.9 STD-NMR experiments of BW-69669 and DS-04115 
 
To obtain further insights into the interaction of antagonists with E-selectin, the 
results of previous STD-NMR experiments of BW-69669 and DS-04115 (Figure 18) 
are included. 
 
 
O
O
HO
O
O
HO
OH
OH
O
COONa
OH
100%
246%
OH
221%
166%
200%
120%
O
O
HO
O
O
HO
OH
OH
O
COONa
OH
100%
225%
OH
210%
145%
191%
175%
72%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: STD-NMR epitope map of BW-69669 (left) and DS-04115 (right) with E-selectin/IgG (Dr. 
Brian Cutting). 
 
The epitope map of BW-69669 and DS-04115 showed a high degree of 
similarity indicating a similar binding mode except for the fucose H-1 (Figure 18). The 
difference between the fucose H-1 STD values might be explained by the nearby 3-
methyl cyclohexane in DS-04115, which is absent in BW-69669. The steric hindrance 
of this group might influence the proximity to the protein surface. 
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4.8.10 Additional studies and comparisons of different epitope maps of 
compound studied  
 
GMI-1077 and DS-0567 have similar KD values (1.46 and 1.49 µM, 
respectively) determined by Biacore. The epitope map of GMI-1077 and DS-0567 
showed a similar pattern (Table 2 and 5). The main differences in the epitopes are in 
the normalized intensities, which are for some resonances 1.2 to 2 times larger than 
for GMI-1077 (Figure 19).  
Similar STD intensities were observed for the 3-methyl cyclohexane in GMI-1077 and 
the 3-ethyl cyclohexane in DS-0567. STD intensity of the fucose H-1 was two times 
larger in GMI-1077. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. STD-NMR epitope map of GMI-1077 (KD= 1.46 µM) and DS-0567 (KD= 1.49 µM) with E-
selectin/IgG. 
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In Figure 20, normalized STD intensities to the fucose H-6 of common 
assigned resonances of four compounds (GMI-1077, BW-580, BW-69669 and DS-
04115) are compared. For the benzoate in the 2-position of galactose the normalized 
STDs were more intense than those for the cyclopropyl carboxylate group in the 
same position in compound BW-580 (Figure 20). For other resonances from the 
galactose and the fucose moiety, a similar pattern was observed. We also noticed 
that the signal of the 3-methyl cyclohexane was significantly stronger for GMI-1077 
(the only compound of the series containing a benzoate group in the 2-position of 
galactose). A similarity in the intensity of the signal of the 3-methyl cyclohexane from 
GMI-1077 and the 3-ethyl cyclohexane of the DS-0567 (see section 4.3.4, Table 2) 
was previously observed. Both compounds contain a benzoate in the 2-position of 
galactose.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. STD-NMR epitope map of common assigned resonances of GMI-1077, DS-04115, BW-
69669 and BW-580 with E-selectin/IgG. 
 
4.8.11 STD-NMR experiments of DS-0560 
 
DS-0560 was synthesized as an intermediate planned for further modification. 
For this reason, an ester group was introduced in the 3-position of cyclohexane. In 
order to verify that the binding mode was not affected by this modification, STD 
experiments were performed. The experiment showed again large STD values for the 
benzoate in the 2-position of galactose (Figure 21).  
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Figure 21: STD-NMR of DS-0560 with E-selectin/IgG. Resonances observed for benzoate in the 2-
position of galactose were highlighted as well as fucose H-6 taken as reference for the STD-NMR 
epitope mapping. 
 
In competitive STD-NMR experiments, the displacement of BW-69669 by the 
DS-0560 in the presence of E-selectin/IgG (15 µM binding site) could clearly been 
shown. The presence of STD signals for the benzoate in the 2-position of galactose, 
present only in DS-0560, demonstrated the displacement of BW-69669 (Figure 22 A-
C).  A decay of the intensity of the signal of BW-69669 of about 50% was observed in 
the presence of 200 µM of DS-0560 (Figure 22 D). The loss of signal in Figure 22 D 
is attributed to BW-69669 since no signals from the benzoate of DS-0560 were 
visible (Figure 22 B). 
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Figure 22. A: STD experiment of BW-69669 (1 mM) in the presence of E-selectin/IgG (15 µM binding 
site). B: STD experiment of BW-69669 (1 mM) in presence of E-selectin/IgG (15 µM binding site) and 
DS-0560 (200 µM). C: STD experiment of BW-69669 (1 mM) in presence of E-selectin/IgG (15 µM 
binding site) and DS-0560 (300 µM). D: Overlay of A and B. Loss of intensity of the signal is indicated. 
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4.9 Conclusion 
 
The expression of isotopically enriched E-selectin in mammalian cells such as 
Chinese Ovarian Cells (CHO) is only possible at high costs [45]. Therefore, we 
choose NMR techniques based on ligand-observation for the detection and the 
characterization of interactions between E-selectin and antagonists. Only small 
amounts of unlabelled protein were required to perform relaxation (10 µM binding 
site) and STD experiments (30-40 µM binding site). Spin-spin and spin-lattice 
experiments were performed with the lead compound, BW-69669, and the optimized 
first-site ligand, GMI-1077. The changes in relaxation induced by the presence of the 
protein showed the interaction between E-selectin/IgG and these compounds. A 
competitive spin-spin relaxation experiment was performed and the relative affinity of 
GMI-1077 was comparable to those determined by Biacore and ITC.  
 
In order to obtain further information on the binding mode, STD-NMR 
experiments were performed and the binding epitope of several ligands elucidated. A 
comparison between STD-NMR epitopes of GMI-1077 and DS-0567 with E-
selectin/IgG showed large STD values for the benzoate in the 2-position of galactose 
in both cases. The same experiment was conducted with GMI-1077 and a 
monomeric construct of E-selectin (LecEGF_CR2 construct), where large STD values 
for benzoate in the 2-position of galactose were also observed. The issue of an 
artifact due to the dimeric form of E-selectin can therefore be excluded. Nevertheless, 
in the presence of the monomeric and the dimeric forms of E-selectin differences in 
signal intensities were observed for the same compound (GMI-1077). This is 
probably due to the difference of molecular weight of the protein and to a variation in 
the number of consensus repeats (CRs). 
 
In the presence of EDTA, STD signals of DS-0567 in the presence of E-
selectin/IgG were significantly attenuated, negating the hypothesis of non-specific 
binding. Furthermore, it was demonstrated that the observed signals were not due to 
other artifacts such as spin diffusion, intensity of the power used to saturate the 
protein, subtraction errors or slow relaxation times. To improve the sensitivity of the 
measurement, the saturation power was distributed at two frequencies [40]. 
Performing this experimental setup in the absence of E-selectin/IgG, where no effects 
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could be observed, indicated that the method used to saturate the protein did not 
lead to artifacts.  
 
In order to study the structure dependency in the STD signal of groups in the 
2-position of the galactose, an STD-NMR experiment with BW-580 (cyclopropyl in the 
2-position of galactose) was performed and compared to GMI-1077 and DS-0567.  
For all three compounds, a signal was observed for the substituent in the 2-position 
of galactose. The relative intensity of the STD signals observed for the cyclopropyl in 
the 2-position of galactose in BW-580 were lower than those observed for the 
benzoate in the 2-position of the galactose moiety of GMI-1077 and DS-0567. For 
these two compounds an explanation for the strong signal might be a closer proximity 
to the protein surface in the stabilized conformation. Indeed, it is known that a 3-
methyl and 3-ethyl cyclohexane (GMI-1077 and DS-0567) stabilized the bioactive 
conformation [46]. The lower relative intensity of the STD signal of the cyclopropyl in 
BW-580 might be attributed to an unfavorable effect of the amide bond which orients 
the cyclopropyl group differently compare to the ester bond present in GMI-1077 and 
DS-0567. The differences in steric hindrance and in electron density of the 
cyclopropyl group compare to the benzyl group probably also influence the observed 
STD signal. Further investigations are required to see if it is possible to correlate the 
STD differences with the proximity of the ligand to the surface of the protein and with 
the structure of the group in the 2-position of galactose. 
 
Finally, two compounds (DS-0567 and GMI-1077) showed a similar affinity in 
the Biacore assay (1.49 and 1.45 µM, respectively) and similar STD patterns, 
revealing a similar mode of binding.  
 
After these measurements, the hypothesis of another mode of binding 
persists. The idea of a reverse binding mode (already postulated by Prof. Beat Ernst 
ten years ago) was discarded with the elucidation of the crystal structure in presence 
of the natural ligand sLex. To provide further insight, an X-ray structure elucidation of 
the protein co-crystallized with one of the compounds previously cited will be 
performed (Roland Preston).  
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5. Fragment-based screening approach for the design of a second 
generation of E-selectin antagonists 
 
 
5.1 Introduction 
 
5.1.1 Need for fragment-based approaches in drug design  
 
In the early stage of drug discovery, a holistic approach was applied. This 
approach was based on an early evaluation of molecules using in vivo models 
without the necessity of a preliminary identification of a target. In such an approach, 
the number of compounds tested was restricted either due to a limited chemical 
diversity or insufficient pharmacokinetic properties of the compounds (e.g. 
bioavailability) [1].  
 
The early stage of modern drug discovery is aimed at the identification of 
molecular targets that are disease relevant and at the identification small organic 
molecules that can functionally interfere with the characterized target. Progress in 
genomics, molecular biology and biotechnology allows the rapid identification of 
targets as well as their expression. In this target-centric approach the in vivo 
evaluation is shifted to a later stage of the drug discovery process.  
In parallel, the large libraries of compounds designed via combinatorial 
chemistry necessitate high-throughput screening platforms [2]. Surprisingly, as noted 
by Betz in 2005, this approach did not fulfill the expectations in terms of return on 
investment [3,4]. This can be at least partially explained by: 
 
• the hit selection which was frequently not based on physicochemical 
properties critical for clinical success (e.g. high molecular weight, high 
lipophilicity, low solubility, poor stability) [5,6] 
 
•  the high throughput screening of large libraries of compounds with insufficient 
diversity. 
 
The above limitations led to the concept of fragment-based approaches as a 
more efficient alternative for lead generation. Fragment-based approaches include 
fragment screening, leading to hit identification, and the merging of these hits to 
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obtain new lead compounds. In this approaches, early selection of compounds 
showing promising drug-like properties and incorporation of early ADME evaluations 
are particularly attractive for improving the success rate [7-9]. As consequences,  
fragment-based drug discovery led to a number of clinical and preclinical candidates 
within the last decade [10,11]. 
 
5.1.2 Fragment-based screening and linked-fragment approaches 
 
The fragment-based screening approach is based on the idea that the binding 
pocket of a target can be seeing as a collection of subsites. Thus, each subsite is an 
individual target for low molecular weight compounds (50-250 Da). The identification 
of these “building blocks” is the aim of fragment-based screening [1]. The main 
advantage of this approach is the huge diversity of ligands accessible even with a 
library of limited size. Indeed, the number of ligands virtually assessed in a fragment-
based screening is a power function of the number of subsites and of the different 
possibilities to link them (e.g. 109 possible combinations with a library of 104 
compounds, a target containing two subsites and ten possible linker) [12-13].  
The success in the screening is only the first step of fragment-based drug 
design. The small molecule hits usually exhibit only a weak binding affinity (> 100 
µM). The required high affinity ligands are only obtained after combination of the 
selected hits. The linkage of the hits is one possibility to improve the affinity in 
fragment-based methods. The benefit of the linkage can be explained by the gain in 
free energy of the linked compound (corresponding to the sum of the free energies of 
the fragments) and the potential additional gain of entropy (Figure 1) [14]. With this 
approach, promising new leads can be designed and specificity for a target can be 
rapidly assessed. In 2004, O’Brien et al. showed an overview of fragment-based 
approaches in drug discovery and success of the fragment-linked method (e.g. 
improvement of the affinity of a ligand for DNA gyrase by a factor of 660) [8].  
Besides the linking of fragments,  alternative strategies emerged and can also 
be used for the generation of high affinity ligands, e.g. merged-fragment, elaboration 
or design of combinatorial libraries [15,16]. 
 
 
 
 
 
147 
Screening A
B
!GA
!GB
A
B
!GA !GB + x!GAB= +
Linkage
 
 
 
 
 
 
 
 
 
 
Figure 1. Linked-fragment approach. 
 
In the early stage of fragment-based drug discovery, a large variety of 
biophysical techniques were used for fragment screening, such as nuclear magnetic 
resonance (NMR), surface plasmon resonance (SPR), fluorescence anisotropy (FA) 
and fluorescence life-time (FL) [17]. The weak affinity of the small molecules, their 
binding to large targets and the necessity of an efficient screening method placed 
NMR as an ideal technology. In 1996, Fesik et al. described for the first time a 
structure-activity relationship by NMR (SAR by NMR) and the success of its use in a 
fragment-based approach [18]. 
 
5.1.3 SAR by NMR  
 
SAR by NMR is an extension of chemical shift mapping. In this method, 
protein chemical shift changes are used to identify small molecules binding with a 
weak affinity to subsites of the binding pocket of a target (Figure 2).  Thus, 
preliminary requirements for SAR by NMR are the assignment of 15N and 1H 
backbone resonances and the 3D structure of the target. Limitations are the inherent 
necessity of the 3D structure and, the isotopic enrichment of the target protein.  
 
In SAR by NMR, HSQC experiments are frequently used to provide 
informations on both binding constant and binding mode. The structural informations 
obtained on the ligand-binding mode are used for guiding the linking of the 
fragments. Indeed, knowledges on the structure of the target and on the relative 
position of the small ligands are precious for the design of an ideal linker. The 
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challenge of this crucial step of the process is the maintenance of the spatial 
orientation of the hits with respect to each other and to the target.  
 
Progress in instrumentation considerably contributed to the efficiency of the 
process. In 1999, Hajduk et al. reported the possibility of screening 1000 small 
molecules in several hours [19].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. SAR by NMR in five steps for a target containing two subsites; step1: identification of a first-
site ligand; step 2: optimization of the first-site ligand identified; step 3: screening for a second site 
ligand; step 4: optimization of the second-site ligand identified; step 5: linkage of the fragments.  
 
After SAR by NMR, other methods emerged for lead generation by NMR, such 
as SHAPES screening described by Fejzo et al. in 1999. This method differs from 
SAR by NMR by the screened libraries, which are restricted to low molecular weight 
compounds corresponding to fragments of existing drugs [20].  
In 2002, another method called “structurally oriented library valency 
engineering” (NMR-SOLVE) was proposed. In this case, the genetic identity existing 
in large families of targets for the design of focused libraries of small molecules is 
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used [21]. In that case, only a restricted labeling of the binding site is needed for the 
identification of the key protons.  
The main advantage of SHAPES compare to SAR by NMR is the increase of 
the hit rate leading to a reduction of the quantity of protein required. The concept of 
SOLVE is advantageous, because fully labeled protein is not required. Nevertheless, 
the restricted labeling scheme for an assignment of the key protons in the binding 
site can also be a complication of the method. 
 
For other approaches, such as inter-ligand transferred NOEs [22,23] 
isotopically labeling of the target is no longer required.  These methods allowed a 
direct identification of several ligands binding close to each other. In this Ph.D. work, 
a spin-labeled ligand was used for characterizing protein-mediated ligand-ligand 
interactions [24]. This led to the identification of small molecules binding in the 
vicinity of the paramagnetic center.   
 
5.1.4 Spin-label approach 
 
Spin-labels have been used in NMR for many different purposes, such as 
measuring distances, dynamic studies or protein surface accessibilities [25]. In 2000, 
Jahnke and coworkers introduced a new application for spin labels with the possibility 
of detecting the simultaneous binding of different ligands to a target [26]. This 
method is based on the proportionality between spin-spin relaxation rate (R2) and the 
product of the square of the involved spins gyromagnetic ratio γ [Eq. (1)]. 
 
  
! 
R2" #1
2#2
2                  (1) 
 
The presence of a paramagnetic center (unpaired electron), as it exists in 
spin-label molecules, dramatically increases R2 relaxation on protons via the larger 
electron-proton dipole-dipole interaction compared to the effect of a nuclear-nuclear 
interaction. This enlarged effect is called paramagnetic relaxation enhancement 
R2para, and is due to the large gyromagnetic ratio of the unpaired electron, which is 
658 times that of the proton.  
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In this thesis, the detection of the paramagnetic relaxation enhancement 
indicates the simultaneous binding of the two ligands (spin-labeled and second-site 
ligand), at neighboring binding sites (Figure 3). 
 
 
 
 
 
Figure 3. Spin-labels for second-site screening. R2 of the second-site ligand 1 is enhanced by the 
paramagnetic interaction with the unpaired electron. The second-site ligand 2 is binding too far away 
from the spin-labeled ligand and molecule 3 is not binding to the target. 
 
The use of a spin-labeled molecule has a significant practical advantage: the 
needed amount of target and ligand is considerably reduced (roughly 10 times less 
target protein than for the majority of other screening methods). Another advantage is 
the possibility to explore longer distances between the two binding sites (≈ 20 Å). 
Nevertheless, one major limitation is inherently linked to this approach: a possible 
modification of the binding by the introduction of the spin-labeled cannot be excluded. 
Jahnke et al. illustrated this approach by linking a TEMPO moiety to a weak 
ligand of Bcl-xL (IC50 = 140µM), which failed in the optimization by traditional 
medicinal chemistry. The affinity of the TEMPO ligand was approximately retained 
and a second-site screening allowed the identification of hits. 
 
This approach was used is this Ph.D. thesis. A TEMPO spin-label was coupled 
to a first-site ligand of E-selectin and used for the screening of second-site ligands.    
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5.2 Materials and methods 
 
For all ligands measured, the chemical structure can be found in Appendix III and IV. 
 
5.2.1 Biacore capture assay 
 
E-selectin/IgG was immobilized following the method described in Chapter 3, 
section 3.2.5.2 and 3.2.5.3 by capture on an anti-human IgG surface immobilized via 
amine coupling on a CM5 sensor chip. All the compounds analyzed were 
synthesized in-house by Jonas Egger [27] and dissolved to prepare a 50 mM stock 
solution in DMSO. 
All the binding experiments were performed in HBS-P buffer supplemented 
with 20 mM calcium chloride and 5% DMSO (v/v) (D8418, Sigma-Aldrich Chemie, 
Steinheim, Germany). Prior to compound evaluation, the surface was equilibrated in 
the buffer described above at a flow rate of 5 µl/min for four hours. For each 
experiment, ten twofold dilutions of ligand were randomly injected. The stability of the 
surface after immobilization and its use to determine binding constants was followed 
by injection of ten twofold dilutions of a reference compound (GMI-1077). Prior to 
each assay, DMSO solutions and blank injection of buffer were performed as 
described in Chapter 3, section 3.2.5.6.  
 
Data were processed with Scrubber-2.0a (BioLogic Software Pty Ltd., 
Campbell, Australia). Equilibrium binding constants were determined using a simple 
steady-state affinity 1:1 binding model. Kinetic data were also fit with Scrubber-2.0a. 
Double referencing was applied to correct bulk effects and other systematic artifacts 
(subtraction of reference surface and blank injection) [28]. 
 
5.2.1.1 Biacore characterization of TEMPO ligands 
 
Two TEMPO ligands were synthesized by Jonas Egger, respectively with and 
without a benzoate group in the 2-position of galactose. For the TEMPO ligand with a 
benzoate in the 2-position of galactose, saturation was reached at a concentration of 
15.6 µM. Nine twofold serial dilutions starting from this concentration were prepared 
in HBS-P buffer supplemented with 20 mM calcium chloride and injected. A final 
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concentration of 5% DMSO was kept constant in all the dilutions. An association time 
and a dissociation time of 60 s were used and the flow rate was set to 20 µl/min. A 
similar procedure was applied for the characterization of a TEMPO ligand without 
benzoate in the 2-position of galactose, with dilutions prepared from a concentration 
at saturation of 312.5 µM.  
 
5.2.1.2 Optimization of the Biacore method used for first-second-site 
antagonists analysis 
 
All the first-second-site antagonists were synthesized in-house by Jonas 
Egger and dissolved to prepare a 50 mM stock solution in DMSO. For the first 
synthesized compound resulting from the second-site screening approach, the 
association time and the dissociation time were increased to 120 s and the flow rate 
set to 30 µl/min. Saturation was reached at a concentration of 8 µM and a total of ten 
twofold dilutions were injected.  
 
The above conditions did not appear optimal for the other first-second-site 
antagonists. Therefore, a further optimization of the method was performed. The 
association and dissociation rates were increased up to 600 s and a flow rate of 20 
µl/min was used. Saturation was reached at a concentration of 1 µM and a total of 
eleven twofold dilutions were injected. In addition, to prevent the presence of residual 
traces of compound, a blank injection was performed between each injection of 
ligand dilution. As an additional precaution, the solutions of ligands were injected in 
an increasing order of concentration. The same method was applied for the analysis 
of a set of most potent compounds selected according to the data obtained with the 
ranking procedure.  
 
5.2.1.3 Affinity ranking experiments 
 
The ranking of the antagonists was performed in order to obtain qualitative 
information about the binding strength of twenty first-second-site antagonists 
synthesized by Jonas Egger. Similar parameters as described in the previous section 
were used for the ranking. Prior to each assay, DMSO solutions and blank injection 
of buffer were performed as described in Chapter 3, section 3.2.5.6. In addition, 
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blank injections were performed between each injection of ligand. In this type of 
binding experiment, SPR signals were recorded at a single concentration (0.05µM) 
and divided by the molecular weight of the compounds. The result obtained was 
normalized to the response obtained with an internal standard (JE-81) in order to 
avoid problems related to the measurement on different chips with different surfaces.  
 
5.2.2 NMR  
 
All spectra were recorder in-house with a Bruker DRX-500 (Bruker BioSpin 
AG, Fällanden, Switzerland) equipped with Z-gradient SEI probe. E-selectin/IgG was 
used in all the experiments in this chapter. The preparation of the protein was 
performed as described in Chapter 4 and concentrations of 15 µM binding site were 
prepared (estimated by Bradford assay). As described in the materials and methods 
section of the Chapter 4, Shigemi tubes (Sigma Aldrich GmbH, Buchs, Switzerland) 
were used for samples containing E-selectin/IgG and ordinary 5 mm NMR tubes were 
used for samples containing only ligands (Sigma Aldrich GmbH, Buchs, Switzerland). 
All tubes were cleaned with bidistilled water and washed twice with D2O. Before each 
experiment, the spectrometer was optimized for the sample introduced in order to 
achieve an optimal resolution and sensitivity (see Chapter 4, section 4.2.1). Identical 
software packages as described in Chapter 4, section 4.2.3 were used for recording 
and analyzing the data. The second-site screening approach is based on spin-spin 
relaxation measurements, which were recorded with the parameters described in 
Chapter 4, section 4.2.4.1. 
  
5.2.2.1 Pre-selection of promising compounds by screening of small 
sublibraries of second site compounds 
 
A library of sixty compounds was designed in-house by Dr. Sachin Shelke and 
Dr. Brian Cutting. To facilitate the screening procedure, the library was divided in 
sublibraries containing 6-8 compounds each.  
T1ρ measurements at 10 ms and 200 ms spin-lock durations were recorded. 
Sets of four samples were measured for each sublibrary as described in Table 1. A 
concentrated stock solution of 100 mM in d6-DMSO of each compound was 
prepared. The sublibraries were prepared by mixing the compounds at a final 
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concentration of 15 mM each in d6-DMSO. This solution was used to prepare four 
types of samples as describe in Table 1. This general procedure was applied for all 
sublibraries. The dilutions were performed in d11-Tris buffer (50 mM d11-Tris, 150 
mM NaCl, 1 mM CaCl2). 
 
Table 1. Composition of the samples prepared for T1ρ measurements. 
 
Sample 
E-selectin/IgG 
[µM] 
Sublibrary 
[µM of each 
compound] 
JE-16 
[µM] 
Ascorbic acid 
[mM] 
1 - 300 - - 
2 15 300 - - 
3 15 300 150 - 
4 15 300 150 3 
 
For compounds with uncertain assignment, isolated resonances were 
determined by recording H1-NMR after adding successively each compound in the 
sublibrary. Then, a series of T1ρ measurements with increasing spin-lock duration 
(10, 50, 100, 150, 200 and 250 ms) were recorded on samples 2, 3 and 4 for each 
sublibrary (Table 1).  A series of seven promising hits was selected after the 
screening of all the sublibraries (see section 5.3.5, Figure 12). 
 
5.2.2.2 Analysis of promising hits 
 
The selected hits were individually analyzed. T1ρ measurements with 
increasing spin-lock duration (10, 50, 100, 150, 200 and 250 ms) were recorded on 
samples 1, 2, 3 and 4 where the sublibrary was replaced by the selected hit alone 
(Table 1).  
 
5.2.2.3 STD and waterLOGSY experiments 
 
STD-NMR experiment 
 
The STD experiment confirmed the binding of the best selected second-site 
compound with the measurement of a sample containing 15 µM of binding site of E-
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selectin/IgG mixed with 250 µM of the selected second-site compound. The same 
procedure as described in Chapter 4, section 4.2.4.2 was applied. 
 
 
waterLOGSY experiment 
 
A sample containing E-selectin/IgG (15 µM binding site) mixed with the 
TEMPO ligand (100 µM), the second-site ligand (400 µM) and ascorbic acid (400 µM) 
was prepared. The sample contained 65% H2O. Fifty mM stock solutions of TEMPO 
ligand and of second-site compound in d6-DMSO were used for the preparation of 
the sample. 
The pulse program used was described by Dalvit et al. [29,30] and optimized 
for our sample by Dr. Brian Cutting. 
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5.3 Results and discussion 
 
The tetrasaccharide mimic BW-69669 was previously recognized as a lead 
compound for E-selectin antagonists, and its structure used as a starting point for the 
development of more potent antagonists. During his PhD, Dr. Daniel Schwitzer 
worked on two different optimization strategies. One was to target a hydrophobic 
area on the lectins surface by attaching hydrophobic fragments in the 6-position of 
the galactose moiety. Unfortunately, the synthesized ligands did not show affinity in 
the static cell free assay (rIC50 > 10 mM, relative to sLex). The second strategy was 
dedicated to the optimization of the ligand pre-organization by stabilization of the 
bioactive conformation. Following this approach, a first generation of a first-site ligand 
was synthesized and led to a considerable improvement of the affinity by a factor of 
approximately 100. With this strategy, the low micromolar affinity was reached (BW-
529, KD = 0.37 µM, see section 3.3.3, chapter 3). Despite this improvement of the 
affinity, all new derivatives still exhibited fast kinetic profiles as determined by 
Biacore. In order to improve the affinity and kinetic profile of E-selectin ligands, a 
fragment-based approach was initiated. This approach called “fragment-based ligand 
discovery” was first described by Jencks in 1981. With this approach, two weak 
binders that bind close to each other on the protein are identified and linked together 
to produce a high affinity ligand due to additive binding energies and favorable 
entropic effects. Having already an optimized first-site ligand in the micromolar affinity 
range, NMR screening was initiated for the identification of a second-site small 
molecule binding simultaneously and in the vicinity of the first-site ligand. For that 
purpose, a technique using a spin-labeled analogue of the first-site ligand [31] was 
applied to E-selectin. JE-16, a spin labeled analogue of GMI-1077 was synthesized 
in-house by Jonas Egger. 
 
For all ligands measured, the chemical structure can be found in Appendix III and IV. 
 
5.3.1 Evaluation of JE-16 with the Biacore capture assay 
 
As shown in chapter 3, the introduction of a carboxymethyl group in the 5-
position of the GlcNAc mimic moiety (DS-0560, KD= 1.90 µM) did not show a drastic 
impact on the affinity compared to GMI-1077 (KD= 1.45 µM). In addition, also further 
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modification of DS-0560 for the introduction of a TEMPO moiety (JE-16) did not 
affect the affinity of the ligand for E-selectin/IgG (Table 2). 
  
Table 2. Structures of GMI-1077, DS-0560, JE-16 and JE-61. The affinities determined by the Biacore 
capture assay are also reported.  
Compound Structure 
 
KD* [µM] 
(Biacore) 
 
GMI-1077 O
O
HO
OBz
O
CO2Na
O
HO
OH
OH
O
HO
 
1.45 
DS-0560 
O
O
O
HO
OH
OBz
COOH
COOMe
O
HO
OH
OH
O
 
1.90 
JE-16 OOO
HO
OH
OBz
COOH
Me
O
HO
OH
OH
O
O
H
N NH
O
N O•
 
1.25 
JE-61 
 
12.46 
* experimental KD derived from steady state response fit to a single binding site model 
 
To study the influence of the benzoate group the spin labeled first-site 
compounds JE-16 and JE-61 were studied. In Biacore experiments, JE-61 showed a 
ten-fold reduced affinity compared to JE-16. As shown in chapter 3, a similar 
decrease of the affinity was observed between DS-04115 (absence of the benzoate 
in the 2-position of galactose) and GMI-1077. This observation suggests that the 
presence of the TEMPO moiety did not affect the binding mode of the first-site ligand. 
For both compounds, JE-16 and JE-61, fast kinetics were observed (Table 3). 
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Table 3. Kinetic and affinity evaluation of GMI-1077, DS-0560, JE-16 and JE-61.  
 
Analyte kon [105 M-1s-1] koff [s-1] KD kin [µM]* KD eq [µM]** t1/2 [s]*** 
GMI-1077 8.5 0.9 1.0 1.45 0.8 
DS-0560 77.0 1.9 1.6 1.60 0.4 
JE-16 3 0.36 1.2 1.25 1.9 
JE-61 - 0.2 - 12.46 3.5 
*calculated KD using KD = koff/kon ** experimental KD derived from steady state response fit to a single binding site model *** 
calculated t1/2 using t1/2 = ln2/koff. 
 
5.3.2 NMR evaluation of the paramagnetic activity of JE-16 and reducing 
conditions  
 
 
 To find the conditions for the reduction and to validate the paramagnetic 
activity of JE-16, T1ρ relaxation was measured. Two spectra of JE-16 were recorded 
at 50 ms and 150 ms durations of spin lock at a concentration of 1 mM. Broad signals 
as well as strong decay in intensity due to paramagnetic relaxation were observed 
(Figure 4A). The same experiments were repeated after addition of an excess of 10 
mM ascorbic acid to the sample. The ten-fold excess ensured the complete reduction 
of the radical (Figure 4B). The line narrowing and a negligible decay (less than 2 %) 
of the intensity were observed compared to the paramagnetically active form of JE-
16, demonstrating the diamagnetic form of the molecule in presence of ascorbic acid. 
 
 
 
 
 
 
                          A 
 
 
 
 
 
                          B 
 
 
 
Figure 4. (A) Paramagnetic activity of JE-16 (B) Reduction of JE-16 in the presence of 10-fold excess 
of ascorbic acid. 
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5.3.3 Second site screening by NMR 
 
A library of sixty compounds was composed in-house by Drs. Sachin Schelke 
and Brian Cutting in 2004 for MAG project (Myeline-associated glycoprotein). The 
compounds were selected based on diversity, drug-like character, solubility, 
dispersion of their NMR signals and synthetic accessibility. 
The library was divided into eight sublibraries containing 6-8 compounds each. 
The compounds were associated according to their chemical compatibility (chemical 
reaction of the compounds in a sublibrary was not suitable) and in a way to have at 
least one isolated resonances each in a H1-NMR spectrum. 
 
5.3.4 Assignment of isolated resonances for each compound of each 
sublibrary 
 
 The process below describes the procedure for one of the sublibraries (Figure 
5). A similar procedure was applied to the other sublibraries as well.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Composition of sublibrary 1. 
 
A hypothetical spectrum of the sublibrary was created by overlaying H1-NMR 
spectra of each compound individually recorded (Figure 6A). By comparison with the 
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         9              8            7      ppm 
H1-NMR spectrum of the sublibrary (Figure 6B), unambigious and isolated 
resonances were assigned for each compound (Figure 6C).  
 
 
A 
 
 
 
                        C  
 
 
                                                               
                              
 
 
 
 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Hypothetical H1 spectrum of sublibrary 1 (A). H1 spectrum of sublibrary 1 (B). Resonance 
assignment of the sublibrary (C). 
 
 
5.3.5 Screening of the sublibraries  
 
 In order to qualitatively estimate the binding potential of each compound to 
E-selectin, a first relaxation measurement was performed with a sample containing E-
selectin/IgG (15 µM binding site) and sublibrary 1 (300 µM) at two spin-lock durations 
(10 and 200 ms). All compounds of sublibrary 1 except SH-104-12 showed an 
enhancement of their relaxation rate in presence of E-selectin/IgG indicating a 
binding to E-selectin/IgG (Figure 7 and 8). As shown in Figure 8, a further decay of 
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the relative intensity roughly estimated between 15% and 55 % was observed for SH-
104-1, SH-104-2, SH-104-3, SH-104-4, SH-104-8, SH-105-10 and SH-104-16. The 
relaxation of SH-104-12 was not strongly modified (less than 5% decay of the relative 
intensity, Figure 8) in the presence of E-selectin/IgG indicating minimal binding. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. T1ρ relaxation measurement of sublibrary 1 at 10 ms (red) and 200 ms (green) spin-lock in 
the presence of E-selectin/IgG. Isolated resonances of compound SH-104-4 and SH-104-12 are 
indicated by arrows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Variation of the intensity of the signal of each compound of sublibrary 1 in T1ρ relaxation 
experiments recorded at two spin-lock durations (10 ms and 200 ms). The experiments were recorded 
on the sublibrary 1 alone, in the presence of E-selectin/IgG, after adding JE-16 and after reduction of 
JE-16 by ascorbic acid. 
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 This cycle of two measurements was repeated with a sample containing E-
selectin/IgG (15 µM binding site), sublibrary 1 of second-site ligand (300 µM each) 
and JE-16 (150 µM). The cycle was recorded again after reduction of the TEMPO-
ligand by adding ascorbic acid (3 mM) (Figure 9). An enhancement of the relaxation 
rate was expected in presence of JE-16 if the compound bound in the vicinity of JE-
16. This effect should be cancelled after reduction of the TEMPO moiety with 
ascorbic acid. 
 
 
 
 
                                 JE-16                                                                                JE-16 reduced 
 
Figure 9. Reduction of JE-16 with ascorbic acid. 
 
 The effect of JE-16 on the relaxation rate was not the same for all the 
compounds of sublibrary 1 indicating differences in the proximity between the ligands 
(Figure 8): 
 
• Compounds SH-104-2, SH-104-3 and SH-104-16 were not significantly 
affected by the presence of JE-16 in either state: radical and reduced. These 
compounds bound to the protein but not in the vicinity of JE-16.  
• Compound SH-104-8 showed an unexpected behavior with a recovery of 
110% of the relaxation rate in presence of the reduced form of JE-16.  
• Compound SH-104-1 indicated its binding to E-selectin/IgG but probably does 
not experience a paramagnetic effect. 
• Compound SH-104-12 showed a low affinity for the E-selectin/IgG as 
previously mentioned. Nevertheless, the relaxation rate seemed to be 
disturbed in the presence of JE-16 indicating that SH-104-12 might bind in its 
proximity. 
• The additional relaxation due to JE-16 appeared only significant for 
compounds SH-104-4 and SH-104-10. However, the proximity of the assigned 
resonance of SH-104-10 used for the analysis to the resonance of other 
compounds underscored the need for caution in our conclusions. 
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 According to these results, after screening sublibrary 1, SH-104-4 was the 
only compound clearly recognized as a hit. Indeed, in the presence of the E-
selectin/IgG, the decay in intensity of the signals of SH-104-4 was twice as large as 
that without E-selectin/IgG. This quicker relaxation rate is due to the longer rotational 
correlation time of the ligand in a bound form, indicating an interaction with the 
protein. In the presence of JE-16, a further enhancement of the decay in intensity by 
a factor of 1.5 was observed due to the presence of the radical in the vicinity of SH-
104-4 (within a radius of about 20 Å) [32,33]. This effect was cancelled by reduction 
of JE-16 with ascorbic acid leading to a recovery of 90 % of the relaxation (Figure 7 
and 8). 
 
 Due to uncertainty in the results obtained for compounds SH-104-1, SH-
104-8, SH-104-10 and SH-104-12, a new analysis of their relaxation rates was 
performed. In that purpose, series of six T1ρ experiments with increasing spin-lock 
duration (10, 50, 100, 150, 200 and 250 ms) were measured. 
 Prior to the relaxation measurements, each of these four compounds was 
added independently to a E-selectin/IgG sample and a H-1 spectrum was recorded in 
order to ensure a precise assignment and to verify that an isolated resonance was 
observed for SH-104-10 (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Assignment of the resonances by adding successively the compounds SH-104-1, SH-104-
8, SH-104-10 and SH-104-12 to E-selectin/IgG and recording H-1 spectrum. 
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 Then, new cycles of relaxation measurement were performed. As shown on 
Figure 11, none of the compounds, whose binding was questionable when analyzed 
in the sublibrary, were confirmed as a hit. A similar relaxation rate was observed in 
the presence of JE-16 under both states: radical active or reduced. The variation 
observed for SH-104-10 in Figure 8 was probably due to the overlap of the signal 
with other resonances of other compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. T1ρ relaxation measurement of compounds SH-104-8, SH-104-1, SH-104-10 and SH-104-
12 in the presence of E-selectin/IgG, JE-16 (■) and with JE-16 reduced by ascorbic acid (▲). 
 
 
 A similar procedure of T1ρ relaxation measurement on isolated resonances from 
compounds within the different sublibraries of the library was performed. This global 
screening leads to the identification of six promising hits in addition to the SH-104-4 
(Figure 12). As shown in Figure 13, for all of the hits, a binding to E-selectin/IgG in 
the vicinity of JE-16 was observed.  
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Figure 12. Structure of promising hits selected by NMR screening. 
 
 
 
 
Figure 13. T1ρ relaxation measurement on isolated resonances of compounds SH-104-33, SH-104-
19, SH-104-24, SH-104-11, SH-104-7 and SH-104-17 in the presence of E-selectin/IgG (■A), with JE-
16 (▲B) and with JE-16 reduced by ascorbic acid (▼C). 
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The indole moiety appeared to be an important epitope for binding to the 
second-site (see ligands SH-104-4, SH-104-7, SH-104-11, SH-104-19 and SH-104-
24, Figure 12). Three of the hits found were chosen for further studies: SH-104-4, 
SH-104-19 and SH-104-17. Each of these compound was analyzed individually in the 
presence of E-selectin/IgG, JE-16 and JE-16 reduced with ascorbic acid. 
 
5.3.6 SH-104-17 
 
The relaxation rate of SH-104-17 was measured in the presence of E-
selectin/IgG, JE-16 was then added to the sample and a last cycle of relaxation 
measurements were performed after reducing JE-16 with ascorbic acid. A set of four 
resonances of SH-104-17, which did not overlap with the resonances of JE-16, was 
chosen for the study (Figure 14). As shown in Figure 14B, an enhancement of the 
relaxation rate was observed in the presence of E-selectin/IgG, demonstrating the 
binding of SH-104-17 to E-selectin/IgG. Nevertheless, no additional effect was 
observed in presence of JE-16, as well as after reduction of the radical by ascorbic 
acid (Figures 15, 14C and 14D). Therefore, SH-104-17 was found to be a hit in the 
global screening (binding to E-selectin/IgG in the proximity of JE-16) but could not be 
confirmed as a hit when isolated (binding to E-selectin/IgG but not in the vicinity of 
JE-16). 
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Figure 14. T1ρ relaxation measurement at 10 ms (red) and 250 ms (green) spin-lock durations. (A) 
SH-104-17, (B) SH-104-17 and E-selectin/IgG, (C) SH-104-17, E-selectin/IgG and JE-16, (D) SH-104-
17, E-selectin/IgG, JE-16 and ascorbic acid. Resonances of SH-104-17 are indicated (dashed 
square). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. T1ρ relaxation measurement on isolated resonances of compounds SH-104-17 in the 
presence of E-selectin/IgG (□A), with JE-16 (△B) and with JE-16 reduced by ascorbic acid (▽C). 
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5.3.7 SH-104-19 
 
 A set of five isolated resonances of SH-104-19 was chosen for T1ρ relaxation 
studies in order to substantiate or negate the result of the global screening (Figure 
16).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Overlay of H-1 spectrum of SH-104-19 (200 µM, red) and JE-16 (200 µM, green). 
Resonances of SH-104-19 chosen for the T1ρ relaxation experiments are inscribed in rectangles. 
 
As shown in Figure 17, an enhancement of the relaxation was observed in the 
presence of E-selectin/IgG confirming the binding of SH-104-19 to the protein. The 
relaxation rate was significantly affected in presence of JE-16 and restored after 
reduction of the TEMPO-ligand by ascorbic acid. Therefore, SH-104-19 was 
confirmed as a hit binding in the vicinity of the first-site ligand. 
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Figure 17. T1ρ relaxation measurement on isolated resonances of compounds SH-104-19 alone 
(■A), in the presence of E-selectin/IgG (▲B), with JE-16 (▼C) and with JE-16 reduced by ascorbic 
acid (◆D). 
 
 
 As previously shown, the relaxation rate of the screening hit was affected by 
the paramagnetic influence of JE-16. The size of this influence is directly related to 
the distance between the observed hydrogen and the radical. Therefore, it was 
possible to estimate the orientation of the second-site ligand. Indeed, an optimal 
placement of the linker is crucial for the potency of the linked compounds. 
 
 The four best-isolated resonances of SH-104-19 were chosen for a detailed 
analysis of the orientation (7.86 ppm, 3.58 ppm, 2.93 ppm and 1.98 ppm). Relaxation 
data were fit using Eq. (2) and relaxation rates estimated from the fit where C is a 
constant, Y is the relative intensity obtained for each spin-lock duration, X is the spin-
lock duration and K corresponds to relaxation rate, R1ρ.  
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Because of an incomplete recovery of the signal after reduction of JE-16 by ascorbic 
acid, the relaxation of SH-104-19 in the presence of E-selectin differed from its 
relaxation in the presence of E-selectin and the reduced form of JE-16. For this 
reason, the differences in the relaxation rate obtained for SH-104-19 mixed to E-
selectin/IgG in the presence and absence of JE-16 were chosen for the analyses 
(indicated as Δ in Figure 18). An example is shown in Figure 18 on the left for the 
resonance at 7.86 ppm and the results obtained for the different resonances are 
summarized in the table. 
Figure 18. Enhancement of the relaxation rate observed for SH-104-19 mixed with E-selectin/IgG in 
presence and absence of JE-16 (Δ). Plot A: SH-104-19 alone, plot B: SH-104-19 and E-selectin/IgG, 
plot C: SH-104-19, E-selectin/IgG and JE-16, plot D: SH-104-19, E-selectin/IgG, JE-16 and ascorbic 
acid. The hydrogen found to be closer to the radical are highlighted in red on the structure of SH-104-
19 (top right). 
 
As a result, hydrogen in position 4 of the indole moiety and hydrogens in 
position 1’and 2’ of the propanol chain were more affected by the presence of the 
TEMPO, indicating their proximity to JE-16. A schematic view of the orientation of 
JE-16 and SH-104-19 is presented in Figure 19. In the linked compound, the linker 
should be preferentially attached on the site of SH-104-19 closest to JE-16 in order 
to obtain the ideal orientation of the molecules. 
 
 
 
 
 
 
 
 
Figure 19. Schematic view of JE-16 and SH-104-19. 
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5.3.8 SH-104-4 
 
SH-104-4 was immediately recognized as a hit after the screening of 
sublibrary 1. Indeed, the relaxation rate of SH-104-4 was enhanced in the presence 
of E-selectin/IgG (proving the binding) and was further enhenced by the presence of 
JE-16 (proving the proximity between the two molecules). The same procedure as 
previously described for SH-104-19 was applied to SH-104-4. Thus, the first step was 
the validation of SH-104-4 as a hit by repeating the T1ρ relaxation measurement with 
the isolated compound. 
  
Assignment of SH-104-4  
 
transferNOE experiment were recorded with SH-104-4 and E-selectin/IgG  and 
assigned by Dr. Cutting and Jonas Egger. As shown in Figure 20, only resonances of 
hydrogens in position 3 and 4 of SH-104-4 were completely isolated from those of 
JE-16. Signals of hydrogens in position 2 and 7 of SH-104-4 were partially 
overlapping with resonances of JE-16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Overlay of H-1 spectrum of JE-16 reduced by ascorbic acid (red) and H-1 spectrum SH-
104-4 in the presence of E-selectin/IgG (green). 
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Validation of SH-104-4 as a hit  
 
The relaxation curves are displayed for the H-1 resonances in position 3, 4 
and 7 of SH-104-4 (Figure 21). The interaction with E-selectin/IgG was clearly 
confirmed as well as the proximity to the radical. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Variation of the relaxation rate observed for SH-104-4. Plot A: SH-104-4 alone, plot B: SH-
104-4 and E-selectin/IgG, plot C: SH-104-4, E-selectin/IgG and JE-16, plot D: SH-104-4, E-
selectin/IgG, JE-16 and ascorbic acid. The hydrogen studied are indicated on the structure of SH-104-
4 (bottom right). 
 
 STD-NMR measurements were used as a complementary approach to 
confirm the binding of SH-104-4 to E-selectin/IgG. As shown in Figure 22B, the 
binding was confirmed through the observation of the nitroindole STD signals. 
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Figure 22. Confirmation of the binding of SH-104-4 to E-selectin/IgG with STD-NMR experiments. (A); 
H-1 spectrum of SH-104-4 (250 µM) in the presence of E-selectin/IgG (B), (C); STD-NMR and 
reference spectra of SH-104-4 (250 µM) in the presence of E-selectin/IgG (D), (E); STD-NMR and 
reference spectra of SH-104-4 (250 µM) without E-selectin/IgG. 
 
 An example of the high reproducibility of the relaxation rate measurement of 
SH-104-4 in the presence of E-selectin/IgG is shown in Figure 23. The level of 
reproducibility suggests that the method could be applied to check the quality of an 
E-selectin sample after purification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Relaxation rate of SH-104-4 in the absence and in the presence of two different batches of 
E-selectin/IgG. 
 
 WaterLOGSY was used as a complementary approach in order to verify the 
independant binding of SH-104-4 and JE-16 to E-selectin/IgG. This method is used 
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to identify compounds that bind to a target using water-mediated NOEs [31,34,35]. In 
this experiment, it is possible to distinguish binding and non-binding ligands, since, 
provided the fraction of unbound ligand is not too large, their resonances appear with 
opposite sign. 
 Ascorbic acid and DMSO did not bind to E-selectin/IgG and showed 
resonances with an opposite sign as those of SH-104-4 and JE-16 (Figure 24). 
Therefore, the independent binding of JE-16 and SH-104-4 to E-selectin/IgG was 
confirmed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Overlay of H-1 spectrum of JE-16 reduced by ascorbic acid (red) and WaterLOGSY 
spectrum of SH-104-4 in the presence of E-selectin/IgG and JE-16 reduced by ascorbic acid (green). 
Resonances of SH-104-4 and JE-16 (respectively dashed and solid lines) were highlighted. 
  
Orientation of SH-104-4  
 
 The determination of the orientation of SH-104-4 to the radical was 
performed for the resonances of hydrogens in positions 3, 4 and 7. For hydrogens in 
positions 3 and 4, the analysis was straightforward since no overlap with the 
resonances of JE-16 was present. The data obtained for the hydrogen in position 7 
were also processed. A minimal overlap was observed for the component of the 
multiplet at 7.52 ppm, justifying the use of hydrogen 7 in this analysis. Two 
measurements on two different samples were performed. A nearly complete removal 
of the effect of the radical on the relaxation was obtained by reduction of JE-16 with 
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ascorbic acid. Therefore, the differences in relaxation rates obtained for SH-104-4 
mixed with E-selectin/IgG in the presence of JE-16 and in the presence of reduced 
JE-16 were calculated and compared (indicated as Δ in Figure 25). As shown in 
Figure 25, the hydrogen in position 7 of SH-104-4 (7.52 ppm) appeared to be closer 
to the radical, followed by the hydrogen in position 3 of SH-104-4 (6.73 ppm) and 
finally, the hydrogen in position 4 of SH-104-4 (8.6 ppm), which appeared to be the 
most remote. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Enhancement of the relaxation rate observed for SH-104-4 mixed with E-selectin/IgG in the 
presence and in the absence of JE-16 (Δ). Plot A: SH-104-4 and E-selectin/IgG, plot B: SH-104-4, E-
selectin/IgG and JE-16, plot C: SH-104-4, E-selectin/IgG, JE-16 and ascorbic acid. Red circles 
indicate the proximity of the hydrogen of SH-104-4 to JE-16 according to their size (the bigger the 
closer). 
 
Complementary studies  
 
 The influence of the high concentration of ascorbic acid (5 mM) on the 
relaxation of SH-104-4 (150 µM) was checked in the absence of E-selectin/IgG 
immediately after mixing the compounds, after 48h of incubation and after 72h of 
incubation. No significant perturbation of the relaxation was observed (0.017 < 
coefficient of variation < 0.042, Figure 26A). In addition, no perturbation of the 
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relaxation was observed in presence of a first-site ligand (BW-69669), in the absence 
and in the presence of E-selectin/IgG was observed (Figure 26B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26.  (A) Relaxation rate of SH-104-4 (150 µM) in presence of ascorbic acid (5 mM). (B) 
Relaxation rate of SH-104-4 in presence of BW-69669 with and without E-selectin/IgG. 
 
Conclusion  
 
After being successfully used with the MAG for the development of more 
portent ligands [32,36-38], SH-104-4 was chosen for further development of E-
selectin antagonists. According to the results previously shown for E-selectin, the 
hydrogen in position 7 of SH-104-4 (7.52 ppm) appeared to be closest to the radical. 
Nevertheless, the partial overlap of the hydrogen in position 7 indicated that caution 
is required when choosing the position of SH-104-4 for the linkage of first and second 
site ligands. Therefore, 2 series of new generations of E-selectin antagonists were 
synthesized in-house by Jonas Egger. In the first series, the linker in the second-site 
ligand is connected to the nitrogen of the indole system. In the second series, the 
linker is connected to the carbon in position 3 of the indole system (Figure 27). 
Compounds belonging to the same series differ from each other by the length of the 
spacer on either side of the triazole. 
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Figure 27. Schematic view of the two series of first-second-site antagonists. For the linker, the 
nomenclature refers to the number of carbons on the fist-site side or on the second-site side of the 
triazole. a indicates that anti-triazoles are investigated, N indicates that the linker is connected to the 
nitrogen of the indole system, C indicates that the linker is connected to the carbon in the 3 position of 
the indole system. 
 
 
5.3.9 Analysis of the first compound synthesized and optimization of the 
Biacore method 
 
 JE-63 was the first synthesized compound resulting from the second-site 
screening approach. A first evaluation of JE-63 was performed under the conditions 
used in the Biacore assay for the first-site ligand (Flow rate = 20 µl/min, association 
time = dissociation time = 60 s, see chapter 5). As shown in Figure 28A, the 
association time was too short to reach the steady state. Therefore, three conditions 
were tested: 
 
(i) Flow rate = 20 µl/min, association time = dissociation time = 120 s 
(ii) Flow rate = 30 µl/min, association time = dissociation time = 120 s 
(iii) Flow rate = 30 µl/min, association time = dissociation time = 150 s 
 
For the optimization of the conditions, only four concentrations were injected, 
starting at 2.5 µM with a dilution factor of 2. Conditions (ii) were optimal and were 
therefore used for the complete analysis of JE-63 (Figure 28B). 
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          A 
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Figure 28. Sensorgrams of JE-63 binding to E-selectin/IgG immobilized on the CM5 surface by 
capture assay via anti-human IgG. (A) Flow rate 20 µl/min, association time 60 s, dissociation time 60 
s (B) Flow rate 30 µl/min, association time 120 s, dissociation time 120 s. 
 
The linked compound showed an improvement in the affinity by a factor of 3 
compared to the unlinked compound DS-04115 (Figure 29). When the three most 
concentrated samples were injected, an incomplete return to the baseline was 
observed. This was probably due to a small “rebinding effect” of the compound on 
the surface [38] and these concentrations were not taken into account for the kinetic 
evaluation.  
 
 
 
 
            
            DS-04115                                                               JE-63 
  KD = 6.6 µM                                                     KD = 1.42 µM 
 
Figure 29. Structure of DS-04115 and JE-63 and related KDs calculated from the kinetic parameters 
measured by Biacore. 
 
The kinetic parameters of the binding were different for JE-63 compared to all 
other E-selectin ligand until then investigated. Although both kon (5.15x104 M-1s-1) and 
koff (0.073 s-1) rates were slower, the koff rate showed a stronger reduction and 
resulted in a t1/2 of 9.49 s (Figure 30).  
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Figure 30. (A) Plot of the binding isotherm for JE-63 binding to E-selectin/IgG fit with a 1:1 binding 
model. (B) Kinetic fit of the sensorgrams for injections of JE-63 between 1 µM and 31.25 nM. (C) 
Example of a kinetic fit using the 1 µM concentration. 
 
5.3.10 Optimization of assay conditions for JE-57 
 
The parameters of the method optimized for JE-63 were not optimal for JE-57 
(Figure 31). In particular, an association time of 120 s was not sufficient to reach the 
steady state. Therefore, the association time was increased to 600 s. The 
dissociation time was also increased to 600 s to reach a stable baseline in- between 
each sample injection and a flow rate of 20 µl/min was used. In addition, one blank 
injection was performed between each injection of JE-57. This blank injection 
ensured that the system did not contain any residual of JE-57 prior to each new 
injection of the compound. These buffer injections washed the surface without risk of 
damaging the E-selectin/IgG immobilized (data not shown).  
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Figure 31. (A) Structure of JE-57. Sensorgrams of JE-57 binding to E-selectin/IgG immobilized on the 
CM5 surface by the capture assay via anti-human IgG. (B) Flow rate 20 µl/min, association time 120 s, 
dissociation time 600 s (C) Flow rate 20 µl/min, association time 600 s, dissociation time 600 s. 
 
 
JE-57 was measured over two surfaces in order to study the reproducibility. 
The affinity was improved by a factor of 10 compared to the first generation of 
compounds, as e.g. GMI-1077, tested on the same surface (KD = 1.24µM). In 
addition, the kon was 10 times slower and koff 180 times slower (Table 4). 
 
Table 4. Kinetic and affinity evaluation of JE-57. Plots of the equilibrium binding isotherm plots are 
shown in the bottom (A) JE-57 measurement 1 (B) JE-57 measurement 2. 
*calculated KD using KD = koff/kon ** experimental KD derived from the steady state response fit to a single binding site model *** 
calculated t1/2 using t1/2 = ln2/koff. 
  
 
 
 
 
 
Analyte KD eq [µM]** KD kin [µM]* kon [104 M-1s-1] koff [s-1] t1/2 [s]*** 
JE-57meas. 1 0.14 0.15 2.6 0.004 173 
JE-57meas. 2 0.13 0.13 3.9 0.005 138 
GMI-1077 1.24 1.2 46.5 0.560 1.24 
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The same parameters were applied to determine the affinity and kinetic 
parameters of other first-second-site antagonists as well as for the ranking study.  
 
5.3.11 Ranking 
 
A ranking of the antagonists was performed in order to obtain qualitative 
information about the binding strength of 20 first-second-site antagonists synthesized 
by Jonas Egger.  
 
Preliminary studies for optimization of the ranking procedure.  
 
The binding constant of JE-57 was previously determined (KD = 0.14 µM). 
Saturation was reached with a 1 µM injection. Therefore, in a first attempt, JE-56, JE-
57 and JE-58 were injected at a concentration of 1 µM and 0.1 µM over the same 
surface. To ensure that all analyte is removed from the chip surface, before the 
injection of a new compound, two injections of buffer were performed after each 
injection of analyte. The response observed in Biacore is directly related to the 
molecular weight of the analyte. Therefore, in order to rank the ligands, the response 
obtained for each injection was divided by the molecular weight of the corresponding 
compound. All the compounds showed a similar normalized response (Figure 32). 
Indeed, the ranking observed for the two concentrations injected appeared nearly 
identical.  
 
 
 
 
 
 
 
 
 
                                                       JE-56             JE-58            JE-57 
Figure 32. Response of JE-56, JE-57 and JE58 at 0.1µM and 1 µM normalized to the respective 
molecular weight of the compounds. 
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Following these preliminary studies for the ranking procedure, GMI-1077 was 
used as a test compound in order to check the quality of the surface. As shown in 
Figure 33, the lack of activity did not allow further studies and a new surface had to 
be prepared.  
 
A                                                                                   B 
 
 
 
 
 
 
 
 
           C                                                                                   D 
 
 
 
 
 
 
 
 
Figure 33. Sensorgrams and binding isotherm plots of GMI-1077 for E-selectin/IgG before (A and B) 
and after (C and D) injections of JE-56, JE-57 and JE-58 for ranking studies. 
 
Use of different surfaces for the ranking 
 
A new E-selectin/IgG surface was prepared and 0.5 µM of JE-56, JE-57 and 
JE-58 were injected. As shown in Figure 34A, it appeared not possible to directly 
compare the results obtained with measurements over different surfaces. 
Specifically, the intensity of the response obtained is related to the level of 
immobilization of protein (E-selectin/IgG and anti-human IgG used for the capture). 
The proportionality of the concentration injected and the response recorded is not 
identical between different surfaces due to a variation in the level of protein 
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immobilized (e.g. 0.5 µM exhibits a higher normalized response than 1 µM measured 
on a different surface, Figure 34A). The level of immobilization can differ considerably 
from one to another immobilization, even when a similar standard operating 
procedure is followed (Table 5). In addition, because all ligands analyzed exhibited a 
low response, the density of the immobilized protein was increased, resulting in a 
significant change in the response recorded. This variation had a strong impact on 
the result of the ranking in which compounds are evaluated according to the 
response obtained for a single injection. As shown in Figure 34B, the relative ranking 
order was the same with a set of compound tested over the different surfaces but the 
normalized response of a compound tested over surface 2 can not be included in the 
ranking obtained over surface 1.  
 
A                                                                            B 
 
 
 
 
 
 
 
  
Figure 34. (A) Normalized response obtained for JE-56, JE-57 and JE-58 at 1 µM, 0.5 µM and 0.1 
µM. 1 µM and 0.1 µM were recorded on the same surface. (B) Normalized response obtained for JE-
87, JE-78, JE-85 and JE-81 at 0.05 µM on two different surfaces described in Table 1.  
 
Table 5. Comparison of the response obtained for a 1.9 µM injection of GMI-1077, as well as a full 
series to obtain the KD over 2 surfaces with different levels of immobilization of protein (anti-
human/IgG and E-selectin/IgG). 
Surface Analyte 
Surface 
Capacity 
Antibody anti-
hIgG(Fc) [RU] 
Surface Capacity 
E-selectin/IgG [RU] 
Response at 
1.9 µM [RU] 
Rmax 
[RU] 
Exp. 
KD* 
[µM] 
1 GMI-1077 10971 4290 14.2 23.4 1.3 
2 GMI-1077 16350 9446 17.6 30.2 1.4 
*Experimental values obtained by fitting the steady state responses to a 1:1 binding model 
 
In order to compare compounds analyzed over different surfaces, two 
possibilities were considered: (i) a normalization to the Rmax observed for each 
compound (ii) a normalization to an internal standard. The first option was 
unacceptable, because it implied a complete analysis of each compound, thus 
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negating any advantage in time and cost from a ranking. Therefore, JE-81 was 
chosen as an internal standard for the next series of measurements. With this 
internal standard, measurements made over different surfaces showed similar 
normalized response and could be compared between each other (Figure 35). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35. Normalized response obtained for JE-78, JE-81, JE-85 and JE-87 at 0.05 µM on two 
different surfaces (Table 4) with a second normalization to JE-81 chosen as an internal standard. 
 
Justification of the choice of the concentration injected for the ranking 
 
 As previously mentioned, in the preliminary test performed with JE-56, JE-57 
and JE-58, three concentrations were tested based on the results obtained for the 
complete characterization of JE-57. Therefore, the concentration at saturation (1 µM) 
was injected as well as a concentration close to the KD value [KD (JE-57) = 0.14 µM, 
concentration injected 0.1 µM]. With both concentrations, a similar ranking was 
observed. An intermediate concentration of 0.5 µM was also successfully tested and 
was applied for the ranking of a second series of compounds: JE-78, JE-81, JE-85 
and JE-87. However, as shown in Figure 36, this concentration appeared to be too 
high for these compounds. An increasing slope in steady state and no return to the 
baseline during the dissociation phase were observed showing a persistence of the 
compound on the surface. 
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Figure 36. Sensorgram obtained after injection of 0.5 µM of JE-78 and a blank injection. 
 
Therefore, a new cycle of injections was performed at a concentration of 0.05 
µM. This concentration was finally suitable for the entirety set of compound and was 
used for the global ranking of 20 first-second-site antagonists synthesized by Jonas 
Egger.  
 
Final result of the ranking 
 
The results obtained were normalized to both, the response of JE-81, and their 
molecular weight (Figure 37). A mean value is reported for the compounds measured 
more than once (labeled with *). 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Ranking of 20 first-second-site antagonists according to their normalized response at a 
concentration of 0.05 µM (SPR signal divided by the molecular weight and normalized to JE-81).  
 
The ranking clearly showed a higher binding strength for the compounds 
linked to the nitrogen of 5-nitroindole. Indeed, four out of the five compounds showing 
the highest affinity were linked to the nitrogen of the 5-nitroindole (JE-81, JE-85, JE-
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86, JE-97). In addition, a linker length of six carbons (Figure 34, a+N = 6) led to 
improved binding affinities (JE-86 and JE-81) in the N-linked case. A significant 
decrease in affinity was observed between the JE-86 and JE-89 showing that a linker 
length of six carbons was not optimal for compounds linked to the carbon-3 of the 5-
nitroindole. Only one compound (JE-83) linked to the carbon-3 on the 5-nitroindole 
belongs to the five compounds with the best affinities. Its homologue (JE-78) with a 
similar length of the linker (2a+3N = 5) but linked to the nitrogen of the 5-nitroindole 
showed a clear decrease in affinity. In addition, all the N-linked compounds with a 
total length of five carbons for the linker exhibited a lower affinity (JE-58, JE-78, JE-
87 and JE-113) than the one with the extended linker. 
Based on the previous observations, it is apparent that the total length of the 
linker influenced the binding strength. Additionally, the site of linkage on the 5-
nitroindole also influenced the binding strength. These effects are compensatory, for 
example, JE-81 and JE-83 exhibited different linker length and at the same time are 
not linked to the same position of the 5-nitroindole, but showed similar binding 
strengths. Finally, among the compounds investigated, JE-86 possessed the best 
affinity.  
 
5.3.12 Binding assay for JE-55, JE-81, JE-83, JE-85, JE-86 and JE97 
 
A detailed study of the five compounds with the highest affinities was 
performed with the Biacore. In addition, JE-55, a first-site ligand with an n-butinyl 
linker, was investigated as well. Affinity and kinetic characterization of this compound 
was of interest as a precursor for in-situ click chemistry experiment. In Table 6, 
affinity and kinetic parameters are summarized. 
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Table 6.  Kinetic evaluation of JE-55, JE-83, JE-81, JE-86, JE-85 and JE-97. The reported KDs are 
derived from the steady-state fit to a single binding site model. Structure of JE-55 is shown in the 
bottom. 
Analyte KD eq [µM]** KD kin [µM]* kon (M-1.s-1) koff (s-1) t1/2 (s)*** 
JE-55  1.12 1.12 3.54 x 106 3.98 0.174 
JE-81 (2a4N) 0.049 0.035 7.97 x 104 0.0028 240 
JE-86 (3a3N) 0.030 0.018 1.42 x 105 0.0026 250 
JE-85 (1a3N) 0.057 0.037 6.79 x 104 0.0025 280 
JE-83 (2a3C) 0.050 - - - - 
JE-97 (3a1N) 0.089 0.036 6.35 104 0.0023 310 
*calculated KD using KD = koff/kon ** experimental KD derived from the steady state response fit to a single binding site model *** 
calculated t1/2 using t1/2 = ln2/koff. 
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5.4 Conclusion 
 
 A second-site screening approach based on a spin-labeled first-site ligand 
was previously applied in-house to MAG and led to substantial improved antagonist. 
A similar approach was applied to E-selectin. For that purpose, Jonas Egger 
synthesized a first-site ligand with a TEMPO moiety (JE-16). The presence of the 
TEMPO did not significantly affect the affinity of the ligand, as shown with Biacore 
investigations. From an NMR screening of a small library of second-site compounds, 
seven promising hits were selected. Three of them contain an indole moiety, and two 
others are indole derivatives (either an imidazol or a thiazol). Finally, the 5-nitroindole 
(SH-104-4) was chosen for further development.  
 The best first-second-site antagonists showed a 1300-fold improvement of 
the KD compared to the lead BW-69669.  This improvement can mainly be attributed 
to the pre-organisation of the core in the bioactive conformation and the successful 
linking of a second-site fragment. Concerning the kinetic characteristics, all first-site 
ligands (e.g. GMI-1077) showed fast association and dissociation rates, which are 
typical for carbohydrate-protein interactions (flat, solvent-accessible binding site) [39-
42]. A significant change in the kinetic profile of the first-second-site antagonist was 
observed. For the proper analysis of these new compounds, a Biacore assay was 
developed to allow a preliminary ranking. Later on, a complete analysis of the five 
best compounds was performed. Figure 38 shows KD values, as determined from the 
ratio of their off and on rates. As already mentioned, fast association and dissociation 
rates are clearly observed in Figure 38 for all the first-site ligands: all are located on 
the right side of the chart. However, the successfully first-second-site antagonists 
displayed dissociation rates that were at least one order of magnitude slower than 
those of the first-site compounds. Therefore, a displacement to the left side of the 
chart is observed. 
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Figure 38. Map of on and off rates of E-selectin antagonists. 
 
 The association of a first-site ligand with a second-site fragment was 
chemically achieved. In a near future, in-situ click chemistry will be used for the 
combination of the two partners [43].  
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6. Conclusions and outlook 
 
In acute and chronic inflammatory diseases, an excessive recruitment of 
leukocytes is problematic. Therefore, the modulation of leukocyte recruitment by 
interfering with cell tethering is of therapeutical interest. This modulation can be 
achieved by targeting CAMs like selectins, which play a key role in leukocytes 
transmigration.  
Selectins are calcium dependant carbohydrate-binding proteins involved in the 
early stage of the homing process. This family of protein, discovered in 1989, was 
intensively studied and their role in the leukocytes recruitment is well understood. 
Therefore, selectins are regarded as potential target in drug discovery. Recent 
advances in the development of selectin antagonists are aiming on carbohydrates-
mimetics drugs. Nevertheless, the development of carbohydrate-derived drugs is still 
challenging due to unfavorable pharmacokinetic profiles inherently linked to 
carbohydrates (e.g. fast association and dissociation rates, poor solubility, high 
polarity) and insufficient pharmacodynamics properties (low KDs). 
  
Based on the relevant pharmacophores of the natural ligand of selectins, the 
tetrasaccharide sLex, a first mimic was identified (BW-69669). Then, several 
antagonists were synthesized in order to achieve a stabilization of the bioactive 
conformation and thereby to improve the potency.  
For the evaluation of new antagonists synthesized reliable assay formats 
became necessary. Biacore was available in-house with all the advantages linked to 
this technology (e.g. direct evaluation, real-time measurement, labeling not required, 
access to affinity and kinetic parameters). For a better understanding of the binding 
mode, Biacore data were combined with STD-NMR and NMR relaxation studies.  
 
6.1 Biacore assay development 
 
The presence of lysines in the vicinity of the binding pocket of E-selectin led to 
the failure of the direct immobilization of the E-selectin/IgG, i.e binding pocket no 
longer accessible. Therefore, a capture assay format was established with the 
advantage of generating oriented surfaces. Two intermediate proteins for the 
capture, both targeting the Fc part of the E-selectin construct, were tested: protein A 
and anti-human IgG (Fc specific). In both cases, the capture surfaces allow the 
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analysis of E-selectin antagonists. Nevertheless, the anti-human IgG was preferred, 
because it allows a better level of capture of E-selectin was achieved, leading to a 
better quality of the data. Indeed, reasonable levels of response for antagonists were 
obtained (Rmax ≈ 30 RU), when considering the difficulties to evaluate low molecular 
weight compounds with Biacore technology. In addition, a higher stability of the 
surface was observed. The drawback of the high stability of the surface was the 
impossibility of complete removal of E-selectin.  
The evaluation of the first generation of E-selectin antagonists showed an 
improvement of the binding by a factor of two when introducing a benzoate in the 2-
position of the galactose moiety (LT-0236). An improvement of the affinity by a factor 
of five was observed in the presence of a methyl group in the 5-position of the 
GlcNAc mimic (DS-04115). By combining these modifications, a gain in affinity by a 
factor of 30 was obtained (GMI-1077). The introduction of a p-fluorobenzoate in the 
2-position of galactose did not improve the affinity (BW-510), whereas the p-
methoxybenzoate (BW-529) showed an increase in the affinity by another factor of 
four compare to GMI-1077. Unfortunately, none of the other modifications showed a 
significant improvement of the affinity.  
Concerning the kinetic profile of this generation of E-selectin antagonists, a 
fast association and a fast dissociation rates were always observed and could not be 
improved.  
  
6.2 STD-NMR and relaxation experiments 
 
In parallel to Biacore evaluation, spin-spin and spin-lattice NMR experiments 
were performed. This qualitatively confirmed binding and helped to establish the 
conditions for competitive spin-spin relaxation experiments. These experiments 
allowed determining the affinity of E-selectin antagonists relative to BW-69669. The 
data obtained were consistent with the affinity observed in Biacore. 
In order to obtain further informations on the binding mode, STD-NMR 
experiments were performed for some of the antagonists in presence of E-
selectin/IgG and in presence of the Lec EGF_CRD2 construct. With both proteins, 
similar STD patterns were observed with all antagonists, revealing a similar binding 
mode. The observed contact of the substituent in the 2-position of galactose with the 
protein observed by STD-NMR led to the hypothesis of another binding mode. 
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6.3 Second-generation of E-selectin antagonists 
  
In order to improve affinity and kinetic of E-selectin ligands, a fragment-based 
approach was initiated. An optimized first-site ligand of the first generation of E-
selectin antagonists with a micromolar affinity was chosen as a starting point.  
A spin-labeled analogue of this ligand (JE-16) was synthesized in-house by 
Jonas Egger and used for the identification of small second-site ligands binding to 
the E-selectin in the vicinity of JE-16. After screening of a library of second site 
ligands, seven promising hits were found. One representative thereof, 5-nitroindole 
was further developed.  
The design of the linker of first- and second-site ligands was guided by NMR. 
Thus, relaxation rates of the second-site ligand proton in the presence of the spin-
labeled ligand first-site ligand gave information on its relative orientation.  
Jonas Egger synthesized a library of twenty “first-second-site” antagonists with 
linkers of different length. Their binding affinity to E-selectin/IgG was evaluated by a 
ranking procedure on the Biacore. Subsequently, a complete characterization of the 
best five antagonists was performed. The two first-second-site antagonists with the 
highest affinity contained linkers with a total length of six carbons and were linked to 
the nitrogen in the 1-position of the 5-nitroindole. The best first-second-site 
antagonist showed a 1300-fold improvement of the KD compared to the lead BW-
69669 and displayed a 380-fold slower dissociation rate. 
 
 
6.4 Outlook 
 
 
The capture Biacore assay is well established and can be routinely used for 
the evaluation of E-selectin antagonists. Nevertheless, the difficulties to remove E-
selectin from the chip surface make the assay less feasible. When the E-selectin 
antagonist is immobilized on the sensorchip, affinity data comparable to the capture 
assay format were obtained. The immobilization of high affinity ligands on the surface 
will: 
 
• decrease the protein consumption,  
• reduce the necessity of frequent new immobilization, 
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• allow the evaluation of new compounds in a competitive format and 
• allows the characterization of the affinity of other proteins, such as murine E-
selectin. 
 
After STD-NMR experiments of ligands from the first-generation, the possibility 
of another binding mode persists. An X-ray structure elucidation E-selectin co-
crystallized of with a first-generation ligand will provide further insight.  
Until now, STD-NMR and group epitope mapping (GEM) of first-second-site 
antagonists was compromised by their limited solubility at the concentration required 
for STD-NMR experiments. An improvement of the solubility could be achieved e.g. 
by replacement of the nitro group of the 5-nitroindole by an amine or an acetamide.  
Finally, after the second-site screening, seven hits were selected. So far, only 
one of them was used for the development of first-second-site antagonists. The six 
hits left offers promising perspective for the design and synthesis of other libraries of 
first-second-site antagonists. 
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Appendix I 
E-­‐Selectin-­‐IgG(Fc)-­‐secreted	
  construct	
  (Novartis:	
  frank	
  Kolbinger)	
  
 
MIASQFLSALTLVLLIKESGAWSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLN 
SILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREK 
DVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIVNC 
TALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVV 
ECDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCK 
AVTCRAVRQPQNGSVRCSHSPAGEFTFKSSCNFTCEEGFMLQGPAQVECTTQGQWTQQIP 
VCEAFQCTALSNPERGYMNCLPSASGSFRYGSSCEFSCEQGFVLKGSKRLQCGPTGEWDN 
EKPTCEAVRCDAVHQPPKGLVRCAHSPIGEFTYKSSCAFSCEEGFELYGSTQLECTSQGQ 
WTEEVPSCQVVKCSSLAVPGKINMSCSGEPVFGTVCKFACPEGWTLNGSAARTCGATGHW 
SGLLPTCEVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV 
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCK 
VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE 
SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS 
LSPGK 
 
E-Selectin-IgG(Fc) [Theoretical pI: 5.41 / Mw (average mass): 86692.61] 
 
The molecular weight is around 148 KDa on a reducing SDS-PAGE. 
 
 
E-selectin:  Amino acids 1-548 
  
 
IgG (FC): Amino acids 549-785 
  
CH1:  549-554 
Hinge: 555-570 
CH2:  571-682 
CH3:  682-785 
 
 
 
 
 
 
 
 
 
 
 
 
 
201 
Appendix II 
 
Lec	
  EGF_CD2	
  domain	
  construct	
  (Roland	
  Preston)	
  
 
0	
  
WSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVWVWVGTQKPLTEEAKN
WAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTAACTNTSCSGHGECVETINNYTCKCDPGFSG
LKCEQIV 
     157 
158 
 NCTALESPEHGSLVCSHPLGNFSYNSSCSISCDRGYLPSSMETMQCMSSGEWSAPIPACNVVE 
CDAVTNPANGFVECFQNPGSFPWNTTCTFDCEEGFELMGAQSLQCTSSGNWDNEKPTCKA 
 
E-Selectin-IgG(Fc) [Theoretical pI: 4.74/ Mw (average mass):31281.72] 
 
The molecular weight is around 70 KDa on a reducing SDS-PAGE. 
 
 
Lec and EGF domains:  Amino acids 1-157 
CRD domains:  Amino acids 158-281 
 
 
    0          100         200         300 
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Appendix III 
Compound Structure Mol. Wt. 
rIC50 competitive 
binding assay 
GMI, ref. sLex 
KD (µM) 
Biacore, 
25°C 
 
BW-69669 
 
600.64 0.08 – 0.12 44.90 
BW-510 
 
736.75 0.00515 1.27 
BW-529 
 
748.79 0.00626 0.34 
BW-534 
 
682.73 0.00618 2.32 
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Compound Structure Mol. Wt. 
rIC50 
competitive 
binding 
assay GMI, 
ref. sLex 
KD (µM) 
Biacore, 
25°C 
 
BW-538 
 
794.85 0.0147 n.d. 
DS-0565 O
O
HO
OBz
O
O
HO
OH
OH
O
COOH
OH
 
722.82 0.032 5.36 
DS-0567 
 
710.35 0.007 1.49 
DS-0548 O
O
HO
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O
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O
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HO CO2Me
 
768.36 0.008 1.62 
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Compound Structure Mol. Wt. 
rIC50 
competitive 
binding 
assay GMI, 
ref. sLex 
KD (µM) 
Biacore, 
25°C 
 
DS-04115 
BW-40800 
 
614.29 0.016 7.64 
GMI-1077 
BW-40801 
 
718.32 0.004 1.50 
JE-12 
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O
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O
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Compound Structure Mol. Wt. 
rIC50 
competitive 
binding 
assay GMI, 
ref. sLex 
KD (µM) 
Biacore, 
25°C 
 
JE-57 
 
1023.09 - 0.138 
JE-61 
 
860.48 - 12.46 
LT-0236 
 
704.30 - 18.8 
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Appendix IV 
 
 
Nomenclature for identification of the linking pattern. 1: number of CH2 groups in the first-site 
linker; a: type of conjunction (a = anti; s = syn); 2: number of CH2 groups in the second-site 
linker; N: site of attachment at the second-site linker (N: nitrogen, C: carbon). 
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HN 1s2C
NO2
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N NO2
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5 
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